IRAQ PROTACS4
PROTACs target IRAK4 for degradation, addressing the limitations of IRAK4 kinase inhibitors by effectively modulating inflammatory signaling and offering new treatment options for various diseases.
Patent Information
- Application Number
- BR112025021654
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-14
- Filing Date
- 2024-04-05
- Publication Date
- 2026-11-10
AI Technical Summary
Current IRAK4 kinase inhibitors are limited in their therapeutic efficacy for treating inflammatory diseases, and there is a need for a more effective approach to degrade IRAK4 to modulate inflammatory signaling.
Development of PROTACs that selectively target IRAK4 for degradation by recruiting the E3 ligase CRBN, leading to polyubiquitination and proteasomal degradation of IRAK4.
PROTACs offer a differentiated therapeutic approach by effectively degrading IRAK4, potentially providing improved treatment options for inflammatory diseases, cancer, asthma, and chronic autoimmune/autoinflammatory diseases.
Abstract
Description
[0001] This descriptive report refers to certain proteolysis targeting chimera (PROTAC) compounds and, at a minimum, to their ability to degrade interleukin-1 receptor-associated kinase 4 (IL-1R) (IRAK4), and are therefore useful as therapeutic agents. FIELD OF THE DESCRIPTIVE REPORT
[0002] Interleukin-1 receptor-associated kinase 4 (IL-1R) (IRAK4) is an essential regulator of immune signaling. IRAK4 is expressed by multiple cell types and mediates signal transduction of Toll-like receptors (TLRs) and interleukin-1 (IL-1) family receptors, including IL-1R, IL-18R, and the IL-33 ST2 receptor (Suzuki et al., 2002, Ku et al., 2007, Schmitz et al., 2005, Suzuki et al., 2003). TLRs recognize and respond to ligands derived from microbes, such as lipopolysaccharide (LPS) or microbial RNA or DNA, while IL-1 family receptors can be activated by endogenous ligands produced by TLR-activated cells (IL-1β and IL-18) or by tissue damage (IL-1α and IL-33).Following the activation of TLRs or IL-1 receptors by their ligands, the primary myeloid differentiation response of adaptor protein 88 (MyD88) is recruited to the receptor and forms a multimeric protein complex, called the Myddosome, along with proteins from the IRAK family (IRAK1, IRAK2, and IRAK4). The myddosome serves as a signaling platform to induce nuclear factor kB (NF-κB) and mitogen-activated protein kinase (MAPK) signal transduction pathways, culminating in the activation of NF-κB, activator protein 1 (AP1), c-AMP response element-binding protein (CREB), and interferon regulatory factor 5 (IRF5) transcription factors, driving the transcription of inflammatory cytokines and chemokines (reviewed in (Balka and De Nardo, 2019)).Mice lacking IRAK4 are viable but lack an inflammatory cytokine response to IL-1β, IL-18, and LPS (Suzuki et al., 2003; Suzuki et al., 2002). Humans with loss-of-function mutations in IRAK4 exhibit an immunocompromised phenotype, and their immune cells show a nullified cytokine response to TLR agonists and IL-1 receptor ligands (Ku et al., 2007; Medvedev et al., 2003; Alsina et al., 2014). Petition 870260111673, dated 10 / 29 / 2026, p. 6 / 831 2 / 375
[0003] IRAK4 is characterized by an N-terminal death domain that mediates interaction with MyD88 and a centrally located kinase domain. Myddosome formation promotes IRAK4 autophosphorylation, which modulates Myddosome stability and downstream signaling (De Nardo et al., 2018; Cushing et al., 2017). IRAK4 kinase activity is required for cytokine induction by TLRs and IL-1R, as shown by studies in knock-in mice expressing an inactive IRAK4 kinase, as well as in studies using small molecule IRAK4 kinase inhibitors (Koziczak-Holbro et al., 2007; Lye et al., 2004; Lee et al., 2017). Given the critically important role of IRAK4 in inducing an inflammatory response, IRAK4 kinase inhibitors are under clinical development for the treatment of various inflammatory diseases.
[0004] IRAK4 can regulate inflammatory signaling both through its kinase activity and its scaffolding function. Studies using mouse cells with inactive IRAK4 kinase and IRAK4 knockout mice indicate that IRAK4 removal has a more profound effect on suppressing TLR-induced NFKB activation and cytokine release compared to removing kinase activity alone (Pereira et al. 2022, De Nardo et al. 2018). Therefore, there is the potential to achieve a differentiated biological and therapeutic effect by degrading IRAK4 compared to inhibiting its kinase activity.
[0005] PROTACs are heterobifunctional molecules containing two small molecule-binding moieties, joined by a ligand. One of the small molecule ligands is designed to bind with a very high degree of affinity to a target protein in the cell, while the other ligand is capable of binding with a very high degree of affinity to an E3 ligase. In the cell, the PROTAC selectively locates and binds to the target protein of interest. PROTAC then recruits a target protein-specific E3 ligase to form a ternary complex with the target protein and the E3 ligase held in close proximity. The E3 ligase then recruits an E2 conjugating enzyme to the ternary complex. E2 is then able to ubiquitinate the target protein by tagging an available lysine residue on the protein and then dissociates from the ternary complex.E3 can then recruit additional E2 molecules, resulting in polyubiquitination of the target protein, marking the target protein for potential degradation by the cell's proteasome machinery. A PROTAC is then able to dissociate from the target protein and initiate another catalytic cycle. A. Petition 870260111673, dated 10 / 29 / 2026, p. 7 / 831 3 / 375 The polyubiquitinated target protein is then recognized and degraded by the proteasome. Here, the designated PROTACs targeting IRAK4 for degradation contain an IRAK4 ligand moiety at one end of the ligand and an E3 ligase (such as cereblon, CRBN) at the other end. In cells, the IRAK4 PROTAC selectively recruits the E3 ligase CRBN to IRAK4 and leads to the degradation of IRAK4.
[0006] The development of innovative IRAK4 PROTACs may provide a differentiated approach to IRAK4 kinase inhibitors that could offer an efficacy advantage for the treatment of IRAK4-driven pathologies. IRAK4 PROTACs have potential for the treatment of various diseases and conditions, although, to date, no PROTAC has been approved for clinical use. One objective of this descriptive report is to provide novel IRAK4 PROTACs with physicochemical and selectivity profiles that make them suitable for clinical use, for example, in the treatment of inflammatory diseases, cancer, asthma, COPD, and chronic autoimmune / autoinflammatory diseases. In particular, the present researchers have surprisingly found that certain compounds in this descriptive report show beneficial bioavailability. SUMMARY
[0007] In a first aspect, the present descriptive report refers to compounds according to formula (IA) or pharmaceutically acceptable salts thereof: given that: X is: Petition 870260111673, dated 10 / 29 / 2026, p. 8 / 831 4 / 375 or R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl or -O-(C1-C6)alkylenyl-O(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Q is CH or N; Y is a direct bond, C(O), CH2, -CH2CH2-, -C(O)CH2-, where CH2 is attached to Q, -CH2C(O)-, where C(O) is attached to Q or -CH2C(O)NMe-, where N is attached to Q; L is - (Ci-Ce)alkylenyl-NH-*, - (Ci-C6)alquilenyl-N-((Ci-Ce)alquila)-*; - O-(Ci-Ce)alquilenyl-NH-*, - O-(Ci-C6)alquilenyl-N((Ci-C6)alquila)-*, - (Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-NH-*, - (Ci-C6)alquilenyl-O-(Ci-C6)alquilenyl-N-((Ci-C6)alquila)-*, - NH-(Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-NH-*, -NH-(Ci-C6)alquilenyl-O-(Ci-C6)alquilenyl-O-(Ci-C6)alquilenyl-N-((CiC6)alquila)-*, -NH(Ci-C6)alquilenyl-NH-*, -((Ci-C6)alquil)-N-(Ci-C6)alquilenyl-N-((Ci-C6)alquila)-*, heterocycloalquilenyl-* of 4 to 6 members; heterocycloalquilenyl of 4 to 6 members-(Ci-C6)alquilenyl-NH-*, heterocycloalquilenyl of 4 to 6 members-(Ci-C6)alquilenyl-N-((CiC6)alquila)-*, Petition 870260111673, 29 / 10 / 2026, pág. 9 / 831 5 / 375 heterocycloalquilenyl from 4 to 6 members-heterocycloalquilenyl-* from 4 to 6 members, -(C1-C6)alkylenyl-heterocycloalquilenyl-* from 4 to 6 members, -(C1-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-NH-*, -(C 1-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-N-((C1C6)alkyl)-*, -(C1-C6)alkylenyl-heterocycloalkylenyl C6)alkylenyl-NH-*, -(C1-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(C1-C6)4-6-membered alkylenyl-N-((C1-C6)alkyl)-*, 4-6-membered heterocycloalkylenyl-(C1-C6)4-6-membered alkylenyl-heterocycloalkylenyl-*, 4-6-membered heterocycloalkylenyl-(C1-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(C1-C6)4-6-membered alkylenyl-NH-*, 4-6-membered heterocycloalkyl-(C1-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(C1-C6)4-6-membered alkylenyl-NH-*, 4-6-membered heterocycloalkyl-(C1-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(C1-C6)4-6-membered alkylenyl-N-((C1-C6)alkyl)-*, - alkynelenyl-(C1-C6)alkylenyl-NH-*, - alkynylenyl-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-heterocycloalkylenylNH-*, - 4 to 6 membered alkynylenyl-(C1-C6)alkylenylheterocycloalkylenyl-N((C1-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-*, - (C3-C6)cycloalkylenyl-*, - 4- to 6-membered (C3-C6)cycloalkylenylheterocycloalkylenyl-*, - 4- to 6-membered (C1-C6)alkylenyl-C(O)-heterocycloalkylenyl-*, or - heteroaryl-* with 5 to 6 members; the connection marked with an * is fixed to Y; Petition 870260111673, dated 10 / 29 / 2026, p. 10 / 831 6 / 375 Me Petition 870260111673, dated 10 / 29 / 2026, p. 11 / 831 7 / 375 and W is N or CH.
[0008] In a second aspect, this descriptive report refers to compounds according to formula (IA) or pharmaceutically acceptable salts thereof:
[0009] where:
[0010] X is: 7 or R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl or -O-(C1-C6)alkylenyl-O(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Q is CH or N; Y is a direct link, C(O), CH2, -CH2CH2-, -C(O)CH2-, where CH2 is attached to Q or -CH2C(O)-, where C(O) is attached to Q; L is -(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*; -O-(C1-C6)alkylenyl-NH-*, -O-(C1-C6)alkylenyl-N((C1-C6)alkyl)-*, Petition 870260111673, dated 10 / 29 / 2026, page 12 / 831 8 / 375 - (Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-NH-*, - (Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - NH-(Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-NH-*, -NH-(Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-N-((Ci- C6)alkyl)-*, -NH(Ci-C6)alkylenyl-NH-*, -((Ci-C6)alkyl)-N-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-*; 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenyl-N-((CiC6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-heterocycloalkylenyl-* of 4 to 6 members, - (Ci-C6)alkylenyl-heterocycloalkylenyl-* 4 to 6 members, - (Ci-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-NH-*, - (C i-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-N-((Ci- C6)alkyl)-*, - (Ci-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-(Ci- C6)alkylenyl-NH-*, - (Ci-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-(Ci- C6)alkylenyl-N-((Ci-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenylheterocycloalkylenyl-*, 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenylheterocycloalkylenyl-4- to 6-membered-(Ci-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkyl-(Ci-C6)alkylenylheterocycloalkylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - alkynylenyl-(Ci-C6)alkylenyl-NH-*, Petition 870260111673, dated 10 / 29 / 2026, page. 13 / 831 9 / 375 - alkynylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(Ci-C6)alkylenyl-heterocycloalkylenylNH-*, - 4- to 6-membered alkynylenyl-(Ci-C6)alkylenyl-heterocycloalkylenyl-N((Ci-C6)alkyl)-*, or - alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-* of 4 to 6 members, and the linkage marked with an * is attached to Y; and W is N or CH.
[0011] In a third aspect, the present descriptive report refers to compounds according to formula (I) or pharmaceutically acceptable salts thereof: Petition 870260111673, dated 10 / 29 / 2026, p. 14 / 831 10 / 375 given that: X is: R2 or O R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl or -O-(C1-Ce)alkylenyl-O(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-Ce)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; -(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*; -O-(C1-C6)alkylenyl-NH-*, -O-(C1-C6)alkylenyl-N((C1-C6)alkyl)-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1-C6)alkyla)-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1-C6)alkyla)-*, Petition 870260111673, de 29 / 10 / 2026, pág. 15 / 831 11 / 375 -NH(C1-C6)alkylenyl-NH-*, -((Ci-C6)alquil)-N-(Ci-C6)alquilenil-N-((Ci-C6)alquila)-*, heterocicloalquilenila-* de 4 a 6 members; heterocicloalquilenila de 4 a 6 membros-(C1-C6)alquilenil-NH-*, heterocicloalquilenila de 4 a 6 membros-(C1-C6)alquilenil-N-((C1C6)alquila)-*, heterocicloalquilenila de 4 a 6 membros-heterocicloalquilenila-* de 4 a 6 membros, -(Ci-C6)alquilenil-heterocicloalquilenila de 4 a 6 members-NH-*, -(C 1-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-N-((C1C6)alkyl)-*, - (Ci-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-(Ci- C6)alkylenyl-NH-*, - (Ci-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-(Ci- C6)alkylenyl-N-((Ci-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenylheterocycloalkylenyl-*, 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenylheterocycloalkylenyl-4- to 6-membered-(Ci-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkyl-(Ci-C6)alkylenylheterocycloalkylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - alkynylenyl-(Ci-C6)alkylenyl-NH-*, - alkynylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(Ci-C6)alkylenyl-heterocycloalkylenylNH-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-heterocycloalkylenyl-N((C1-C6)alkyl)-*, or - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-*, Petition 870260111673, dated 10 / 29 / 2026, p. 16 / 831 12 / 375 where the connection marked with an * is fixed to Y; and W is N or CH.
[0012] In a fourth aspect, the present descriptive report refers to compounds according to formula (I) or pharmaceutically acceptable salts thereof: (I) where: X is: or Petition 870260111673, dated 10 / 29 / 2026, p. 17 / 831 13 / 375 R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl or -O-(C1-C6)alkylenyl-O(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y é uma direct connection, C(O) or CH2; L é -(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*; -O-(C1-C6)alkylenyl-NH-*, -O-(C1-C6)alkylenyl-N((C1-C6)alkyl)-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1-C6)alkyla)-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1-C6)alkyla)-*, -NH(C1-C6)alkylenyl-NH-*, -((C1-C6)alquil)-N-(C1-C6)alquilenil-N-((C1-C6)alquila)-*, heterocicloalquilenila-* de 4 a 6 members; heterocicloalquilenila de 4 a 6 membros-(C1-C6)alquilenil-NH-*, heterocicloalquilenila de 4 a 6 membros-(C1-C6)alquilenil-N-((C1C6)alquila)-*, heterocicloalquilenila de 4 a 6 membros-heterocicloalquilenila-* de 4 a 6 membros, -(C1-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-NH-*, -(C 1-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-N-((C1C6)alkyl)-*, Petition 870260111673, dated 10 / 29 / 2026, page. 18 / 831 14 / 375 -(Ci-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-(CiC6)alkylenyl-NH-*, -(Ci-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(CiC6)alkylenyl-N-((Ci-Ce)alkyl)-*, 4-6-membered heterocycloalkylenyl-(Ci-C6)4-6-membered alkylenyl-heterocycloalkylenyl-*, 4-6-membered heterocycloalkylenyl-(Ci-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(Ci-C6)alkylenyl-NH-*, 4-6-membered heterocycloalkyl-(Ci-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - alkynylenyl-(Ci-C6)alkylenyl-NH-*, - alkynylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenylheterocycloalkylenylNH-*, - 4 to 6 membered alkynylenyl-(C1-C6)alkylenylheterocycloalkylenyl-N((C1-C6)alkyl)-*, or - alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-* of 4 to 6 members, and the linkage marked with an * is attached to Y; Z is Petition 870260111673, dated 10 / 29 / 2026, p. 19 / 831 15 / 375 and W is N or CH.
[0013] In a fifth aspect, this descriptive report refers to compounds according to formula (I) or pharmaceutically acceptable salts thereof: given that: X is: or R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl or -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; Petition 870260111673, dated 10 / 29 / 2026, page 20 / 831 16 / 375 R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; L is -(C1-Ce)alkylenyl-NH-*, -(C1-C6)alkylenyl-N-((C1-Ce)alkyl)-*; -O-(C1-Ce)alkylenyl-NH-*, -O-(C1-C6)alkylenyl-N((C1-C6)alkyl)-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, -NH(C1-C6)alkylenyl-NH-*, -((C1-C6)alkyl)-N-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-*; 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-heterocycloalkylenyl-* of 4 to 6 members, - (C1-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-NH-*, - (C 1-C6)4-to-6-membered alkylenyl-heterocycloalkylenyl-N-((C1C6)alkyl)-*, - 4- to 6-membered (C1-C6)alkylenyl-heterocycloalkylenyl-(C1- C6)alkylenyl-NH-*, - 4- to 6-membered (C1-C6)alkylenyl-heterocycloalkylenyl-(C1- C6)alkylenyl-N-((C1-C6)alkyl)-*, Petition 870260111673, dated 10 / 29 / 2026, page. 21 / 831 17 / 375 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenylheterocycloalkylenyl-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenylheterocycloalkylenyl-4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkyl-(C1-C6)alkylenylheterocycloalkylenyl-4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, - alkynelenyl-(C1-C6)alkylenyl-NH-*, - alkynylenyl-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-heterocycloalkylenylNH-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-heterocycloalkylenyl-N((C1-C6)alkyl)-*, or - alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-* of 4 to 6 members, where the ligation marked with a * is attached to Y; Zé e W é N ou CH.
[0014] In a sixth aspect, the present descriptive report refers to compounds according to formula (I) or pharmaceutically acceptable salts thereof: Petition 870260111673, dated 10 / 29 / 2026, p. 22 / 831 18 / 375 given that: X is: R2 or O R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl or -O-(C1-Ce)alkylenyl-O(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-Ce)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; -(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-N-((C1-Ce)alkyl)-*; -O-(C1-C6)alkylenyl-NH-*, -O-(C1-C6)alkylenyl-N((C1-C6)alkyl)-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, Petition 870260111673, dated 10 / 29 / 2026, page. 23 / 831 19 / 375 -NH(Ci-C6)alkylenyl-NH-*, -((Ci-C6)alkyl)-N-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-*, -(C1-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-NH-*, -(C 1-C6)4- to 6-membered alkylenyl-heterocycloalkylenyl-N-((C1C6)alkyl)-*, - (Ci-C6)alkylenyl-heterocycloalkylenyl C6)alkylenyl-NH-*, - (Ci-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(Ci-C6)4-6-membered alkylenyl-N-((Ci-C6)alkyl)-*, 4-6-membered heterocycloalkylenyl-(C1-C6)4-6-membered alkylenyl-heterocycloalkylenyl-*, 4-6-membered heterocycloalkylenyl-(Ci-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(Ci-C6)alkylenyl-NH-*, 4-6-membered heterocycloalkyl-(Ci-C6)4-6-membered alkylenyl-heterocycloalkylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - alkynylenyl-(Ci-C6)alkylenyl-NH-*, - alkynylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(Ci-C6)alkylenyl-heterocycloalkylenylNH-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-heterocycloalkylenyl-N((C1-C6)alkyl)-*, or - alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-* of 4 to 6 members, where the ligation marked with a * is attached to Y; Petition 870260111673, dated 10 / 29 / 2026, page. 24 / 831 20 / 375 and W is N or CH.
[0015] In a seventh aspect, the present descriptive report refers to compounds according to formula (I) or pharmaceutically acceptable salts thereof: given that: X is: N= / or O ; R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl or -O-(C1-C6)alkyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkyl-O(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; Petition 870260111673, dated 10 / 29 / 2026, p. 25 / 831 21 / 375 L é -(Ci-C6)alkyl-NH-*, -(Ci-C6)alkyl-N-(Ci-Ce)alkyl-*, -O-(Ci-Ce)alkylNH-*, -O-(Ci-C6)alkyl-N(Ci-C6)alkyl-*, -(Ci-C6)alkyl-O-(Ci-Ce)alkyl-NH-*, -(CiC6)alkyl-O-(Ci-C6)alkyl-N-(Ci-C6)alkyl-*, -NH-(Ci-C6)alkyl-O-(Ci-C6)alkyl-O-(CiC6)alkyl-NH-*, -NH-(Ci-C6)alkyl-O-(Ci-C6)alkyl-O-(Ci-C6)alkyl-N-(Ci-C6)alkyl-*, NH(Ci-C6)alkyl-NH-*, -(Ci-C6)alkyl-N-(Ci-C6)alkyl-N-(Ci-C6)alkyl-*, 4- to 6-membered heterocycloalkyl-(Ci-C6)alkyl-NH-*, 4- to 6-membered heterocycloalkyl-(Ci-C6)alkyl-N-(Ci-C6)alkyl-*, 4- to 6-membered heterocycloalkyl-4- to 6-membered heterocycloalkyl-*, -(Ci-C6)alkyl-heterocycloalkyl-NH-* of 4 to 6 members, -(Ci-C6)alkyl-heterocycloalkyl of 4 to 6 members-N-(Ci-C6)alkyl-*, -(CiC6)alkyl-heterocycloalkyl of 4 to 6 members-(Ci-C6)alkyl-NH-*, -(Ci-C6)alkylheterocycloalkyl 4- to 6-membered-Ci-C6)alkyl-N(Ci-C6)alkyl-*, 4- to 6-membered heterocycloalkyl-(Ci-C6)alkyl-heterocycloalkyl-*,4- to 6-membered heterocycloalkyl-(Ci-C6)alkyl-4- to 6-membered heterocycloalkyl-(Ci-C6)alkyl-NH-*, 4- to 6-membered heterocycloalkyl-(Ci-C6)alkyl-4- to 6-membered heterocycloalkyl-(Ci-C6)alkyl-N-(Ci-C6)alkyl-Y, Z-alkynyl-(CiCe)alkyl-NH-*, -alkynyl-(Ci-C6)alkyl-N-(Ci-C6)alkyl-*, -alkynyl-(Ci-C6)alkyl-4- to 6-membered heterocycloalkyl-NH-*, -alkynyl-(Ci-C6)alkyl-4- to 6-membered heterocycloalkyl-N-(Ci-C6)alkyl-*, or -alkynyl-(Ci-C6)alkyl-O-heterocycloalkyl of 4 to 6 members-*, where the ligation marked with a * is fixed to Y;, e W é N ou CH.
[0016] This descriptive report refers to proteolytic targeting chimera composts (PROTAC) of formula (I) and formula (IA) and are pharmaceutically oiled. Petition 870260111673, dated 10 / 29 / 2026, page. 26 / 831 22 / 375
[0017] This descriptive report refers to a pharmaceutical composition comprising a compound of formula (I) or formula (IA) or a pharmaceutically acceptable salt thereof.
[0018] This descriptive report refers to a pharmaceutical composition comprising a compound of formula (I) or formula (IA) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
[0019] This descriptive report refers to a method of degrading IRAK4 in a human being comprising administering to a human being in need thereof an effective amount of a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof.
[0020] This descriptive report refers to the method of reducing the activity level of IRAK4 in a human comprising the compound of formula (I) or formula (IA) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or formula (IA).
[0021] This descriptive report also refers to the method of reducing the level of IRAK4 activity in a human comprising the compound of formula (I) or formula (IA) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof.
[0022] This descriptive report refers to a method of treating IRAK4-mediated diseases or disorders in a human being comprising administering to the human being in need thereof a therapeutically effective amount of a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or formula (IA).
[0023] This descriptive report refers to a method of treating IRAK4-mediated diseases or disorders in a human being comprising administering to the human being in need thereof a therapeutically effective amount of a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a Petition 870260111673, dated 10 / 29 / 2026, p. 27 / 831 23 / 375 compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof.
[0024] Another aspect of this descriptive report refers to a method of treating IRAK-4-mediated diseases or disorders in a human being comprising administering to the human being in need thereof a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder and / or a cancer.
[0025] Another aspect of this descriptive report refers to a method of treating diseases or disorders in a human being that comprises administering to the human being in need thereof a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder and / or a cancer.
[0026] This descriptive report refers to a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof, for use in therapy.
[0027] Another aspect of this descriptive report refers to a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof, for use in the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder and / or cancer.
[0028] Another aspect of this descriptive report relates to a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder, or cancer. BRIEF DESCRIPTION OF THE FIGURES
[0029] Figure 1. Plasma concentrations of the compound from Example 31 after IV and PO dosing. Figure 1: Diagram of plasma concentrations of the compound from Example 31 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h). Petition 870260111673, dated 10 / 29 / 2026, page 28 / 831 24 / 375
[0030] Figure 2. Plasma concentrations of the compound from Example 30 after IV and PO dosing. Figure 2: Diagram of plasma concentrations of the compound from Example 30 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0031] Figure 3. Plasma concentrations of the compound from Example 32 after IV and PO dosing. Figure 3: Diagram of plasma concentrations of the compound from Example 32 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0032] Figure 4. Plasma concentrations of the compound from Example 33 after IV and PO dosing. Figure 4: Diagram of plasma concentrations of the compound from Example 33 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0033] Figure 5. Plasma concentrations of the compound from Example 34 after IV and PO dosing. Figure 5: Diagram of plasma concentrations of the compound from Example 34 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0034] Figure 6. Plasma concentrations of the compound from Example 35 after IV and PO dosing. Figure 6: Diagram of plasma concentrations of the compound from Example 35 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0035] Figure 7. Plasma concentrations of the compound from Example 36 after IV and PO dosing. Figure 7: Diagram of plasma concentrations of the compound from Example 36 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0036] Figure 8. Plasma concentrations of the compound from Example 37 after IV and PO dosing. Figure 8: Diagram of plasma concentrations of the compound from Example 37 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0037] Figure 9. Plasma concentrations of the compound from Example 40 after IV and PO dosing. Figure 9: Diagram of plasma concentrations of the compound from Example 40 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h). Petition 870260111673, dated 10 / 29 / 2026, page 29 / 831 25 / 375
[0038] Figure 10. Plasma concentrations of the compound from Example 41 after IV and PO dosing. Figure 10: Diagram of plasma concentrations of the compound from Example 41 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0039] Figure 11. Plasma concentrations of the compound from Example 51 after IV and PO dosing. Figure 11: Diagram of plasma concentrations of the compound from Example 51 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0040] Figure 12. Plasma concentrations of the compound from Example 56 after IV and PO dosing. Figure 12: Diagram of plasma concentrations of the compound from Example 56 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0041] Figure 13. Plasma concentrations of the compound from Example 57 after IV and PO dosing. Figure 13: Diagram of plasma concentrations of the compound from Example 57 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0042] Figure 14. Plasma concentrations of the compound from Example 58 after IV and PO dosing. Figure 14: Diagram of plasma concentrations of the compound from Example 58 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0043] Figure 15. Plasma concentrations of the compound from Example 65 after IV and PO dosing. Figure 15: Diagram of plasma concentrations of the compound from Example 65 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0044] Figure 16. Plasma concentrations of the compound from Example 68 after IV and PO dosing. Figure 16: Diagram of plasma concentrations of the compound from Example 68 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0045] Figure 17. Plasma concentrations of the compound from Example 74 after IV and PO dosing. Figure 17: Diagram of plasma concentrations of the compound from Example 74 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h). Petition 870260111673, dated 10 / 29 / 2026, page 30 / 831 26 / 375
[0046] Figure 18. Plasma concentrations of the compound from Example 75 after IV and PO dosing. Figure 18: Diagram of plasma concentrations of the compound from Example 75 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h).
[0047] Figure 19. Plasma concentrations of the compound from Example 76 after IV and PO dosing. Figure 19: Diagram of plasma concentrations of the compound from Example 76 after IV dosing (0.5 mg / kg) and PO dosing (1 mg / kg) over time (h). DETAILED DESCRIPTION
[0048] Many aspects of this disclosure are detailed throughout the descriptive report.
[0049] This descriptive report refers to compounds of formula (I) and formula (IA), as defined above, or pharmaceutically acceptable salts thereof.
[0050] This descriptive report refers further to compounds of formula (I), wherein formula (I) is further represented by formula (II):
[0051] This descriptive report refers further to compounds of formula (I), wherein formula (I) is further represented by formula (III): Petition 870260111673, dated 10 / 29 / 2026, p. 31 / 831 27 / 375 (III).
[0052] In some modalities, this descriptive report refers to formulas (IA), (II) and (III), wherein
[0053] X is
[0054] In some modalities, this descriptive report refers to formulas (IA), (II) and (III), wherein and R2 is (C3-C6)cycloalkyl. In some embodiments, R2 is cyclobutyl or cyclopropyl. In some embodiments, R2 is cyclopropyl.
[0055] In some embodiments, this descriptive report refers to formulas (IA), (II) and (III), wherein R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy. In some embodiments, this descriptive report refers to formulas (IA), (II) and (III), wherein R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted one, two or three times with fluorine. In some embodiments, R1 is -O-(C1-C6)alkyl, -O-(C3C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl. In some embodiments, R1 is -O-(C3-C6)cycloalkyl or -O-(C1-C6)alkyl. In some embodiments, R1 is -O-(C3C6)cycloalkyl.In some embodiments, R1 is -O-(C1-C6)alkyl. In some embodiments, R1 is -O-cyclopropyl, -OCH2CH2CH3, -OCH2CH3, and -OCH3. In some embodiments, R1 is -OCH2CH2CH3, -OCH2CH3, and -OCH3. In some embodiments, R1 is -OCH3. In some embodiments, R1 is -O-cyclopropyl. Petition 870260111673, dated 10 / 29 / 2026, p. 32 / 831 28 / 375
[0056] In some embodiments, this descriptive report refers to formula (IA), where Q is CH or N. In some embodiments, Q is CH. In some embodiments, Q is N.
[0057] In some embodiments, this descriptive report refers to formulas (IA), (II) and (III), wherein Y is a direct linkage, C(O), CH2, -CH2CH2-, -C(O)CH2-, wherein CH2 is attached to Q, -CH2C(O)-, wherein C(O) is attached to Q or -CH2C(O)NMe-, wherein N is attached to Q. In some embodiments, this descriptive report refers to formulas (IA), (II) and (III), wherein Y is a direct linkage, C(O), CH2, CH2CH2-, -C(O)CH2-, wherein CH2 is attached to Q or -CH2C(O)-, wherein C(O) is attached to Q. In some embodiments, Y is a direct linkage. In other embodiments, Y is C(O). In other embodiments, Y is CH2. In other embodiments, Y is CH2CH2. In other embodiments, Y is C(O)CH2, where CH2 is attached to Q. In still other embodiments, Y is CH2C(O), where C(O) is attached to Q. In still other embodiments, Y is -CH2C(O)NMe-, where N is attached to Q.
[0058] In some embodiments, the descriptive report refers to the formulas (IA), (II) and (III), where L is -(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-N-((C1-C6)alkyl)*, -O-(C1-C6)alkylenyl-NH-*, -O-(C1-C6)alkylenyl-N((C1-C6)alkyl)-*, -(C1C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, -NH-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-NH-*, -NH(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-O-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, -NH(CiC6)alkylenyl-NH-*, -((C1-C6)alkyl)-N-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-*, 4- to 6-membered heterocycloalkylenyl(C1-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N((C1-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl- 4- to 6-membered heterocycloalkylenyl-*, -(C1-C6)alkylenyl-heterocycloalkylenyl-* of 4 to 6 members, -(C1C6)alkylenyl-heterocycloalkylenyl of 4 to 6 members-NH-*,-(C1-C6)4- to 6-membered alkylenylheterocycloalkylenyl-N-((C1-C6)alkyl)-*, -(C1-C6)4- to 6-membered alkylenylheterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, -(C1-C6)4- to 6-membered alkylenylheterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-heterocycloalkylenyl-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenylheterocycloalkylenyl-4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenylheterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, 4- 6-membered-(C1-C6)alkylenyl-heterocycloalkylenyl 4-6-membered-(C1Petição 870260111673, dated 10 / 29 / 2026, page 33 / 831, 29 / 375 C6)alkylenyl-N-((Ci-C6)alkyl)-*, - alkynylenyl-(Ci-C6)alkylenyl-NH-*, - alkynylenyl-(C1C6)alkylenyl-N-((Ci-C6)alkyl)-*, - alkynylenyl-(Ci-C6)alkylenyl-heterocycloalkylenyl of 4 to 6 members-NH-*, - alkynylenyl-(Ci-C6)alkylenyl-heterocycloalkylenyl of 4 to 6 members-N-((Ci-C6)alkyl)-*, - alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-* of 4 to 6 members, -(C3-C6)cycloalkylenyl-*, -(C3-C6)cycloalkylenylheterocycloalkylenyl-* of 4 to 6 members, -(C1-C6)alkylenyl-C(O)heterocycloalkylenyl-* with 4 to 6 members or heteroaryl-* with 5 to 6 members; being that the ligação marked with a * is fixed to Y; e where a 4- to 6-membered heterocycloalkylenyl is piperidine or piperazine, a (C3-C6)cycloalkylenyl is cyclo-hexyl and a 5- to 6-membered heteroaryl is pyrazolyl.
[0059] In some embodiments, the descriptive report refers to the formulas (IA), (II) and (III), where L is heterocycloalkylenyl-* with 4 to 6 members; 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-heterocycloalkylenyl-*, -(C1-C6)alkylenylheterocycloalkylenyl-NH-*, -(C1-C6)alkylenyl-heterocycloalkylenyl-4- to 6-membered-N-((C1-C6)alkyl)-*, -(C1-C6)alkylenyl-heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-heterocycloalkylenyl-4 to 6-membered-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkyl-heterocycloalkylenyl-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkyl-heterocycloalkylenyl-4- to 6-membered-(C1-C6)alkylenyl-NH-*,4- to 6-membered heterocycloalkylenyl-(C1C6)4- to 6-membered alkylenylheterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, -4- to 6-membered alkylenyl-(C1-C6)alkylenylheterocycloalkylenylNH-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-heterocycloalkylenyl-N-((C1C6)alkyl)-*, 4- to 6-membered -(C1-C6)alkylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-*, and the link marked with an * is fixed to Y; and given that the 4- to 6-membered heterocycloalkylenyl group is piperidine or piperazine.
[0060] In some forms, this descriptive report refers to formulas (IA), (II) and (III), where L is Petition 870260111673, dated 10 / 29 / 2026, p. 34 / 831 30 / 375 Petition 870260111673, dated 10 / 29 / 2026, p. 35 / 831 31 / 375 or Z
[0061] In some forms, this descriptive report refers to formulas (IA), (II) and (III), where L is Me Petition 870260111673, dated 10 / 29 / 2026, p. 36 / 831 32 / 375 , or Z,
[0062] In some forms, this descriptive report refers to formulas (IA), (II) and (III), where L is Petition 870260111673, dated 10 / 29 / 2026, p. 37 / 831 33 / 375
[0063] In some forms, this descriptive report refers to formulas (IA), (II) and (III), where Z is Petition 870260111673, dated 10 / 29 / 2026, p. 38 / 831 34 / 375
[0064] In some forms, this descriptive report refers to formulas (IA), (II) and (III), where Z is Petition 870260111673, dated 10 / 29 / 2026, p. 39 / 831 35 / 375
[0065] In some forms, this descriptive report refers to formulas (IA), (II) and (III), where Z is
[0066] In some forms, this descriptive report refers to formulas (IA), (II) and (III), where Z is
[0067] In some embodiments, this descriptive report refers to formulas (IA), (II) and (III), where W is CH2. In other embodiments, W is N.
[0068] In some embodiments, this descriptive report refers to compounds of formula (II) or pharmaceutically acceptable salts thereof: Petition 870260111673, dated 10 / 29 / 2026, p. 40 / 831 36 / 375 (II) where: X is R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O), CH2, CH-2CH2 or -CH2C(O)NMe-, where N is attached to the carbon of the ring; L is: Petition 870260111673, dated 10 / 29 / 2026, p. 41 / 831 37 / 375 Petition 870260111673, dated 10 / 29 / 2026, p. 42 / 831 38 / 375 , or and W is CH or N.
[0069] In some embodiments, this descriptive report refers to compounds of formula (II) or pharmaceutically acceptable salts thereof: given that: Petition 870260111673, dated 10 / 29 / 2026, p. 43 / 831 39 / 375 R20 R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, where -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O), CH2 or CH-2CH2; L is: Petition 870260111673, dated 10 / 29 / 2026, p. 44 / 831 40 / 375 Me ; and W is CH or N.
[0070] In some forms, this descriptive report refers to formulas (I), (II) and (III), where X is
[0071] In some forms, this descriptive report refers to formulas (I), (II) and (III), where X is and R2 is (C3-C6)cycloalkyl. In some embodiments, R2 is cyclobutyl or cyclopropyl. In some embodiments, R2 is cyclopropyl.
[0072] In some embodiments, the term alkyl may be interchangeable with the term alkylenyl, as both terms must have a divalent form of an alkyl group. In some embodiments, this descriptive report refers to formulas (I), (II) and (III), wherein R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O(C1-C6)alkyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents Petition 870260111673, dated 10 / 29 / 2026, p. 45 / 831 41 / 375 independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy. In some embodiments, this descriptive report refers to formulas (I), (II) and (III), wherein R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkyl-O(C1-C6)alkyl are optionally substituted one, two or three times by fluorine. In some embodiments, R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylO-(C1-C6)alkyl. In some embodiments, R1 is -O-(C1-C6)alkyl. In some embodiments, R1 is -OCH2CH2CH3, -OCH2CH3, and -OCH3. In some embodiments, R1 is -OCH3.In some embodiments, this descriptive report refers to formulas (I), (II) and (III), wherein R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy. In some embodiments, this descriptive report refers to formulas (I), (II) and (III), wherein R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted one, two or three times by fluorine. In some embodiments, R1 is -O-(C1-C6)alkyl, -O-(C3C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl. In some embodiments, R1 is -O-(C1-C6)alkyl. In some forms, R1 is -OCH2CH2CH3, -OCH2CH3, and OCH3.In some disciplines, R1 is -OCH3.
[0073] In some embodiments, this descriptive report refers to formulas (I), (II) and (III), wherein Y is a direct bond, C(O) or CH2. In some embodiments, Y is a direct bond. In other embodiments, Y is C(O). In still other embodiments, Y is CH2.
[0074] In some embodiments, the descriptive report refers to formulas (I), (II) and (III), wherein L is a 4- to 6-membered heterocycloalkylenyl-*; 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, 4 to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, 4 to 6-membered heterocycloalkylenyl-4 to 6-membered heterocycloalkylenyl-*, -(C1-C6)alkylenylheterocycloalkylenyl 4 to 6 members-NH-*, -(C1-C6)alkylenylheterocycloalkylenyl 4 to 6 members-N-((C1-C6)alkyl)-*, -(C1-C6)alkylenylheterocycloalkylenyl 4 to 6 members-(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenylheterocycloalkylenyl from 4 to 6 Petition 870260111673, dated 10 / 29 / 2026, page 46 / 831 42 / 375 members-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylheterocycloalkylenyl-*, 4 to 6-membered heterocycloalkylenyl-(C1-C6)4 to 6-membered alkylheterocycloalkylenyl -(C1-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(C1C6)4- to 6-membered alkylenylheterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, 4- to 6-membered-alkylenylenyl-(C1-C6)alkylenyl-heterocycloalkylenyl membersNH-*, - alkynylenyl-(C1-C6)alkylenyl-heterocycloalkylenyl 4 to 6 members-N-((C1C6)alkyl)-*, -alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-* 4 to 6 members, wherein the linkage marked with an * is attached to Y; and wherein the 4 to 6 member heterocycloalkylenyl is piperidine or piperazine.
[0075] In some forms, this descriptive report refers to formulas (I), (II) and (III), where L is Petition 870260111673, dated 10 / 29 / 2026, p. 47 / 831 43 / 375 or
[0076] In some forms, this descriptive report refers to formulas (I), (II) and (III), where L is
[0077] In some forms, this descriptive report refers to formulas (I), (II) and (III), where L is Petition 870260111673, dated 10 / 29 / 2026, p. 48 / 831 44 / 375 z or
[0078] In some forms, this descriptive report refers to formulas (I), (II) and (III), where L is Petition 870260111673, dated 10 / 29 / 2026, p. 49 / 831 45 / 375
[0079] In some forms, this descriptive report refers to formulas (I), (II) and (III), where L is
[0080] In some forms, this descriptive report refers to formulas (I), (II) and (III), where L is Petition 870260111673, dated 10 / 29 / 2026, p. 50 / 831 46 / 375 Me or
[0081] In some embodiments, the term alkyl may be interchangeable with the term alkylenyl, as both terms are intended to have a divalent form of an alkyl group. In some embodiments, the term 4- to 6-membered heterocycloalkyl may be interchangeable with the term 4- to 6-membered heterocycloalkylenyl, as both terms are intended to have a divalent form of the heterocycloalkyl group. In some embodiments, the term alkynyl may be interchangeable with the term alkynylenyl, as both terms are intended to have a divalent form of an alkynyl group.
[0082] In some forms, this descriptive report refers to formulas (I), (II) and (III), since L is a 4-to-6-membered heterocycloalkyl-(C1-C6)alkyl-NH-*, a 4-to-6-membered heterocycloalkyl-(C1-C6)alkyl-N-(C1-C6)alkyl-*, a 4-to-6-membered heterocycloalkyl-4-to-6-membered heterocycloalkyl-*, -(C1-C6)alkyl-4-to-6-membered heterocycloalkyl-NH-Y, -(C1-C6)alkyl-4-to-6-membered heterocycloalkyl-N-(C1-C6)alkyl-*, -(C1-C6)alkyl-4-to-6-membered heterocycloalkyl-(C1-C6)alkyl-NH-*, -(C1-C6)4- to 6-membered alkyl-heterocycloalkyl-(C1C6)alkyl-N(C1-C6)alkyl-*, 4- to 6-membered heterocycloalkyl-(C1-C6)4- to 6-membered alkyl-heterocycloalkyl-*, 4- to 6-membered heterocycloalkyl-(C1C6)4- to 6-membered alkyl-heterocycloalkyl-(C1-C6)alkyl-NH-*, 4- to 6-membered heterocycloalkyl-(C1-C6)4- to 6-membered alkyl-heterocycloalkyl-(C1-C6)alkyl-N(C1-C6)alkyl-*, -4- to 6-membered alkynyl-(C1-C6)alkyl-heterocycloalkyl-NH-*, Petition 870260111673, dated 10 / 29 / 2026, p. 51 / 831 47 / 375 4- to 6-membered alkynyl-(C1-C6)alkyl-heterocycloalkyl-N-(C1-C6)alkyl-*, 4- to 6-membered alkynyl(C1-C6)alkyl-O-heterocycloalkyl-*, and the linkage marked with an * is attached to Y, where the 4- to 6-membered heterocycloalkyl is piperidine or piperazine.
[0083] In some forms, this descriptive report refers to formulas (I), (II) and (III), where L is
[0084] In some modalities, L is Petition 870260111673, dated 10 / 29 / 2026, p. 52 / 831 48 / 375 or,
[0085] In some modalities, L is
[0086] In some forms, this descriptive report refers to formulas (I), (II) and (III), where Z is Petition 870260111673, dated 10 / 29 / 2026, p. 53 / 831 49 / 375
[0087] In some forms, this descriptive report refers to formulas (I), (II) and (III), where Z is
[0088] In some forms, this descriptive report refers to formulas (I), (II) and (III), where Z is
[0089] In some forms, this descriptive report refers to formulas (I), (II) and (III), where Z is Petition 870260111673, dated 10 / 29 / 2026, p. 54 / 831 50 / 375
[0090] In some embodiments, this descriptive report refers to formulas (I), (II) and (III), where W is CH2. In other embodiments, W is N.
[0091] In some embodiments, this descriptive report refers to compounds of formula (II) or pharmaceutically acceptable salts thereof: given that: R1 is -O-(C1-Ce)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-Ce)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O), CH2 or CH-2CH2; Petition 870260111673, dated 10 / 29 / 2026, p. 55 / 831 51 / 375 Me Z' THE' L is: z N % 5 / 0 Me, Petition 870260111673, dated 10 / 29 / 2026, p. 56 / 831 52 / 375 and W is CH or N.
[0092] In some embodiments, this descriptive report refers to compounds of formula (II) or pharmaceutically acceptable salts thereof: given that: X is R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1C6)alkyl. (Reference 870260111673, 29 / 10 / 2026, p. 57 / 831) 53 / 375 (C1-C6)alkyl groups are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy groups; R2 is (C3-C6)cycloalkyl; Y is direct bond, C(O) or CH2; L is: Me zX 0 zX / y , . s ΛΛ z—N—' Z—bN N— , L Á >Y 1 Me , Z \ — III ύ Z % H , FnY zr / \ / °\ AX 1 7Y Me z H , , / —NH / \ \ Z-^-NN—( N-^-Y , , 1 νγ ζ-Ύ'Ζ'Χ Me Me , , ^1 / Z'X Me Me , , Ν—^-Υ Ζ——( Ν-^-Υ ' or \— / ; O 1· ^ > '-ΥΊ •ΖΖ ^w* O , , WZ X 0Z-^Xf 'L; Petition 870260111673, dated 10 / 29 / 2026, p. 58 / 831 54 / 375
[0093] In some embodiments, this descriptive report refers to compounds of formula (II) or pharmaceutically acceptable salts thereof: given that: X is R1 is -O-(C1-Ce)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-Ce)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; L is: Petition 870260111673, dated 10 / 29 / 2026, p. 59 / 831 55 / 375 Z is and W is CH.
[0094] In some embodiments, this descriptive report refers to compounds of formula (II) or pharmaceutically acceptable salts thereof: given that: or Petition 870260111673, dated 10 / 29 / 2026, p. 60 / 831 56 / 375 R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, where -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; L is: and W is CH.
[0095] In some embodiments, the term alkyl may be interchangeable with the term alkylenyl, as both terms must have a divalent form of an alkyl group. In some embodiments, the term 4 to 6 heterocycloalkyl Petition 870260111673, dated 10 / 29 / 2026, p. 61 / 831 The term 57 / 375 members can be interchangeable with the term 4- to 6-membered heterocycloalkylenyl, since both terms are intended to have a divalent form of the heterocycloalkyl group. In some embodiments, the term alkynyl can be interchangeable with the term alkynylenyl, since both terms are intended to have a divalent form of an alkynyl group.
[0096] In some embodiments, this descriptive report refers to compounds of formula (II) or pharmaceutically acceptable salts thereof: given that: X is r—N f K ' or R1 is -O-(C1-Ce)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-Ce)alkyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkyl-O(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; L is: Petition 870260111673, dated 10 / 29 / 2026, p. 62 / 831 58 / 375 or and W is CH. Me
[0097] In some embodiments, this descriptive report refers to compounds of formula (III) or pharmaceutically acceptable salts thereof: (III) where: Petition 870260111673, dated 10 / 29 / 2026, p. 63 / 831 59 / 375 ; R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; L is: Z is Petition 870260111673, dated 10 / 29 / 2026, p. 64 / 831 60 / 375 and W is CH or N.
[0098] In some embodiments, this descriptive report refers to compounds of formula (III) or pharmaceutically acceptable salts thereof: (III) where: X is R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; Petition 870260111673, dated 10 / 29 / 2026, p. 65 / 831 61 / 375 L is: Z is and W is CH.
[0099] In some embodiments, this descriptive report refers to compounds of formula (III) or pharmaceutically acceptable salts thereof: Petition 870260111673, dated 10 / 29 / 2026, p. 66 / 831 62 / 375 (III) where: R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl, where -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; L is: Petition 870260111673, dated 10 / 29 / 2026, p. 67 / 831 63 / 375 Z is and W is CH.
[0100] In some embodiments, the term alkyl may be interchangeable with the term alkylenyl, as both terms are intended to have a divalent form of an alkyl group. In some embodiments, the term 4- to 6-membered heterocycloalkyl may be interchangeable with the term 4- to 6-membered heterocycloalkylenyl, as both terms are intended to have a divalent form of the heterocycloalkyl group. In some embodiments, the term alkynyl may be interchangeable with the term alkynylenyl, as both terms are intended to have a divalent form of an alkynyl group.
[0101] In some embodiments, this descriptive report refers to compounds of formula (III) or pharmaceutically acceptable salts thereof: (III) where: Petition 870260111673, dated 10 / 29 / 2026, p. 68 / 831 64 / 375 or The R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkyl-O-(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkyl-O(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 is (C3-C6)cycloalkyl; Y is a direct bond, C(O) or CH2; L is: or and W is CH. Petition 870260111673, dated 10 / 29 / 2026, p. 69 / 831 65 / 375 The specific compounds described in this report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamide - Isomer 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; Petition 870260111673, 29 / 10 / 2026, pág. 70 / 831 66 / 375 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-il)propoxy) )propil)(metil)amino)ciclo-hexil)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamida -Isômero 4; 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 1; 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 2; Petition 870260111673, on 10 / 29 / 2026, page. 71 / 831 67 / 375 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)piperazin-1il)etil)amino)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamide - Isômero 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida - Isomer 2; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)pipendin-1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomere 1; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)pipendin-1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomere 2; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-5-yl)piperazine-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methyl-2-toxyl-H-H-incarzone; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)pipendine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxi)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 72 / 831 68 / 375 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; And N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamide; 2-((1 r,4 r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2 H)-yl)-1 H-indol-1 yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; 2-((1 r,4 r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)cyclohexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamida; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopipendin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6methoxy-2 H-indazol-5-carboxamide; 2-((1 r,4 r)-4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazine-1-carbonyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 Hindazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,4dioxotetra-hidropyridin-1 (2H)-yl)-1 H-indol-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-6methoxy-2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)-1 H-indol-1 -yl)piperidin-1 yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,6dioxopiperidin-3-yl)-1 H-indol-1-yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol5-carboxamide; Petition 870260111673, 29 / 10 / 2026, pág. 73 / 831 69 / 375 6-cyclopropoxy-2-((1r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1(2H)-yl)1H-indol-1-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-2-methyl-1 Hindol-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1r,4r)-4-((4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-3-metil-1 Hindol-1 -il)piperidin-1 -il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 2-((1r,4r)-4-((4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1 H-indol-1 -il)[1,4'-bipiperidin]-1'-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 2-((1r,4r)-4-(4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1H-indol-1 -il)[1,4'-bipipendina]-T-carbonil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 2-((1r,4r)-4-((4-((4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1 H-indol-1 il)metil)piperidin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 2-((1r,4r)-4-(2-(4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1 il)piperidin-1-il)etil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida; N-(1-ciclopropil-2-oxo-1,2-di-hydropiridin-3-il)-2-((1 r,4r)-4-(2-(4-(4-(2,4dioxotetra-hydropirimidin-1(2H)-il)-1H-indol-1-il)piperidin-1-il)etil)ciclo-hexil)-6-metoxi2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-((4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1 il)piperidin-1-il)metil)piperidin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6metoxi-2H-indazol-5-carboxamida; 2-((1r,4r)-4-(4-((4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1 il)piperidin-1-il)methyl)piperidina-1-carbonil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)6-metoxi-2H-indazol-5-carboxamida; Petition 870260111673, on 10 / 29 / 2026, page. 74 / 831 70 / 375 2-(4-((4-(2-(4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1il)pipendin-1-il)etil)pipendin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]pindazin-3-il)-6metoxi-2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(2-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 yl)ethyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 6-cyclopropoxy-2-(1 -(2-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 Hindol-1-yl)piperidin-1-yl)acetyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2H-indazol5-carboxamida; 6-cyclopropoxy-2-(1 -(2-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 Hindol-1 -yl)piperidin-1 -yl)-2-oxoethyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 6-cyclopropoxy-2-(1 -(2-(4-((4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 Hindol-1-yl)methyl)piperidin-1-yl)acetyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(6-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindol-2-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-1 H-indol-4-yl)piperazin1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; 2-((1r,4r)-4-((4-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)-3fluorophenyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamide; and N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-((2,6dioxopiperidin-3-yl)carbamoyl)-3-fluorophenyl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamide; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-5-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 75 / 831 71 / 375 N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperidin-1yl)methyl)cyclo-hexyl)-6-methoxi-2H-indazol-5-carboxamida 6-cyclopropoxy-2-((1r,4r)-4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo2,3-di-hidro-1 H-benzo[d]pyridazin-5-yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-2H-indazol-5-carboxamide; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]pyridazin-4-yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazine-3-yl)6-methoxy-2H-indazol-5-carboxamida; 6-cyclopropoxy-2-((1r,4r)-4-((4-(1-(2,6-dioxopipendin-3-yl)-3-methyl-2-oxo2,3-di-hidro-1 H-benzo[d]pyridazin-4-yl)piperazin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-2H-indazol-5-carboxamide; 2-((1 r,4r)-4-((4-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-((1 -(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-3methylphenyl)pipendin-4-yl)methyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazine-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-((1 -(4-(2,4dioxotetra-hidropinmidin-1(2H)-yl)-3-methylphenyl)pipendin-4-yl)methyl)piperazin-1yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(6-(2,4dioxotetra-hidropyrimidin-1(2H)-yl)-1-methyl-1H-indol-2-yl)piperidin-1-yl)methyl)cyclo-hexyl)6-methoxy-2H-indazol-5-carboxamide; 6-cyclopropoxy-2-((1r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,6dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 76 / 831 72 / 375 2-((1r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)-3-methylphenyl)piperazin-1yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,6dioxopiperidin-3-yl)-3-methylphenyl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5carboxamida; 2-((1r,4r)-4-((4-(4-(4-(2,6-dioxopipendin-3-yl)phenyl)piperazin-1-yl)pipendin1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; 2-((1r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)-3-methoxyphenyl)piperazin-1yl)methyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide; 2-((1r,4r)-4-(2-(4-(4-(2,6-dioxopiperidin-3-yl)fenil)piperazin-1-yl)ethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -ciclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-(2-(4-(4-(2,6dioxopiperidin-3-yl)fenil)piperazin-1-yl)ethyl)ciclo-hexyl)-6-methoxy-2H-indazol-5-carboxamide; 2-((1r,4r)-4-((4-(6-(2,6-dioxopipendin-3-yl)pindin-3-yl)piperazin-1yl)metil)ciclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; 2-((1r,4r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)piperazin1-yl)methyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1r,4r)-4-((4-((1-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5yl)piperidin-4-yl)methyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamide; Petition 870260111673, 29 / 10 / 2026, pág. 77 / 831 73 / 375 2-((1r,4r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-7-methoxy-1-oxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-7-methoxy-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6methoxy-2H-indazol-5-carboxamide; 2-((1 r,4r)-4-((4-(3-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindazol-7-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(3-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindazol-7-yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida; 2-((1 r,4r)-4-(2-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 il)piperidin-1-yl)-N-methylacetamido)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(2-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 yl)acetyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 il)cyclo-hexyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomer 1; 2-((1 r,4r)-4-((4-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 il)cyclo-hexyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomer 2; 6-cyclopropoxy-2-(1 -(((1 r,4r)-4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)1 H-indol-1-yl)cyclo-hexyl)methyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-1 H-indazol-4yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol5-carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 78 / 831 74 / 375 6-ciclopropoxy-2-((1r,4r)-4-((4-(1-(2,6-dioxopiperidin-3-il)-3-metil-1) Hindazol-4-il)piperazin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-2H-indazol5-carboxamida; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-il)-3-metil-1 H-indazol-5il)piperazin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol5-carboxamida; 2-((1r,4r)-4-((4-(1-(2,6-dioxopiperidin-3-il)-3-methyl-1 H-indazol-4-il)-1 Hpirazol-1-il)methyl)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida; 2-((1r,4r)-4-((4-(4-(2,4-dioxotetra-hydropirimidin-1(2H)-il)isoquinolin-8il)piperazin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol5-carboxamida; 2-((1r,4r)-4-((4-(3-(2,6-dioxopiperidin-3-il)-2-oxo-2,3-dihidrobenzo[d]oxazol-7-il)piperazi n-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3il)-6-metoxi-2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(1 '-(2,6-dioxopiperidin-3-yl)-2'-oxospiro[cyclopropane-1,3'indolin]-5'-yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(7-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindol-3-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(3-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)imidazo[1,5a]pyridin-8-yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(3-(2,4dioxotetra-hidropyrimidin-1(2H)-yl)benzo[d]isoxazol-6-yl)piperazin-1-yl)methyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1 s,4s)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol5-carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 79 / 831 75 / 375 2-((1 s,4s)-4-((4-(6-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindol-2-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; you know it pharmaceutically aceitáveis dos mesmos. The specific compositions of this descriptive report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-il)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-il)methyl)piperidin-4-il)etil)(methyl)amino)ciclo-hexyl)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamide - Isômero 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-il)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-il)methyl)piperidin-4-il)etil)(methyl)amino)ciclo-hexyl)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamide - Isômero 2; Petition 870260111673, on 10 / 29 / 2026, page. 80 / 831 76 / 375 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-il)propil)piperidin-4-il)(metil)amino)ciclo-hexil)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamida - Isômero 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-il)propoxy) )propil)(metil)amino)ciclo-hexil)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamida -Isômero 4; Petition 870260111673, on 10 / 29 / 2026, page. 81 / 831 77 / 375 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 1; 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 2; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)piperazin-1il)etil)amino)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamide - Isômero 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida - Isomer 2; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)pipendin-1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomere 1; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperazin-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)pipendine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; Petition 870260111673, of 29 / 10 / 2026, p. 82 / 831 78 / 375 N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxi)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; And N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamide; 2-((1 r,4 r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2 H)-yl)-1 H-indol-1 yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; 2-((1 r,4 r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)cyclohexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamida; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopipendin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6methoxy-2 H-indazol-5-carboxamide; 2-((1 r,4 r)-4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazine-1-carbonyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 Hindazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,4dioxotetra-hidropyridin-1(2H)-yl)-1H-indol-1-yl)piperidin-1-yl)methyl)cyclo-hexyl)-6methoxy-2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)-1 H-indol-1 -yl)piperidin-1 yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 83 / 831 79 / 375 N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,6dioxopiperidin-3-yl)-1 H-indol-1-yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol5-carboxamide; 6-cyclopropoxy-2-((1r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1(2H)-yl)1H-indol-1-yl)pipendin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-2-methyl-1 Hindol-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-3-methyl-1 Hindol-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1r,4r)-4-((4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1 H-indol-1 -il)[1,4'-bipiperidin]-1'-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 2-((1r,4r)-4-(4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1H-indol-1 -il)[1,4'-bipiperidina]-1'-carbonil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 2-((1r,4r)-4-((4-((4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1 H-indol-1 il)metil)piperidin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 2-((1r,4r)-4-(2-(4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1 il)piperidin-1-il)etil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida; N-(1-ciclopropil-2-oxo-1,2-di-hydropiridin-3-il)-2-((1 r,4r)-4-(2-(4-(4-(2,4dioxotetra-hydropirimidin-1(2H)-il)-1H-indol-1-il)piperidin-1-il)etil)ciclo-hexil)-6-metoxi2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-((4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1 il)piperidin-1-il)metil)piperidin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6metoxi-2H-indazol-5-carboxamida; Petition 870260111673, on 10 / 29 / 2026, page. 84 / 831 80 / 375 2-((1r,4r)-4-(4-((4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1 H-indol-1 il)pipendin-1-il)metil)pipendina-1-carbonil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)6-metoxi-2H-indazol-5-carboxamida; 2-(4-((4-(2-(4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1 H-indol-1il)pipendin-1-il)etil)pipendin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6metoxi-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-(2-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1 il)etil)piperazin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 6-cyclopropoxy-2-(1 -(2-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 Hindol-1-yl)piperidin-1-yl)acetyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2H-indazol5-carboxamida; 6-cyclopropoxy-2-(1 -(2-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 Hindol-1 -yl)piperidin-1 -yl)-2-oxoethyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 6-cyclopropoxy-2-(1 -(2-(4-((4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 Hindol-1-yl)methyl)piperidin-1-yl)acetyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(6-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindol-2-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-1 H-indol-4-yl)piperazin1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; 2-((1r,4r)-4-((4-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)-3fluorophenyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamide; and N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-((2,6dioxopiperidin-3-yl)carbamoyl)-3-fluorophenyl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamide; you know it pharmaceutically aceitáveis dos mesmos. Petition 870260111673, 29 / 10 / 2026, pág. 85 / 831 81 / 375 The specific compositions of this descriptive report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; Petition 870260111673, 29 / 10 / 2026, pág. 86 / 831 82 / 375 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-il)propoxy) )propil)(metil)amino)ciclo-hexil)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamida -Isômero 4; 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 1; 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 2; Petition 870260111673, on 10 / 29 / 2026, page. 87 / 831 83 / 375 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)piperazin-1il)etil)amino)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamide - Isômero 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida - Isomer 2; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)piperides n-1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxi2H-indazol-5-carboxamida - Isomer 1; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperazin-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazole-4 -yl)prop-2-in-1yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazole-5-carboxamide; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-carboxy; in Petition 870260111673, of 29 / 10 / 2026, p. 88 / 831 84 / 375 N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl-6-6- H-indazole-5-carboxamide; 2-((1 r,4 r)-4-((4-(4-(2,4-dioxotetra-hydropyrimidine-1 (2 H)-yl)-1 H-indol-1 yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazine-3-methoxy-6-2 H-indazole5-carboxamide; 2-((1 r,4 r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)ciclohexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamide; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6methoxy-2 H-indazol-5-carboxamide; and 2-((1 r,4 r)-4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazine-1-carbonyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 Hindazol-5-carboxamida; you know it pharmaceutically aceitáveis dos mesmos. The specific compositions of this descriptive report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; Petition 870260111673, 29 / 10 / 2026, pág. 89 / 831 85 / 375 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; Petition 870260111673, 29 / 10 / 2026, pág. 90 / 831 86 / 375 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 4; 2-(4-((2-((2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5carboxamide - Isomer 1; 2-(4-((2-((2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5carboxamide - Isomer 2; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)ciclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)ciclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 2; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)piperidin -1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomer 1; Petition 870260111673, 29 / 10 / 2026, pág. 91 / 831 87 / 375 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperazin-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazole-4 -yl)prop-2-in-1yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazole-5-carboxamide; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-carboxy; and N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamide; 2-((1 r,4 r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2 H)-yl)-1 H-indol-1 yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; And 2-((1 r,4 r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)cyclohexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamida; you know it pharmaceutically aceitáveis dos mesmos. Petition 870260111673, 29 / 10 / 2026, pág. 92 / 831 88 / 375 The specific compositions of this descriptive report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; Petition 870260111673, 29 / 10 / 2026, pág. 93 / 831 89 / 375 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-il)propoxy) )propil)(metil)amino)ciclo-hexil)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamida -Isômero 4; 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 1; 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 2; Petition 870260111673, on 10 / 29 / 2026, page. 94 / 831 90 / 375 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)piperazin-1il)etil)amino)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamide - Isômero 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida - Isomer 2; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)piperides n-1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxi2H-indazol-5-carboxamida - Isomer 1; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperazin-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazole-4 -yl)prop-2-in-1yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazole-5-carboxamide; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; And Petition 870260111673, 29 / 10 / 2026, pág. 95 / 831 91 / 375 N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2 H-indazol-5-carboxamide; you know it pharmaceutically aceitáveis dos mesmos.
[0102] The specific compositions of this descriptive report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; Petition 870260111673, 29 / 10 / 2026, pág. 96 / 831 92 / 375 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-il)propoxy) )propil)(metil)amino)ciclo-hexil)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamida -Isômero 4; Petition 870260111673, on 10 / 29 / 2026, page. 97 / 831 93 / 375 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 1; 2-(4-((2-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5il)oxi)etil)amino)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamida - Isômero 2; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)piperazin-1il)etil)amino)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5carboxamide - Isômero 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida - Isomer 2; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)pipendin-1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomere 1; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperazin-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)pipendine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; and Petition 870260111673, of 29 / 10 / 2026, p. 98 / 831 94 / 375 N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxi)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; you know it pharmaceutically aceitáveis dos mesmos. Specific compositions added to this descriptive report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)propoxy )propyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 3; Petition 870260111673, 29 / 10 / 2026, pág. 99 / 831 95 / 375 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)propoxy )propyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 4; 2-(4-((2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl)oxi)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxi-2H-indazol-5carboxamida - Isomer 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida - Isomer 1; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)pipendin-1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomere 1; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperazin-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)pipendine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazole-4 -yl)prop-2-in-1yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazole-5-carboxamide; Petition 870260111673, dated 10 / 29 / 2026, p. 100 / 831 96 / 375 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazine-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazine-3-yndazoxyl)--2-6-methoxy N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridine-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidine-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamide; 2-((1 r,4 r)-4-((4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2 H)-yl)-1 H-indol-1 il)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazine-5-amidazine-carboxyl-methol-yl) and 2-((1 r,4 r)-4-((4-(4-(2,6-dioxopiperidine-3-yl)phenyl)piperazine-1-yl)methyl)cyclohexyl)-N-(imidazo[1,2-b ]pyridazine-3-yl)-6-methoxy-2 H-indazol-yl-yl) or you know pharmaceutically accept two same. Specific compounds I added from this descriptive report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; Petition 870260111673, 29 / 10 / 2026, pág. 101 / 831 97 / 375 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)propoxy )propyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 4; 2-(4-((2-((2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5carboxamide - Isomer 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)ciclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 1; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)piperidin-1-yl)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazole-5-carboxamide - Isomer 1; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-5-yl)piperazin-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methyl-2-tox-amyl-H-incarzone; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; Petition 870260111673, of 29 / 10 / 2026, p. 102 / 831 98 / 375 N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazole-4 -yl)prop-2-in-1yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazole-5-carboxamide; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-carboxy; and N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamide; you know it pharmaceutically aceitáveis dos mesmos. Specific compositions added to this descriptive report include: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; Petition 870260111673, 29 / 10 / 2026, pág. 103 / 831 99 / 375 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 4; 2-(4-((2-((2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5carboxamide - Isomer 1; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida - Isomer 1; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)methyl)piperidin -1-yl)ethyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomer 1; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperazin-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 104 / 831 100 / 375 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; and N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazole-4 -yl)prop-2-in-1yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazole-5-carboxamide; or pharmaceutically acceptable salts thereof.
[0103] In one embodiment, this descriptive report refers to a compound that is 2-((1r,4r)-4-((4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-yl)piperidin-1-yl)methyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide or a pharmaceutically acceptable salt thereof.
[0104] In one embodiment, this descriptive report refers to a compound that is 2-((1r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)cyclohexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; Petition 870260111673, dated 10 / 29 / 2026, p. 105 / 831 101 / 375 or a pharmaceutically acceptable salt thereof.
[0105] In one embodiment, this specification refers to a compound that is 2-((1r,4r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1yl)methyl)cyclohexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5carboxamide or a pharmaceutically acceptable salt thereof.
[0106] In another embodiment, this descriptive report refers to a compound that is N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide Petition 870260111673, dated 10 / 29 / 2026, p. 106 / 831 102 / 375 or a pharmaceutically acceptable salt thereof.
[0107] In another embodiment, this descriptive report refers to a compound that is 2-((1r,4r)-4-(2-(4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)ethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide or a pharmaceutically acceptable salt thereof.
[0108] In another embodiment, this descriptive report refers to a compound that is 2-((1r,4r)-4-(2-(4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-yl)piperidin-1-yl)ethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide or a pharmaceutically acceptable salt thereof.
[0109] In another embodiment, this descriptive report refers to a compound that is N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-(2-(4-(4Petition 870260111673, of 10 / 29 / 2026, page 107 / 831 103 / 375 (2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-yl)piperidin-1-yl)ethyl)cyclohexyl)-6methoxy-2H-indazole-5-carboxamide or a pharmaceutically acceptable salt thereof.
[0110] In another embodiment, this descriptive report refers to a compound that is N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-(2-(4-(4(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)ethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide or a pharmaceutically acceptable salt thereof.
[0111] It should be understood that the references herein are compounds of formula (I), (IA), (II) or (III) or pharmaceutically acceptable salts thereof. Thus, in one embodiment, the descriptive report refers to a compound of formula (I), (IA), (II) or (III). In another embodiment, the descriptive report refers to a pharmaceutically acceptable salt of a compound of formula (I), (IA), (II) or (III). In a further embodiment, the descriptive report refers to a compound of formula (I), (IA), (II) or (III) or a pharmaceutically acceptable salt thereof.
[0112] This descriptive report refers to proteolysis-targeting chimeric compounds (PROTAC) of formulas (I), (IA), (II) and (III) and pharmaceutically acceptable salts thereof.
[0113] Another aspect of this descriptive report refers to a pharmaceutical composition comprising a conjugate of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. This descriptive report refers to a pharmaceutical composition comprising a compound of formula (I) or formula (IA). This descriptive report Petition 870260111673, dated 10 / 29 / 2026, p. 108 / 831 104 / 375 refers to a pharmaceutical composition comprising a compound of formula (I) or formula (IA), or a pharmaceutically acceptable salt thereof.
[0114] This descriptive report refers to a pharmaceutical composition comprising a conjugate of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
[0115] This descriptive report refers to a method of degrading IRAK4 in a human being comprising administering to a human being in need thereof an effective amount of a compound of formula (I), (IA), (II), (III) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), (IA), (II) or (III).
[0116] This descriptive report refers to a method of degrading IRAK4 in a human being comprising administering to a human being in need thereof an effective amount of a compound of formula (I), (IA), (II), (III) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof.
[0117] This descriptive report also refers to the method of reducing the level of IRAK4 activity in a human comprising the compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), (IA), (II) or (III).
[0118] This descriptive report refers to a method of treating IRAK4-mediated diseases or disorders in a human being comprising administering to the human being in need thereof a therapeutically effective amount of a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), (IA), (II) or (III).
[0119] Another aspect of this descriptive report refers to a method of treating IRAK-4-mediated diseases or disorders in a human being comprising administering to the human being in need thereof a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt of Petition 870260111673, dated 10 / 29 / 2026, page 109 / 831 105 / 375 same, where the disease or disorder is a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder, and / or cancer.
[0120] Another aspect of this descriptive report refers to a method of treating diseases or disorders in a human that comprises administering to the human in need thereof a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder and / or a cancer.
[0121] This descriptive report refers to a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, for use in therapy.
[0122] Another aspect of this descriptive report refers to a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, for use in the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder and / or cancer.
[0123] Another aspect of this descriptive report refers to a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder or cancer.
[0124] Another aspect of this descriptive report relates to a method of treating an IRAK4-mediated disease or disorder in a human being in need thereof comprising administering to the human being a therapeutically effective amount of a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0125] One aspect of this descriptive report relates to a method of degrading IRAK4 in a human being comprising administering to a human being in need thereof an effective amount of a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, or a Petition 870260111673, dated 10 / 29 / 2026, p. 110 / 831 106 / 375 pharmaceutical composition comprising a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0126] Another aspect of this descriptive report refers to a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, for use in the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder and / or cancer.
[0127] Another aspect of this descriptive report refers to a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder or cancer.
[0128] Another aspect of this descriptive report relates to the method of reducing the level of IRAK4 activity in a human being comprising administering to a human being in need thereof an effective amount of a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0129] Another aspect of this descriptive report refers to a method of treating inflammatory and autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, inflammatory bowel disease, atopic dermatitis, hidradenitis suppurativa and psoriasis, respiratory diseases and cancer.
[0130] Another aspect of this descriptive report refers to a method of treatment for systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, inflammatory bowel disease, atopic dermatitis, hidradenitis suppurativa and psoriasis.
[0131] In another aspect, the use of a conjugate of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an IRAK4-mediated disease or disorder is provided. In another aspect, the use of a conjugate of formula (I), (IA), Petition 870260111673, dated 10 / 29 / 2026, page 111 / 831 107 / 375 (II) or (III), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease and / or cancer. In another aspect, the use of a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an inflammatory disease or disorder is provided. In another aspect, the use of a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a respiratory disease or disorder is provided. In another aspect, the use of a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an autoimmune disease or disorder is provided.In another aspect, the use of a compound of formula (I), (IA), (II) or (III), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer is provided. Another aspect of this descriptive report refers to a method of treating inflammatory and autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, inflammatory bowel disease, atopic dermatitis, hidradenitis suppurativa and psoriasis, respiratory diseases and cancer. Another aspect of this descriptive report refers to a method of treating systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, inflammatory bowel disease, atopic dermatitis, hidradenitis suppurativa and / or psoriasis.Another aspect of this descriptive report refers to a treatment method for systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, inflammatory bowel disease, atopic dermatitis, hidradenitis suppurativa, and psoriasis.
[0132] Due to its potential use in medicine, it will be recognized that a salt of a compound of formulas (I) to (III) or of formula (IA) is pharmaceutically acceptable.
[0133] Pharmaceutically acceptable salts include, among others, those described in Berge, J. Pharm. Sci., 66, 1 to 19, (1977) or those mentioned in PH Stahl and CG Wermuth, editors, Handbook of Pharmaceutical Salts; Properties, Petition 870260111673, dated 10 / 29 / 2026, page 112 / 831 108 / 375 Selection and Use, Second Edition Stahi / Wermuth: Wiley-VCH / VHCA (2011) (see http: / / www.wiley.com / WileyCDA / WileyTitle / productCd-3906390519.html).
[0134] Suitable pharmaceutically acceptable salts may include acidic or basic addition salts.
[0135] These basic addition salts can be formed by reacting a compound of formulas (I) to (III) or a compound of formula (IA) (which, for example, contains a 1H-tetrazole or other acidic functional group) with the appropriate base, optionally in a suitable solvent, such as an organic solvent, to yield the salt which can be isolated by various methods, including crystallization and filtration.
[0136] These acidic addition salts can be formed by reacting a compound of formulas (I) to (III) or a compound of formula (IA) (which, for example, contains a basic amine or other basic functional group) with the appropriate acid, optionally in a suitable solvent, such as an organic solvent, to yield the salt which can be isolated by various methods, including crystallization and filtration.
[0137] Salts may be prepared locally during the final isolation and purification of a compound of formulas (I) to (III) or of formula (IA). If a basic compound of formulas (I) to (III) or of formula (IA) is isolated as a salt, the corresponding free base form of that compound may be prepared by any suitable method known in the art, including treatment of the salt with an inorganic or organic base. Similarly, if a compound of formulas (I) to (III) or of formula (IA) containing a carboxylic acid or other acidic functional group is isolated as a salt, the corresponding free acid form of that compound may be prepared by any suitable method known in the art, including treatment of the salt with an inorganic or organic acid.
[0138] It will be understood that if a compound of formulas (I) to (III) or of formula (IA) contains two or more basic moieties, the salt-forming stoichiometry may include 1, 2 or more acid equivalents. These salts would contain 1, 2 or more acidic counterions, for example, a dichloride salt.
[0139] The stoichiometric and non-stoichiometric forms of a pharmaceutically acceptable salt of a compound of formulas (I) to (III) or of formula (IA) are included in the scope of the descriptive report, including salts Petition 870260111673, dated 10 / 29 / 2026, p. 113 / 831 109 / 375 substoichiometric, for example, in which a counterion contains more than one acidic proton.
[0140] Representative pharmaceutically acceptable acidic addition salts include, but are not limited to, 4-acetamidobenzoate, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate (besylate), benzoate, bisulfate, bitartrate, butyrate, calcium edetate, camphorate, camphorsulfonate (cansylate), caprate (decanoate), caproate (hexanoate), caprylate (octanoate), cinnamate, citrate, cyclamate, digluconate, 2,5-dihydroxybenzoate, disuccinate, dodecyl sulfate (estolate), edetate (ethylenediaminetetraacetate), estolate (lauryl sulfate), ethane-1,2-disulfonate (edisylate), ethanesulfonate (esylate), formate, fumarate, galactarate (mucate), gentisate (2,5-dihydroxybenzoate) lactate, lactobionate, laurate, malate, maleate, malonate,mandelate, methanesulfonate (mesylate), methylsulfate, mucate, naphthalene1,5-dissulfonate (napadisylate), naphthalene-2-sulfonate (napsilate), nicotinate, nitrate, oleate, palmitate, p-aminobenzenesulfonate, p-aminoxacyclate, pamoate (embonate), pantothenate, pectinate, persulfate, phenylacetate, phenylethylbarbiturate, phosphate, polygalacturonate, propionate, p-toluenesulfonate (tosylate), pyroglutamate, pyruvate, salicylate, sebacate, estearate, subacetate, succinate, sulfamate, sulfate, thanate, tartrate, theoclate (8-chlorotheophylinate), thiocyanate, triethiodetox, undecanoate, undecylenate, and valerate.
[0141] Representative pharmaceutically acceptable basic addition salts include, but are not limited to, aluminum, 2-amino-2-(hydroxymethyl)-1,3-propanediol (TRIS), arginine, benetamine (N-benzylphenethylamine), benzathine (N,N'-dibenzylethylenediamine), bis-(2-hydroxyethyl)amine, bismuth, calcium, chloroprocaine, choline, clemizole (1-p-chlorobenzyl-2-pyrrolildine-T-ylmethylbenzimidazole), cyclohexylamine, dibenzylethylenediamine, diethylamine, diethyltriamine, dimethylamine, dimethylethanolamine, dopamine, ethanolamine, ethylenediamine, L-histidine, iron, isoquinoline, lepidine, lithium, lysine, magnesium, meglumine (N-methylglucamine), piperazine, piperidine, potassium, procaine, quinine, quinoline, sodium, strontium, t-butylamine, tromethamine (tris(hydroxymethyl)aminomethane) and zinc. Petition 870260111673, dated 10 / 29 / 2026, page 114 / 831 110 / 375
[0142] The compound of formulas (I) to (III) or of formula (IA) or a salt thereof may exist in stereoisomeric forms (e.g., containing one or more asymmetric carbon atoms). Individual stereoisomers (enantiomers and diastereomers) and mixtures thereof are included within the scope of this descriptive report. Similarly, it is understood that a compound or salt of formulas (I) to (III) or of formula (IA) may exist in tautomeric forms different from those shown in the formula and these are also included within the scope of this descriptive report. It should be understood that this descriptive report includes all combinations and subsets of the specific groups defined earlier in this document. The scope of this descriptive report includes mixtures of stereoisomers as well as purified enantiomers or enantiomerically / diastereomerically enriched mixtures.It should be understood that this descriptive report includes all combinations and subsets of the specific groups defined earlier in this document.
[0143] The descriptive report in question also includes isotopically labeled compounds, which are identical to those mentioned in formulas (I) to (III) and in formula (IA) and following, but in that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number generally found in nature. Examples of isotopes that may be incorporated into the compounds of the descriptive report and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as 2H, 3H, 11C, 13C, 14C, 15N, 17O, 18O, 31P, 32P, 35S, 18F, 36Cl, 123I and 125I.
[0144] The compounds of this descriptive report and pharmaceutically acceptable salts of said compounds containing the aforementioned isotopes and / or other isotopes of other atoms are within the scope of this descriptive report. Isotopically labeled compounds of this descriptive report, for example, those in which radioactive isotopes such as 3H, 14C are incorporated, are useful in drug and / or substrate tissue distribution assays. Tritiated isotopes, i.e., 3H, and carbon-14, i.e., 14C, are particularly used for their ease of preparation and detectability. The isotopes 11C and 18F are particularly useful in PET (positron emission tomography) and the isotope 125I Petition 870260111673, dated 10 / 29 / 2026, page 115 / 831 111 / 375 are particularly useful in SPECT (single-photon emission computed tomography), all useful in brain imaging. Furthermore, substitution with heavier isotopes, such as deuterium, i.e., 2H, can provide certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and therefore can be used in some circumstances. The isotopically labeled compounds of formulas (I) to (III) and following of this descriptive report can generally be prepared by performing the procedures disclosed in the Schemes and / or Examples below, replacing a readily available isotopically labeled reagent with a non-isotopically labeled reagent.
[0145] The descriptive report further provides a pharmaceutical composition (also called a pharmaceutical formulation) comprising a compound of formulas (I) to (III) or of formula (IA) or a pharmaceutically acceptable salt thereof and one or more excipients (also referred to as carriers and / or diluents in pharmaceutical techniques). Excipients are acceptable in the sense that they are compatible with the other ingredients of the formulation and are not harmful to the recipient thereof (i.e., the patient).
[0146] Suitable pharmaceutically acceptable excipients will vary depending on the specific dosage form selected. In addition, suitable pharmaceutically acceptable excipients may be selected for a specific function they may perform in the composition. For example, certain pharmaceutically acceptable excipients may be selected for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically acceptable excipients may be selected for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the transport of the compound or compounds of the descriptive report, once administered to the patient, from one organ or body part to another organ or body part.Certain pharmaceutically acceptable excipients may be selected for their ability to increase patient adherence to treatment.
[0147] Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, binders, granulating agents, coating agents, agents Petition 870260111673, dated 10 / 29 / 2026, page 116 / 831 112 / 375 Humectants, solvents, cosolvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity-increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents. Those skilled in the art will appreciate that certain pharmaceutically acceptable excipients may serve more than one function and may serve alternative functions depending on how much excipient is present in the formulation and what other ingredients are present in the formulation.
[0148] Those skilled in the art have the knowledge and skill in the art to enable them to select suitable pharmaceutically acceptable excipients in appropriate amounts for use in the descriptive report. In addition, there are several resources available to those skilled in the art that describe pharmaceutically acceptable excipients and may be helpful in selecting suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
[0149] The pharmaceutical compositions in the descriptive report are prepared using techniques and methods known to those skilled in the art. Some methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
[0150] Pharmaceutical compositions may be in unit dose form containing a predetermined amount of active ingredient per unit dose. This unit may contain a therapeutically effective dose of the compound of formulas (I) to (III) or of formula (IA) or a salt thereof, or a fraction thereof of a therapeutically effective dose, so that multiple unit dosage forms may be administered at a given time to achieve the desired therapeutically effective dose. Unit dosage formulations are those containing a daily dose or subdose, as previously mentioned in this document, or an appropriate fraction thereof, of an active ingredient. Furthermore, these pharmaceutical compositions may be prepared by any of the methods well known in the pharmaceutical art. Petition 870260111673, dated 10 / 29 / 2026, page 117 / 831 113 / 375
[0151] Pharmaceutical compositions may be adapted for administration by any suitable route, for example, oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal). These compositions may be prepared by any method known in the pharmaceutical art, for example, by combining the active ingredient with the excipient(s).
[0152] When adapted for oral administration, pharmaceutical compositions may be in distinct units such as tablets or capsules; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whipped creams; liquid oil-in-water emulsions or liquid water-in-oil emulsions. The compound or salt thereof of the descriptive report or the pharmaceutical composition of the descriptive report may also be incorporated into a sublingual candy, lozenge and / or strip formulation for administration as a fast-dissolving medicament.
[0153] For example, for oral administration in the form of a tablet or capsule, the active drug component may be combined with an orally inert, non-toxic, pharmaceutically acceptable carrier, such as ethanol, glycerol, water, and the like. Powders or granules are prepared by fragmenting the compound to a suitable fine size and mixing it with a similarly fragmented pharmaceutical carrier, such as an edible carbohydrate, for example, starch or mannitol. Flavoring agents, preservatives, dispersants, and colorants may also be present.
[0154] Capsules are produced by preparing a powder mixture, as described above, and filling pre-formed gelatin or non-gelatinized sheaths. Glidants and lubricants, such as colloidal silica, talc, magnesium stearate, calcium stearate, solid polyethylene glycol, may be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent, such as agar agar, calcium carbonate, or sodium carbonate, may also be added to improve the bioavailability of the drug when the capsule is ingested.
[0155] In addition, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents may also be used. Petition 870260111673, dated 10 / 29 / 2026, page 118 / 831 114 / 375 incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum and the like.
[0156] Tablets are formulated, for example, by preparing a powder mixture, granulation or compaction, adding a lubricant and a disintegrant, and pressing into tablets. A powder mixture is prepared by mixing the suitably fragmented compound with a diluent or base, as described above, and optionally with a binder such as carboxymethylcellulose and aliginate, gelatin or polyvinylpyrrolidone, a solution retardant such as paraffin, a reabsorption accelerator such as a quaternary salt and / or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by moistening a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing it through a screen. As an alternative to granulation, the powder mixture can be passed through a tablet machine, resulting in imperfectly broken pellets forming granules.The granules can be lubricated to prevent adhesion to tablet-forming dies by adding stearic acid, a stearate salt, talc, or mineral oil. The lubricated mixture is then compressed into tablets. The compound or salt of this descriptive report can also be combined with a free-flowing inert carrier and compressed into tablets directly without going through the granulation or compaction steps. A transparent opaque protective coating can be provided consisting of a shellac sealing coating, a sugar or polymeric coating, and a wax polishing coating. Colorants can be added to these coatings to distinguish different dosages.
[0157] Oral fluids, such as solutions, syrups, and elixirs, may be prepared in the form of dosage units so that a given quantity contains a predetermined amount of active ingredient. Syrups may be prepared by dissolving the compound or salt thereof from the descriptive report in Petition 870260111673, dated 10 / 29 / 2026, page 119 / 831 115 / 375 an appropriately flavored aqueous solution, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions may be formulated by dispersing the compound or salt of the descriptive report in a non-toxic vehicle. Solubilizers and emulsifiers, such as ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil, natural sweeteners, saccharin or other artificial sweeteners and the like, may also be added.
[0158] It should be understood that, in addition to the ingredients specifically mentioned above, pharmaceutical compositions may include other conventional agents in the art considering the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.
[0159] When appropriate, oral dosage unit formulations may be microencapsulated. The formulation may also be prepared to prolong or sustain release, for example by coating or incorporating particulate material in polymers, wax or similar materials.
[0160] Pharmaceutical formulations adapted for parenteral administration include sterile aqueous and non-aqueous injection solutions that may contain antioxidants, buffers, bacteriostatics, and solutes that make the composition isotonic with the blood of the intended recipient; and sterile aqueous and non-aqueous suspensions that may include suspending agents and thickening agents. Pharmaceutical compositions may be presented in single-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately before use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
[0161] According to another aspect of the descriptive report, a process is provided for the preparation of a pharmaceutical composition comprising mixing (or mixing by addition) a compound of formulas (I) to (III) or of formula (IA) or a salt thereof with at least one excipient. Petition 870260111673, dated 10 / 29 / 2026, p. 120 / 831 116 / 375 Definitions
[0162] Terms are used within their accepted meanings. The following definitions are intended to clarify, but not limit, the terms defined.
[0163] As used herein, the term alkyl represents a saturated, linear or branched hydrocarbon moiety with the specified number of carbon atoms. The term (C1-6)alkyl refers to an alkyl moiety containing from 1 to 6 carbon atoms. Alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, pentyl, and hexyl.
[0164] Alkoxy refers to a group containing an alkyl radical, as defined previously in this document, attached via an oxygen bonding atom. The term (C1-C6)alkoxy refers to a linear or branched chain hydrocarbon radical with at least 1 to 6 carbon atoms attached via an oxygen bonding atom. Examples of (C1-C6)alkoxy groups useful in this descriptive report include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, isobutoxy, and t-butoxy.
[0165] When the term alkyl is used in combination with other substituent groups, such as halo(C1-C6)alkyl, aryl(C1-C6)alkyl or (C1-C6)alkoxy(C1C6)alkyl, the term alkyl is intended to encompass a divalent linear or branched chain hydrocarbon radical, the point of attachment being through the alkyl moiety. The term halo(C1-C6)alkyl is intended to mean a radical with one or more halogen atoms, which may be the same or different, on one or more carbon atoms of an alkyl moiety containing from 1 to 6 carbon atoms, which is a linear or branched chain carbon radical. Examples of halo(C1C6)alkyl groups useful in this descriptive report include, but are not limited to, -CF3 (trifluoromethyl), -CCh (trichloromethyl), 1,1-difluoroethyl, 2-fluoro-2-methylpropyl, 2,2-difluoropropyl, 2,2,2-trifluoroethyl, and hexafluoroisopropyl.Examples of aryl(C1-C6)alkyl or phenyl(C1-C6)alkyl groups useful in this descriptive report include, but are not limited to, benzyl and phenethyl. Examples of (C1-C6)alkoxy(C1-C6)alkyl groups useful in this descriptive report include, but are not limited to, methoxymethyl, methoxyethyl, methoxyisopropyl, ethoxymethyl, ethoxyethyl, ethoxyisopropyl, isopropoxymethyl, isopropoxyethyl, isopropoxyisopropyl, t-butoxymethyl, t-butoxyethyl, and t-butoxyisopropyl. The term alkyl is intended to encompass a monovalent, a divalent, or a trivalent alkyl. Petition 870260111673, dated 10 / 29 / 2026, pp. 121 / 831 117 / 375 or a tetravalent within the context of other substituent groups by which it is surrounded. In some embodiments, the term alkyl may be interchangeable with the term alkylenyl, as both terms must have a divalent form of an alkyl group. The term alkylenyl, as used herein, by itself or part of another group, refers to a divalent form of an alkyl group with the specified number of carbon atoms. For example, the term (C1-C6)alkylenyl refers to an alkylenyl moiety containing from 1 to 6 carbon atoms. Exemplary alkylenyl groups include, but are not limited to, -CH2-, -CH(CH3)-, CH2CH2-, -CH2CH2CH2-, -CH2(CH2)2CH2-, and -CH2(CH2)3CH2-.
[0166] The term alkynyl refers to an unsaturated hydrocarbon containing a triple bond, which can be a monovalent or divalent form, which is dependent on other substituent groups by which it is surrounded. In some embodiments, the term alkynyl may be interchangeable with the term alkynylenyl, since both terms refer to a divalent form of an alkynyl group.
[0167] As used herein, the term cycloalkyl refers to a non-aromatic, saturated, cyclic hydrocarbon ring containing the specified number of carbon atoms. The term (C3-C6)cycloalkyl refers to a non-aromatic cyclic hydrocarbon ring with three to six carbon atoms in the ring. Useful exemplary (C3C6)cycloalkyl groups in this descriptive report include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0168] As used herein, 4- to 6-membered heterocycloalkyl represents a group or portion comprising a non-aromatic monovalent monocyclic radical that is saturated or partially unsaturated containing 4, 5, or 6 atoms in the ring, which includes one or two heteroatoms independently selected from oxygen, sulfur, and nitrogen. Illustrative examples of 4- to 6-membered heterocycloalkyl groups useful in this descriptive report include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, pyrazolinyl, imidazolidinyl, imidazolinyl, oxazolinyl, thiazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1,3-dioxolanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dihydropyranyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-oxatiolanyl, 1,3-oxatianyl, 1,3-ditianyl, 1,4-oxatiolanyl, 1,4-oxatianyl and 1,4-ditianyl. The term 4- to 6-membered heterocycloalkyl is intended to encompass a monovalent monocyclic radical or a form Petition 870260111673, dated 10 / 29 / 2026, p. 122 / 831 118 / 375 monocyclic divalent in the context of other substituent groups by which it is surrounded. In some embodiments, the term 4- to 6-membered heterocycloalkyl may be interchangeable with the term 4- to 6-membered heterocycloalkylenyl, since both terms are intended to have a divalent form of the heterocycloalkyl group. The term 4- to 6-membered heterocycloalkylenyl, as used herein, by itself or as part of another group, refers to a divalent form of a heterocycloalkyl group with the specified number of atoms in the ring or divalent monocyclic form.
[0169] Aryl refers to optionally substituted monocyclic, fused bicyclic, or fused tricyclic groups having 6 to 14 carbon atoms and having at least one aromatic ring that conforms to Hückel's rule. Examples of aryl groups are phenyl, naphthyl, indenyl, dihydroindenyl, anthracenyl, phenanthrenyl, and the like.
[0170] Heteroaryl represents a group or portion comprising a monovalent aromatic monocyclic or bicyclic radical containing 5 to 10 ring atoms, including 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. This term also covers bicyclic heterocyclic-aryl compounds containing an aryl ring portion fused to a heterocycloalkyl ring portion, containing 5 to 10 ring atoms, including 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.Illustrative examples of heteroaryls useful in the present disclosure include, but are not limited to, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, benzofuranyl, isobenzofuryl, 2,3-dihydrobenzofuryl, 1,3-benzodioxolyl, dihydrobenzodioxinyl, benzothienyl, indolizinyl, indolyl, isoindolyl, dihydroindolyl, benzimidazolyl, dihydrobenzimidazolyl, benzoxazolyl, dihydrobenzoxazolyl, benzothiazolyl, benzoisothiazolyl, dihydrobenzoisothiazolyl, indazolyl, imidazopyridinyl, pyrazolopyridinyl, benzotriazolyl, triazolopyridinyl, purinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetra-hydroisoquinolinyl, quinoxalinyl, cinolinyl, phthalazinyl, quinazolinyl, 1,5-naphthyridinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8naphthyridinyl and pteridinyl.Examples of 5-membered heteroaryl groups include furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, and oxazolyl. Petition 870260111673, dated 10 / 29 / 2026, pp. 123 / 831 Examples of 6-membered heteroaryl groups include isoxazolyl, oxadiazolyl, thiadiazolyl, and isothiazolyl. Examples of 6-membered heteroaryl groups include oxopyridyl, pyridinyl, pyridazinyl, pyrazinyl, and pyrimidinyl. Examples of 6,6-fused heteroaryl groups include quinolinyl, isoquinolinyl, quinoxalinyl, cinolinyl, phthalazinyl, quinazolinyl, 1,5-naphthyridinyl, 1,6-naphthyridinyl, 1,7-naphthyridinyl, 1,8-naphthyridinyl, and pteridinyl. Examples of 6,5-fused heteroaryl groups include benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, indolizinyl, indolyl, isoindolyl, and indazolyl.
[0171] As used herein, a 5- or 6-membered heteroaryl group represents a group or portion comprising a monovalent aromatic monocyclic radical containing 5 or 6 ring atoms, including at least one carbon atom, and 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Selected 5-membered heteroaryl groups contain a ring heteroatom of nitrogen, oxygen, or sulfur and optionally contain 1, 2, or 3 additional ring nitrogen atoms. Selected 6-membered heteroaryl groups contain 1, 2, or 3 ring nitrogen heteroatoms. Illustrative examples of 5- or 6-membered heteroaryl groups useful in this descriptive report include, but are not limited to, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, and triazinyl.
[0172] The terms halogen and halo represent fluoro, chlorine, bromine, or iodine substituents. Hydroxy or hydroxyl means the -OH radical.
[0173] As used herein, the term optionally means that the event(s) described subsequently may or may not occur and includes both the event(s) that occur and the event(s) that do not occur.
[0174] Pharmaceutically acceptable refers to compounds (including salts), materials, compositions and dosage forms that are, within the scope of medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation or other problem or complication, proportionate to a reasonable risk / benefit ratio.
[0175] As used herein, the term treatment refers to the relief of the specified condition by eliminating or reducing one or more symptoms of the condition, delaying Petition 870260111673, dated 10 / 29 / 2026, page 124 / 831 120 / 375 or eliminating the progression of the condition and delaying the recurrence of the condition in a previously affected or diagnosed patient or individual.
[0176] As used herein, the term effective quantity means the amount of a drug or pharmaceutical agent that will elicit the biological or medical response from a tissue, system, animal, or human being that is being sought, for example, by a researcher or physician.
[0177] The term therapeutically effective amount means any amount which, compared with a corresponding individual who has not received that amount, results in improved treatment, cure or attenuation of a disease, disorder or side effect or a decrease in the rate of progression of a disease or disorder. The term also includes within its scope amounts effective for improving normal physiological function. For use in therapy, therapeutically effective amounts of a compound of formulas (I) to (III) or of formula (IA), as well as salts thereof, may be administered as a crude chemical product. In addition, the active ingredient may be presented as a pharmaceutical composition. Compound preparation Table 1 - Abbreviations atm Standard atmospheric pressure unit aq. Aqueous Bu 3 P Tri-n-butylphosphine t BuXPhos 2-Di-tert-butylphosphino-2',4',6'-tri-isopropylbiphenyl t BuXPhos Pd G3 Palladium(II) [(2-di-tert-butylphosphino-2',4',6'-tri-isopropyl1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)] methanesulfonate CO Carbon monoxide Cs2CO3 Cesium carbonate Cphos 2-Dicyclohexylphosphino-2',6'-bis(N,N-dimethylamino)biphenyl CuI Copper iodide DCM Dichloromethane Petition 870260111673, dated 10 / 29 / 2026, p. 125 / 831 121 / 375 DEAD Diethyl azodicarboxylate DFA 2,2-Difluoroacetic acid DIPEA N,N-Di- / so-propylethylamine DMF N,N-dimethylformamide DMP Dess-Martin periodinane DMSO Dimethyl sulfoxide dPPf 1,1'-Bis(diphenylphosphine)ferrocene dppf Pd G3 Methanesulfonate 1,1-ferrocenodi-yl-bis(diphenylphosphine)(2'amino-1,1'-biphenyl-2-yl)palladium(II) DPPP 1,3-Bis(diphenylphosphine)propane EDC HCl N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride EPhos Dicyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1 '-biphenyl]-2yl)phosphane EPhos Pd G4 Methanesulfonate of {dicyclohexyl[3-(1-methylethoxy)-2',4,6'tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine}(2'-methylamino-1,1'biphenyl-2-yl)palladium(II) EtOAc Ethyl acetate EtOH Ethanol FA Formic acid g Gram(s) h Hour(s) HATU N-[(Dimethylamino)-1H-1,2,3triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide HCl Hydrochloric acid HPLC High-performance liquid chromatography HOBt 1-Hydroxybenzotriazole Petition 870260111673, dated 10 / 29 / 2026, pp. 126 / 831 122 / 375 IPA Isopropyl alcohol K2CO3 Potassium carbonate L Liter(s) LiHMDS Lithium bis(trimethylsilyl)amide LiOH Lithium hydroxide MeCN Acetonitrile MeOH Methanol min Minute(s) mL Milliliter(s) MTBE Methyl tert-butyl ether NaOAc Sodium acetate NaBH3CN Sodium cyanoboride NaBH4 Sodium tetrahydroborate NaBH(OAc)3 Sodium triacetoxyborohydride NaH Sodium hydride NaOH Sodium hydroxide Na2SO3 Sodium sulfite Na2SO4 Sodium sulfate NBS N-Bromosuccinimide NH3 Ammonia NH4HCO3 Ammonium bicarbonate NH4Cl Ammonium chloride NH4OH Ammonium hydroxide N2 Nitrogen Pd / C Palladium on carbon Petition 870260111673, dated 10 / 29 / 2026, pp. 127 / 831 123 / 375 Pd2(dba)3 Tris(dibenzylideneacetone)dipalladium(0) Pd(dppf)Cl2 [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride Pd(dppf)Cl2 - CH2 Cl2 Dichloromethane dichloride complex [1,1'bis(diphenylphosphine)ferrocene]palladium(II) Pd(OAc)2 Palladium(II) acetate Pd(Ph3P)4 Tetrakis(triphenylphosphine)palladium(0) Pd-PEPPSI IHeptCl Dichloro[1,3-bis(2,6-di-4-heptylphenyl)imidazol-2-ylidene](3chloropyridyl)palladium(II) Pd-PEPPSI IPentCl Dichloride [1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) PE Petroleum ether prep. Preparatory i-PrOH 2-Propanol TA Room temperature RuPhos 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenyl RuPhos Pd G2 Chloro(2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2(2'-amino-1,1'-biphenyl)]palladium(II) sat. Saturated SFC Supercritical Fluid Chromatography TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran Ti(Oi-Pr)4 Titanium isopropoxide Xanthos 4,5-Bis(diphenylphosphine)-9,9-dimethylxanthene
[0178] The abbreviations used for analytical data, if not defined above, are consistent with common usage in the field (see J. Med. Chem. Standard). Petition 870260111673, dated 10 / 29 / 2026, pp. 128 / 831 124 / 375 Abbreviations and Acronyms, http: / / pubsapp.acs.org / paragonplus / submission / jmcmar / jmcmar_abbreviations.pdf). Experiments
[0179] The compound names provided below are generated using PerkinElmer ChemDraw Professional, version 21.0.0.28.
[0180] HPLC chromatography of crude target compounds derived from Int I resulted in the separation of cis and trans isomers. These were assigned as Isomer 1 and Isomer 2 based on their elution order during chromatography. When chiral HPLC chromatography was used during the chromatography of these target compounds, four isomers were obtained: the cis and trans isomers of the (S)-3 and (R)3 isomers of 2,6-dioxopiperidine cyclohexyl. These were assigned as Isomer 1 to Isomer 4 based on their elution order during chromatography. The tert-butyl 4-(4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-yl)cyclohexyl)piperazine-1-carboxylate structural unit for the synthesis of Examples 86, 87 was separated by chromatography into Isomer 1 and Isomer 2 and assigned based on their elution order during chromatography. Intermediaries Synthesis of intermediate Int I: N -(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)-2 H -indazol-5carboxamide 4-(5-Bromo-6-methoxy-2H-indazol-2-yl)cyclohexan-1-one I
[0181] TEA (18.5 mL, 133.0 mmol) was added to 4-aminocyclohexan-1-one (5.0 g, 44.2 mmol) and 5-bromo-4-methoxy-2-nitrobenzaldehyde (11.5 g, 44.2 mmol) in i-PrOH (5.0 mL) under N2. The resulting solution was stirred at 80 °C for 15 min before the addition of Bu3P (32.7 mL, 133.0 mmol), and stirring was continued at 80 °C for 14 h. The reaction mixture was cooled to rt, briskly cooled with water (50.0 mL), and extracted with EtOAc (3 x 50.0 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified. Petition 870260111673, dated 10 / 29 / 2026, p. 129 / 831 125 / 375 by C18 flash chromatography (eluting with MeCN at 0 to 70% in water) to yield 4-(5-bromo-6-methoxy-2H-indazol-2-yl)cyclohexan-1-one (2.5 g, 18%) as a gray solid. 1H NMR (300 MHz, DMSO-dβ) δ 2.30 - 2.43 (6H, m), 2.59 - 2.70 (2H, m), 3.87 (3H, s), 4.94 - 5.03 (1H, m), 7.13 (1H, s), 7.99 (1H, s), 8.36 (1H, s). m / z (ESI+), [M+H]+= 323. N -(Imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)-2 H -indazol-5carboxamide (Int I) I
[0182] TEA (4.3 mL, 30.9 mmol) was added to 4-(5-bromo-6-methoxy-2Hindazol-2-yl)cyclohexan-1-one (1.0 g, 3.1 mmol), imidazo[1,2-b]pyridazin-3-amine (478 mg, 3.6 mmol), PdOAc2 (139 mg, 0.6 mmol) and DPPP (510 mg, 1.2 mmol) in MeCN (22 mL) in a sealed tube under N2. The resulting mixture was stirred at 100 °C under CO2 for 18 h, cooled to rt and then concentrated under reduced pressure. The crude product was purified by C18 flash chromatography (eluting with MeCN at 0 to 60% in water) to yield N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)-2H-indazol-5-carboxamide (1.0 g, 80%) as a brown solid. 1H NMR (300 MHz, DMSO-d6) δ 2.33 - 2.47 (m, 6H), 2.60 - 2.78 (m, 2H), 4.13 (s, 3H), 4.95 5.19 (m, 1H), 7.19 - 7.27 (m, 1H), 7.29 (s, 1H), 8.06 (s, 1H), 8.13 - 8.20 (m, 1H), 8.60 (s, 1H), 8.62 - 8.67 (m, 1H), 8.68 (s, 1H), 11.05 (s, 1H). m / z (ESI+), [M+H]+= 405. Synthesis of intermediate Int II: 2-((1r,4r)-4-formylcyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2 Hindazol-5-carboxamide ((1r,4r)-4-(5-Bromo-6-methoxy-2H-indazol-2-yl)cyclohexyl)methanol
[0183] 5-Bromo-4-methoxy-2-nitrobenzaldehyde (8.2 g, 31.7 mmol) was added to TEA (12.6 mL, 90.6 mmol) and the HCl salt of ((1r,4r)-4-aminocyclohexyl)methanol (5.0 g, 30.2 mmol) in i-PrOH (50 mL) at 25 °C under N2. The resulting solution was stirred to Petition 870260111673, dated 10 / 29 / 2026, p. 130 / 831 The solution was heated to 126 / 375 °C for 16 h, then cooled to rt before BU3P (22.4 mL, 90.6 mmol) was added. The resulting solution was stirred at 80 °C for 4 h, cooled to rt, and concentrated. The crude product was purified by flash chromatography on silica (eluting with 0 to 80% EtOAc on PE). The product was then stirred with PE / EtOAc (5:1) (100 mL), and the precipitated solid was collected by filtration and dried under vacuum to yield ((1r,4r)-4-(5-bromo-6-methoxy-2H-indazol-2-yl)cyclohexyl)methanol (4.3 g, 42%) as a colorless solid. m / z (ESI+), [M+H]+ = 339 / 341. 2-((1 r,4 r)-4-(Hydroxymethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2 Hindazol-5-carboxamide
[0184] Imidazo[1,2-b]pyridazin-3-amine (5.9 g, 44.2 mmol), ((1r,4r)-4-(5-bromo-6-methoxy-2H-indazol-2-yl)cyclohexyl)methanol (5.0 g, 14.7 mmol), TEA (20.5 mL, 147.4 mmol), 1,3-bis(diphenylphosphino)propane (2.4 g, 5.9 mmol) and Pd(OAc)2 (0.7 g, 3.0 mmol) in MeCN (200 mL) were stirred under a CO₂ atmosphere at 15 atm and 100 °C for 17 h. Then, the solvent was removed under vacuum. The crude product was purified by flash chromatography on silica (eluting with 0 to 7% MeOH in DCM), followed by crystallization from DCM / MeOH (20:1) (100 mL). The solid was collected by filtration and dried in a vacuum oven to yield 2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (3.7 g, 58%) as a yellow solid, which was used without further purification. m / z (ESI+), [M+H]+= 421. 2-((1r,4r)-4-Formylcyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamide (Int II)
[0185] DMP (4.7 g, 11.1 mmol) was added to 2-((1 r,4 r)-4-(hydroxymethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (3.6 g, 8.6 Petition 870260111673, dated 10 / 29 / 2026, pp. 131 / 831 (127 / 375 mmol), in DCM (80 mL) at 25 °C under N2. The resulting mixture was stirred at 25 °C for 2 days before being poured into a mixture of saturated aqueous NaHCO3 (20 mL), Na2SO3 (2 g) and water (100 mL). The solid was collected by filtration. The filtrate was extracted with DCM (2 x 400 mL), the organic layer dried with Na2SO4, filtered and concentrated to produce a brown solid. The aqueous layer was adjusted to pH < 7 with FA and the precipitate formed was collected by filtration. The solids from both filtrations and the concentrated organic phase were purified by C18-flash chromatography (eluting with 5 to 100% MeCN in water (0.05% NH4OH)) to yield 2-((1r,4r)-4-formylcyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide as a yellow solid. The filtrate was concentrated and purified by C18-flash chromatography (eluting with 5 to 100% MeCN in water (0.05% NH4OH)).The product was combined with the material from the first flash chromatography to produce 2-((1r,4r)-4-formylcyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (1.5 g, 42%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 1.34-1.58 (2H, m), 1.93-2.06 (2H, m), 2.06-2.18 (2H, m), 2.17-2.30 (2H, m), 2.44 (1H, t), 4.13 (3H, s), 4.41 - 4.59 (1H, m), 7.20 - 7.25 (1H, m), 7.26 (1H, s), 8.06 (1H, s), 8.14 - 8.18 (1H, m), 8.58 - 8.64 (3H, m), 9.56 (1H, s), 11.05 (1H, s). m / z (ESI+), [M+H]+= 419. Synthesis of intermediate Int III: N -(1-cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1r,4r)-4-formylcyclohexyl)-6methoxy-2H-indazol-5-carboxamide Methyl 2-((1r,4r)-4-(Hydroxymethyl)cyclohexyl)-6-methoxy-2H-indazole-5-carboxylate
[0186] Pd(dppf)Cl2 - CH2Cl2 (0.2 g, 0.2 mmol), TEA (16.4 mL, 117.9 mmol) and ((1r,4r)-4-(5-bromo-6-methoxy-2H-indazol-2-yl)cyclohexyl)methanol (4.0 g, 11.8 mmol) (synthesis described under synthesis of Int II) in MeOH (200 mL) were stirred under a CO₂ atmosphere at 15 atm and 110 °C for 17 h. The reaction mixture was then concentrated. The crude product was purified by flash chromatography on silica (eluting with 0 to 80% EtOAc on PE) to yield 2-((1r,4r)-4-(hydroxymethyl)cyclohexyl Petition 870260111673, dated 10 / 29 / 2026, p. 132 / 831 128 / 375 methyl hexyl)-6-methoxy-2H-indazol-5-carboxylate (3.6 g, 96%) as a brown solid, which was used without further purification. 2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-6-methoxy-2H-indazole-5-carboxylic acid
[0187] LiOH (0.8 g, 33.8 mmol) was added to methyl 2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxylate (3.6 g, 11.3 mmol) in water (20 mL) and MeOH (20.00 mL). The resulting solution was stirred at 25 °C for 19 h. The pH of the reaction mixture was adjusted to pH = 7 with 12 M HCl. The crude product was purified by C18-flash chromatography (eluting with 5% MeCN at 100% in water (FA at 0.1%)) to yield 2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxylic acid (3.1 g, 90%) as a colorless solid. m / z (ESI+), [M+H]+= 305. N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-6methoxy-2H-indazol-5-carboxamide
[0188] The HCl salt of 3-amino-1-cyclopropylpyridin-2(1H)-one (2.8 g, 14.8 mmol) was added to 2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxylic acid (3.0 g, 9.9 mmol), DIPEA (6.9 mL, 39.4 mmol) and HATU (5.6 g, 14.8 mmol) in DMF (60 mL) at 25 °C under N2. The resulting solution was stirred for 18 h. The crude product was purified by C18-flash chromatography (eluting with 5% MeCN in water (0.05% NH4OH)) to yield N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide (3.0 g, 70%) as a colorless solid. m / z (ESI+), [M+H]+= 437. N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1r,4r)-4-formylcyclohexyl)-6-methoxy2H-indazol-5-carboxamide (Int III) Petition 870260111673, dated 10 / 29 / 2026, p. 133 / 831 129 / 375
[0189] DMP (2.9 g, 6.8 mmol) was added to N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-6-methoxy-2H-indazole-5-carboxamide (2.9 g, 6.7 mmol) in DCM (50 mL) at 25 °C. The resulting solution was stirred for 17 h before being concentrated. The crude product was purified by C18-flash chromatography (eluting with 5% MeCN at 100% in water (0.05% NH4OH)) to yield N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-formylcyclohexyl)-6-methoxy-2H-indazol-5-carboxamide (2.1 g, 73%) as a gray solid. 1H NMR (400 MHz, DMSO-dβ) δ 0.77-0.96 (2H, m), 0.96-1.12 (2H, m), 1.33 - 1.46 (2H, m), 1.85 - 2.30 (6H, m), 2.35 - 2.46 (1H, m), 3.40 - 3.50 (1H, m), 4.09 (3H, s), 4.40 - 4.55 (1H, m), 6.29 (1H, t), 7.23 (1H, s), 7.25 - 7.35 (1H, m), 8.40 - 8.46 (1H, m), 8.49-8.64 (2H, m), 9.63 (1H, s), 11.07 (1H, s). m / z (ESI+), [M+H]+= 435. Synthesis of intermediate Int IV: ácido (1 r,4 r) -4-(5-(imidazo[1,2- b ] pyridazin-3-ilcarbamoil)-6-metoxi-2 H-indazol-2il)ciclo-hexano-1 -carboxílico (1 r,4 r)-4-(5-Bromo-6-metoxi-2 H-indazol-2-il)ciclo-hexano-1-carboxilato de metila
[0190] (1r,4r)-4-Aminocyclohexane-1-carboxylate methyl (10.0 g, 63.6 mmol) was added to 5-bromo-4-methoxy-2-nitrobenzaldehyde (16.5 g, 63.6 mmol) in i-PrOH (100 mL) at 25 °C under N2. The resulting solution was stirred at 80 °C for 17 h and cooled to 100 mL before Bu3P (12.9 g, 63.6 mmol) was added under N2. Stirring was continued at 80 °C for 5 h before the reaction was abruptly cooled with water (350 mL). The solid was collected by filtration and washed with water (100 mL) to yield a colorless solid. The solid was stirred with PE (250 mL) for 1 h, then filtered and dried under vacuum to yield (1r,4r)-4-(5-bromo-6-methoxy-2H-indazol-2-yl)cyclohexane-1-carboxylate methyl (18.0 g, 77%) as a colorless solid, which was used without further purification. Petition 870260111673, dated 10 / 29 / 2026, p. 134 / 831 130 / 375 (1 r,4 r)-4-(5-(Imidazo[1,2-b ]pyridazin-3-ylcarbamoyl)-6-methoxy-2 H-indazol-2-yl)methyl cyclohexane-1-carboxylate
[0191] Pd(OAc)2 (0.7 g, 3.1 mmol), 1,3-bis(diphenylphosphino)propane (2.5 g, 6.1 mmol), imidazo[1,2-b]pyridazin-3-amine (6.0 g, 44.7 mmol), TEA (20.8 mL, 149.8 mmol) and methyl (1r,4r)-4-(5-bromo-6-methoxy-2H-indazol-2-yl)cyclohexane-1-carboxylate (5.5 g, 15.0 mmol) in MeCN (230 mL) were stirred under a CO₂ atmosphere at 15 atm and 110 °C for 16 h. The solvent was then removed under reduced pressure. The crude product was purified by flash chromatography on silica (eluting with 2% MeOH in DCM) to yield crude methyl (1r,4r)-4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexane-1-carboxylate (12.0 g, 55.86 wt.%) as a yellow solid. m / z (ESI+), [M+H]+= 449. (1r,4r)-4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2yl)cyclohexane-1-carboxylic acid (Int IV)
[0192] LiOH (3.5 g, 149.2 mmol) was added in a portion to crude methyl (1r,4r)-4-(5(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexane-1-carboxylate (56 wt%) (12.0 g, 14.9 mmol) in MeOH (80 mL) and water (20 mL) at 25 °C under N2. The resulting mixture was stirred for 2 h. The precipitate was collected by filtration, washed with MeOH / water (40 / 10 mL) and then with EtOAC (50 mL). The solid was dried under vacuum to yield (1r,4r)-4-(5(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexane-1-carboxylic acid (4.8 g, 43%) as a pink solid. 1H NMR (300 MHz, MeOD-d4) δ 1.67 - 1.82 (2H, m), 1.91 - 2.10 (2H, m), 2.18-2.35 (5H, m), 4.18 (3H, s), 4.40-4.50 (1H, m), 7.11-7.20 (2H, m), 7.93 - 7.99 (1H, m), 8.10 (1H, s), 8.43 (1H, s), 8.48 - 8.57 (1H, m), 8.64 (1H, s). m / z (ESI+), [M+H]+= 435. Petition 870260111673, dated 10 / 29 / 2026, p. 135 / 831 131 / 375 Synthesis of intermediate Int V: ácido (1 r,4 r) -4-(5-((1-ciclopropil-2-oxo-1,2-di-hidropirin-3-il)carbamoil)-6metoxi-2 H-indazol-2-il)ciclo-hexano-1-carboxílico (1 r,4 r)-4-(5-Bromo-6-metoxi-2 H-indazol-2-il)ciclo-hexano-1 -carboxilato de ter-butila
[0193] 5-Bromo-4-methoxy-2-nitrobenzaldehyde (6.9 g, 26.3 mmol) was added to TEA (10.5 mL, 75.3 mmol) and tert-butyl (1r,4r)-4-aminocyclohexane-1-carboxylate (5.0 g, 25.1 mmol) in i-PrOH (100 mL) at 25 °C under N2. The resulting solution was stirred at 80 °C for 16 h, then cooled to rt before the addition of Bu3P (18.6 mL, 75.3 mmol). Stirring at 80 °C was then continued for 4 h before the reaction was abruptly cooled with water (400 mL). The solid was collected by filtration. The crude product was purified by crystallization from EtOAc / petroleum ether (1:20) (100 mL) to yield tert-butyl (1r,4r)-4-(5-bromo-6-methoxy-2H-indazol-2yl)cyclohexane-1-carboxylate (7.4 g, 72%) as a colorless solid. m / z (ESI+), [M+H]+= 409 / 411. 2-((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxylate methyl
[0194] Pd(dppf)Cl2 - CH2Cl2 (1.5 g, 1.8 mmol), TEA (25.0 mL, 179.6 mmol) and tert-butyl (1 r,4r)-4-(5-bromo-6-methoxy-2 H-indazol-2-yl)cyclohexane-1-carboxylate (7.4 g, 18.0 mmol) in MeOH (200 mL) were stirred under a CO₂ atmosphere at 15 atm and 110 °C for 17 h. Next, the reaction mixture was concentrated and the crude product was purified by flash chromatography on silica (eluting with 0 to 80% EtOAc on PE) to yield methyl 2-((1r,4r)-4-(ter-butoxycarbonyl)cyclohexyl)-6-methoxy-2hindazol-5-carboxylate (6.3 g, 90%) as a brown solid. m / z (ESI+), [M+H]+= 389. 2-((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)-6-methoxy-2H-indazole-5-carboxylic acid Petition 870260111673, dated 10 / 29 / 2026, p. 136 / 831 132 / 375
[0195] LiOH (1.1 g, 47.9 mmol) was added to methyl 2-((1r,4r)-4-(etherbutoxycarbonyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxylate (6.2 g, 16.0 mmol) in MeOH (30 mL) and water (30.0 mL) at 25 °C. The resulting solution was stirred for 16 h. The pH of the reaction mixture was adjusted to pH 5 with 12 M HCl. The solid was collected by filtration and dried under vacuum to yield the crude product as a colorless solid. The crude product was purified by C18-flash chromatography (eluting with MeCN at 0 to 100% in water (FA at 0.1%)) to yield 2-((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxylic acid (4.8 g, 8%) as a colorless solid. m / z (ESI+), [M+H]+= 375. tert-butyl (1r,4r)-4-(5-((1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)carbamoyl)-6-methoxy-2-Hindazol-2-yl)cyclohexane-1-carboxylate
[0196] 3-amino-1-cyclopropylpyridin-2(1H)-one hydrochloride (3.6 g, 19.2 mmol) was added to 2-((1r,4r)-4-(tert-butoxycarbonyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxylic acid (4.8 g, 12.8 mmol), DIPEA (8.9 mL, 51.2 mmol) and HATU (7.3 g, 19.2 mmol) in DMF (60 mL) at 25 °C under N2. The resulting solution was stirred for 17 h. The reaction mixture was then poured into water (750 mL). The solid was collected by filtration, washed with water (100 mL) and dried in an oven under reduced pressure to yield tert-butyl (1r,4r)-4-(5-((1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)carbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexane-1-carboxylate (5.6 g, 86%) as a solid ash, which was used without further purification. m / z (ESI+), [M+H]+= 507. (1r,4r)-4-(5-((1-cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)carbamoyl)-6-methoxy2H-indazol-2-yl)cyclohexane-1-carboxylic acid (Int V) Petition 870260111673, dated 10 / 29 / 2026, p. 137 / 831 133 / 375
[0197] TFA (6.0 mL, 77.9 mmol) was added to tert-butyl (1r,4r)-4-(5-((1-cyclopropyl-2oxo-1,2-dihydropyridine-3-yl)carbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexane-1-carboxylate (5.6 g, 11.0 mmol) in DCM (24 mL) at room temperature. The resulting solution was stirred for 12 h before being concentrated. The crude product was triturated with MeCN : H2O (4 :1) (200 mL) and the solid was collected by filtration and washed with MeCN (5 mL). The solid was dried under vacuum to yield (1r,4r)-4-(5-((1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)carbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexane-1-carboxylic acid (4.7 g, 95%) as a gray solid. 1H NMR (500 MHz, DMSO-dβ) δ 0.85 - 0.94 (2H, m), 1.01 - 1.11 (2H, m), 1.51 - 1.63 (2H, m), 1.89 - 2.41 (7H, m), 3.40 - 3.49 (1H, m), 4.08 (3H, s), 4.41 - 4.53 (1H, m), 6.28 (1H, t), 7.22 (1H, s), 7.26-7.31 (1H, m), 8.44 (1H, d), 8.53 (1H, s), 8.57 (1H, s), 11.06 (1H, s). m / z (ESI+), [M+H]+= 451. Intermediate synthesis Int VI: 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6dione
[0198] LiHMDS (5.5 g, 33.0 mmol) was slowly added to 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (3.0 g, 13.2 mmol) in THF (30 mL) at 25 °C under N2. The resulting mixture was stirred at rt for 50 min. The mixture was slowly added to 3-bromopiperidine-2,6-dione (5.1 g, 26.4 mmol) in THF (30 mL) at 25 °C for 15 min under N2. The resulting mixture was stirred at 60 °C for 3 h, cooled to rt, and then poured into saturated aqueous Na4Cl solution (100 mL). The mixture was extracted with EtOAc (3 x 100 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under reduced pressure to produce a brown solid, which was then ground with MeCN (200 mL) and dried in a vacuum oven to... Petition 870260111673, dated 10 / 29 / 2026, p. 138 / 831 134 / 375 produce 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (3.0 g, 67%) as a gray solid. Synthesis of intermediate Int VII: tert-butyl 3-(4-(3-(4-aminopiperidin-1-yl)prop-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-1-yl)piperidin-2,6-dione (1-(Prop-2-yn-1-yl)piperidin-4-yl)carbamate
[0199] tert-butyl piperidin-4-ylcarbamate (606 mg, 3.0 mmol) was added to 3-bromoprop-1-yne (240 mg, 2.0 mmol) and K2CO3 (836 mg, 6.1 mmol) in THF (4 mL). The resulting mixture was stirred at 25 °C for 3 h, then filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica (eluting with pentane at 20 to 100% on EtOAc) to yield tert-butyl (1-(prop2-yn-1-yl)piperidin-4-yl)carbamate (380 mg, 79%) as a colorless solid. m / z (ESI+), [M+H]+= 239. tert-butyl (1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4yl)prop-2-yn-1-yl)piperidin-4-yl)carbamate
[0200] Cs2CO3 (1.2 g, 3.5 mmol) was added to tert-butyl (1-(prop-2-yn-1-yl)piperidin-4yl)carbamate (280 mg, 1.2 mmol), Pd(Ph3P)4 (136 mg, 0.1 mmol), CuI (15 mg, 0.1 mmol) and 3-(4-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1yl)piperidine-2,6-dione (Int VI) (397 mg, 1.2 mmol) in DMF (7.0 mL) under N2. The resulting mixture was stirred at 80 °C for 14 h, then cooled to rt, filtered, concentrated under reduced pressure, and then purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to produce (1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)piperidin-4-Petition 870260111673, dated 10 / 29 / 2026, page 1. 135 / 375 tert-butyl carbamate (500 mg, 52%) as a yellow solid. m / z (ESI+), [M+H]+= 496. 3-(4-(3-(4-Aminopiperidin-1-yl)prop-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-1-yl)piperidine-2,6-dione (Int VII)
[0201] TFA (16.3 mL, 211.9 mmol) was added to tert-butyl (1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)piperidin-4-yl)carbamate (3.5 g, 7.1 mmol) in DCM (25 mL). The resulting mixture was stirred at 25 °C for 1 h, then concentrated under reduced pressure. The crude product was purified by C18 flash chromatography (eluting with 0 to 50% MeCN in water) to yield 3-(4-(3-(4-aminopiperidin-1-yl)prop-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (1.9 g, 94%). m / z (ESI+), [M+H]+= 396. Synthesis of intermediate Int VIII: 3-(4-(4-Aminobut-1-in-1-yl)-3-methyl-2-oxo-2,3-di-hydro-1 H -benzo[ d] imidazol-1yl)piperidine-2,6-dione (4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-o-hydro-hydro-2 imidazole-4-yl)but3-in-1-yl)ter-butyl carbamate
[0202] Molecular sieve 4 A (5 mg) was added to Pd(dppf)Cl2 (0.2 g, 0.3 mmol), Cs2CO3 (2.9 g, 8.9 mmol), copper (I) iodide (60 mg, 0.3 mmol), but-3in-1-terbutyl carbonate (1,000 mmol 5.9 mmol) and 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1 H-benzo[ d] imidazole-1 -yl)piperidine-2,6-dione (Int VI) (1.0 g, 3.0 mmol) in DMF Petition 870260111673, of 29 / 10 / 2026, p. 140 / 831 136 / 375 (10 mL) at 25 °C under N2. The resulting mixture was stirred at 90 °C for 10 h, then cooled to room temperature, diluted with EtOAc (50 mL) and washed sequentially with saturated NH4C (1 x 25 mL) and brine (1 x 20 mL). The organic layer was dried with Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by C18-flash chromatography (eluting with MeCN at 30 to 70% in water) to yield tert-butyl (4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1-H-benzo[d]imidazol-4-yl)but-3-yn-1-yl)carbamate (800 mg, 63%) as a yellow solid. m / z (ESI+), [M+H]+= 427. 3-(4-(4-Aminobut-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1yl)piperidine-2,6-dione (Int VIII)
[0203] TFA (4.0 mL, 51.9 mmol) was slowly added to tert-butyl (4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)but-3-yn-1yl)carbamate (800 mg, 1.9 mmol) in DCM (10 mL) at 25 °C under N2. The resulting mixture was stirred at 25 °C for 2 h, then concentrated under reduced pressure to yield 3-(4-(4-aminobut-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (600 mg, 98%) as a yellow oil, which was used without further purification. m / z (ESI+), [M+H]+= 327. Synthesis of intermediate Int IX: 3-(1-Oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione tert-butyl 4-(1-Oxo-1,3-dihydroisobenzofuran-5-yl)piperazine-1-carboxylate Petition 870260111673, dated 10 / 29 / 2026, p. 141 / 831 137 / 375
[0204] Xanthos (32.6 g, 56.3 mmol) was added to 5-bromoisobenzofuran-1(3H)-one (200.0 g, 938.8 mmol), tert-butyl piperazine-1-carboxylate (175.0 g, 938.8 mmol), K3PO4 (155 mL, 1877.7 mmol) and Pd2(dba)3 (43.0 g, 46.9 mmol) in dioxane (2400 mL) at rt under N2. The resulting mixture was stirred at 100 °C for 16 h, then cooled to rt. The solid was removed by filtration and washed with DCM (200 mL) and EA (200 mL). The organic phases were concentrated to dryness. The crude solid was ground with EA (150 mL) and PE (300 mL) to yield a solid which was collected by filtration and then ground with Et2O (400 mL) to yield a solid which was collected by filtration and vacuum dried to yield tert-butyl 4-(1-oxo-1,3-dihydroisobenzofuran5-yl)piperazine-1-carboxylate (120 g, 40%) as a yellow solid. m / z (ESI+), [M+H]+= 319. 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-(hydroxymethyl)benzoic acid
[0205] NaOH (62.3 g, 1557.9 mmol) was added to tert-butyl 4-(1-oxo-1,3-dihydroisobenzofuran-5-yl)piperazine-1-carboxylate (124.0 g, 389.5 mmol) in THF (350 mL) / MeOH (350 mL) / water (350 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 2 h. The reaction mixture was adjusted to pH 4 to 5 with 1M HCl. The precipitate was collected by filtration, washed with water (100 mL), and dried under vacuum to yield 4-(4-(tert-butoxycarbonyl)piperazine-1-yl)-2-(hydroxymethyl)benzoic acid (120.0 g, 92%) as a white solid, which was used without further purification. m / z (ESI+) [M+H]+= 337. tert-butyl 4-(3-(hydroxymethyl)-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate Petition 870260111673, dated 10 / 29 / 2026, p. 142 / 831 138 / 375
[0206] 2 M (Diazomethyl)trimethylsilane in hexane (669 mL, 1337.7 mmol) was added dropwise to 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-(hydroxymethyl)benzoic acid (150 g, 445.91 mmol) in MeOH (700 mL) and EtOAc (700 mL) at -10 °C under N2. The resulting solution was stirred at -10 °C for 15 min. The reaction was suddenly cooled with water (2 L) and the mixture was extracted with EtOAc (3 χ 1 L). The organic layer was dried with Na2SO4, filtered, and concentrated to yield tert-butyl 4(3-(hydroxymethyl)-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (153.0 g, 98%) as a brown oil, which was used without further purification. m / z (ESI+), [M+H]+= 351. tert-butyl 4-(3-(Bromomethyl)-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate
[0207] Triphenylphosphorane (172.0 g, 654.9 mmol) was added to tert-butyl 4-(3(hydroxymethyl)-4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (153.0 g, 436.6 mmol) in carbon tetrabromide (217.0 g, 654.9 mmol) in THF (1500 mL). The resulting solution was stirred at rt for 1 h. The reaction was rapidly cooled with water (2 L) and the mixture was extracted with EA (2 x 2 L). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by flash chromatography on silica (eluting with 0 to 15% EA on PE) to yield tert-butyl 4-(3-(bromomethyl)4-(methoxycarbonyl)phenyl)piperazine-1-carboxylate (95.0 g, 52%) as a pale yellow solid, which was used without further purification. m / z (ESI+), [M+H]+= 413. tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate oo Petition 870260111673, dated 10 / 29 / 2026, p. 143 / 831 139 / 375
[0208] DIPEA (120 mL, 689.6 mmol) was added to tert-butyl 4-(3-(bromomethyl)-4(methoxycarbonyl)phenyl)piperazine-1-carboxylate (95.0 g, 229.9 mmol) and the HCl salt of 3-aminopiperidine-2,6-dione (56.7 g, 344.8 mmol) in DMF (80 mL). The resulting solution was stirred at rt for 2 h, then stirring was continued at 90 °C for 16 h. The reaction mixture was cooled to rt, the precipitate was collected by filtration and washed with MeCN to yield tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate (85.0 g, 86%) as a colorless solid, which was used without further purification. m / z (ESI+), [M+H]+= 429. 3-(1-Oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione (Int IX)
[0209] 4 M HCl in dioxane (875 mL, 3,500.7 mmol) was added to tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate (75.0 g, 175.0 mmol) in dioxane (500 mL). The resulting solution was stirred at rt for 4 h, then filtered through celite to yield the HCl salt of 3-(1-oxo-5-(piperazin-1-yl)isoindolin-2-yl)piperidine-2,6-dione (63.0 g, 99%) as a dirty white solid. m / z (ESI+), [M+H]+= 329. Synthesis of intermediate Int X: 3-(5-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6dione (Int X)
[0210] LiHMDS (18.4 g, 110.0 mmol) was slowly added to 6-bromo-1-methyl-1,3-dihydro-2-Hb-enzo[o]imidazol-2-one (10.0 g, 44.0 mmol) in THF (25.0 mL) at 25 °C under N2. The resulting mixture was stirred at rt for 50 min and then added dropwise over a period of 15 min to 3-bromopiperidine-2,6-dione (16.9 g, 88.1 mmol) in THF (20.0 mL) at 25 °C under N2. The reaction mixture was stirred at Petition 870260111673, dated 10 / 29 / 2026, p. 144 / 831 The organic layer was heated to 140 / 375 °C for 3 hours, then cooled to room temperature before being poured into a saturated NH4Cl solution (100 mL) and extracted with EtOAc (3 x 100 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under reduced pressure to produce a brown solid. The crude product was ground with MeCN (300 mL), filtered, and dried in a vacuum oven to produce 3-(5-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (10.0 g, 67%) as a yellow solid, which was used without further purification. Intermediate synthesis Int XI: 3-(3-methyl-2-oxo-4-(3-(piperidin-4-yloxy)prop-1-yn-1-yl)-2,3-dihydro-1Hbenzo[d]imidazol-1-yl)piperidine-2,6-dione 4-(Prop-2-yn-1-yloxy)piperidine-1-carboxylate tert-butyl
[0211] NaH (4.5 g, 74.5 mmol) was added to tert-butyl 4-hydroxypiperidine-1-carboxylate (5.0 g, 24.8 mmol) in DMF (100 mL) at 0 °C under N2. The reaction mixture was stirred for 1 h before the addition of 3-bromoprop-1-yne (3.0 g, 24.8 mmol) and stirring was continued for 4 h at rt. The reaction was rapidly cooled with saturated aqueous NH4Cl (300 mL) and the mixture was extracted with EtOAc (3 x 300 mL). The organic layer was dried with Na2SO4, filtered, and concentrated to yield crude tert-butyl 4-(prop2-yne-1-yloxy)piperidine-1-carboxylate (1.4 g, 93%) which was used without further purification. m / z (ESI+), [Mt Bu+MeCN+H]+= 225. tert-butyl 4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4yl)prop-2-yn-1-yl)oxy)piperidine-1-carboxylate
[0212] Molecular sieve 4A (10 mg) was slowly added to triphenylphosphine palladium chloride (0.5 g, 0.7 mmol), copper(I) iodide (0.1 g, 0.7 mmol), Cs2CO3 (9.3 g, 28.4 mmol), tert-butyl 4-(prop-2-yn-1-yloxy)piperidine-1-carboxylate (2.6 g, 10.7 mmol) and 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1 Petition 870260111673, dated 10 / 29 / 2026, p. 145 / 831 141 / 375 il)piperidine-2,6-dione (Int VI) (2.4 g, 7.1 mmol) in DMF (50 mL) at 25 °C under N2. The resulting mixture was stirred at 80 °C for 2 h. The reaction mixture was filtered through paper. Then, the reaction was rapidly cooled with saturated NH4Cl (100 mL) and the mixture was extracted with EtOAc (3 x 100 mL). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by C18-flash chromatography (eluting with MeCN at 60-80% in water) to yield tert-butyl 4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]i-midazol-4yl)prop-2-yn-1-yl)oxy)piperidine-1-carboxylate (2.1 g, 60%) as a gray solid. m / z (ESI+), [M+H]+= 397. 3-(3-methyl-2-oxo-4-(3-(piperidin-4-yloxy)prop-1-yn-1-yl)-2,3-dihydro-1Hbenzo[d]imidazol-1-yl)piperidine-2,6-dione (Int XI)
[0213] 4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidine-1-carboxylate tert-butyl (2.1 g, 4.1 mmol) and 4 M HCl in 1,4-dioxane (21 mL) were stirred under a nitrogen atmosphere at rt for 1 h. The reaction was rapidly cooled with water (25 mL) and the solvent was evaporated. The crude product was purified by C18 flash chromatography (eluting with MeCN at 25 to 50% in water) to yield 3-(3-methyl-2-oxo-4-(3(piperidin-4-yloxy)prop-1-yn-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (1.7 g, 81%) as a yellow solid. m / z (ESI+), [M+H]+= 397. Synthesis of intermediate Int XII: 3-(3-methyl-2-oxo-5-(4-(piperidin-4-yl)piperazin-1-yl)-2,3-dihydro-1H benzo[d]imidazol-1-yl)piperidine-2,6-dione tert-butyl 4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5yl)piperazin-1-yl)piperidine-1-carboxylate Petition 870260111673, dated 10 / 29 / 2026, p. 146 / 831 142 / 375 O
[0214] 3-(5-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Int X) (500 mg, 1.5 mmol) was added to tert-butyl 4-(piperazin-1-yl)piperidine-1-carboxylate (398 mg, 1.5 mmol), RuPhos (138 mg, 0.3 mmol), RuPhos Pd G2 (230 mg, 0.3 mmol), LiHMDS (1 M in THF) (8 mL, 8.0 mmol) and 4A molecular sieves (100 mg) in toluene (10 mL) under N2. The resulting mixture was stirred at 80 °C for 2 h, then cooled to rt. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield tert-butyl 4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1-Hbenzo[d]imidazol-5-yl)piperazin-1-yl)piperidine-1-carboxylate (900 mg, 90%) as a brown solid. m / z (ESI+), [M+H]+= 527. 3-(3-methyl-2-oxo-5-(4-(piperidin-4-yl)piperazin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol1-yl)piperidin-2,6-dione (Int XII)
[0215] 4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)piperazin-1-yl)piperidine-1-carboxylate tert-butyl (1.4 g, 2.7 mmol) was added to TFA (5.2 g, 53.2 mmol) in DCM (21 mL). The resulting mixture was stirred at 25 °C for 2 h, then concentrated under reduced pressure. The crude product was purified by C18-flash chromatography (eluting with MeCN at 0 to 100% in water) to yield 3-(3-methyl-2-oxo-5-(4-(piperidin-4-yl)piperazin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (456 mg, 76%) as a brown solid. m / z (ESI+), [M+H]+= 427. Synthesis of intermediate Int XIII: 3-(1-(Piperidin-4-yl)-1H-indol-4-yl)piperidine-2,6-dione Petition 870260111673, dated 10 / 29 / 2026, p. 147 / 831 143 / 375 tert-butyl 4-(4-(2,6-bis(Benzyloxy)pyridin-3-yl)-1H-indol-1-yl)piperidine-1-carboxylate
[0216] Na2CO3 (2.29 g, 21.6 mmol) was added to (2,6bis(benzyloxy)pyridin-3-yl)boronic acid (3.62 g, 10.81 mmol), tert-butyl 4-(4-bromo-1H-indol-1yl)piperidine-1-carboxylate (4.1 g, 10.81 mmol) and [1,1'bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.79 g, 1.08 mmol) in 1,4-dioxane (90 mL) and water (45.0 mL) at 30 °C under nitrogen. The resulting solution was stirred at 100 °C for 12 hours. The mixture was then filtered through celite and concentrated, and the residue was purified by preparative TLC (pentane: EtOAc = 3:1) to yield tert-butyl 4(4-(2,6-bis(benzyloxy)pyridin-3-yl)-1H-indol-1-yl)piperidine-1-carboxylate (4.80 g, 75%) as a yellow gum. m / z (ESI+), [M+H]+= 590. tert-butyl 4-(4-(2,6-dioxopiperidin-3-yl)-1H-indol-1-yl)piperidine-1-carboxylate
[0217] 4-(4-(2,6-bis(Benzyloxy)pyridin-3-yl)-1H-indol-1-yl)piperidine-1-carboxylate tert-butyl (4.8 g, 8.14 mmol) was added to Pd / C (1.44 g, 8.14 mmol) in EtOH (90 mL) and in EtOAc (90 mL) at 25 °C. The resulting solution was stirred at rt for 4 hours under a nitrogen atmosphere. The mixture was then filtered through celite and concentrated to yield 4-(4-(2,6-dioxopiperidin-3-yl)-1H-indol-1-yl)piperidine-1-carboxylate tert-butyl (3.0 g, 90%) as a colorless solid, which was used without further purification. m / z (ESI+), [M+H]+= 412. 3-(1-(Piperidin-4-yl)-1H-indol-4-yl)piperidine-2,6-dione (Int XIII)
[0218] 4-(4-(2,6-dioxopiperidin-3-yl)-1H-indol-1-yl)piperidine-1-carboxylate tert-butyl (700 mg, 1.70 mmol) was added to 4-toluenesulfonic acid (586 mg, 3.40 mmol) in EtOAc (20 mL) at 25 °C under nitrogen. The resulting solution was stirred to Petition 870260111673, dated 10 / 29 / 2026, p. 148 / 831 144 / 375 °C for 12 hours. The solvent was removed under reduced pressure and the crude product was purified by C18-flash chromatography (eluting with 0 to 20% ACN in water) to yield the 4-toluenesulfonic acid salt of 3-(1-(piperidin-4-yl)-1-hindol-4-yl)piperidine-2,6-dione (266 mg, 31%) as a colorless solid. m / z (ESI+), [M+H]+= 312. Synthesis of intermediate Int XIV: N -(Imidazo[1,2-b]pyridazin-3-yl)-2-((1r,4r)-4-(iodomethyl)cyclohexyl)-6-methoxy-2 Hindazol-5-carboxamide
[0219] To a suspension of 2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (described in the synthesis of Int II) (539 mg, 1.28 mmol) in anhydrous pyridine (25 mL) under argon was added methyltriphenoxyphosphonium iodide (1.92 g, 4.08 mmol). The reaction was rapidly cooled with MeOH (1 mL) after stirring for 10 min and then concentrated. The residue was washed with water (10 mL χ 3), redissolved in dichloromethane (40 mL), concentrated to 15 mL, and then purified by silica gel chromatography (eluting with ethyl acetate and then 0 to 10% MeOH in DCM) to yield N-(imidazo[1,2-b]pyridazin-3yl)-2-((1r,4r)-4-(iodomethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide (520 mg, 76%) as a yellow solid.1H NMR (500 MHz, DMSO-d6) δ 11.05 (1H, s), 8.64 (1H, dd), 8.59 (1H, d), 8.58 (1H, s), 8.15 (1H, dd), 8.05 (1H, s), 7.26 (1H, s), 7.22 (1H, dd), 4.45 (1H, tt), 4.12 (3H, s), 3.30 (2H, d), 2.16 (2H, d), 1.98 (4H, tt), 1.49 - 1.59 (1H, m), 1.21 - 1.31 (2H, m). m / z (ESI+), [M+H]+= 531. Synthesis of intermediate Int XV: ((1r,4r)-4-(5-((1-cyclopropyl-2-oxo-1,2-dihydropyridin-3yl)carbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)methyl methanesulfonate Petition 870260111673, dated 10 / 29 / 2026, p. 149 / 831 145 / 375
[0220] Methanesulfonic anhydride (120 mg, 0.69 mmol) was added to TEA (0.144 mL, 1.03 mmol) and N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4(hydroxymethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide (described under synthesis of Int III) (150 mg, 0.34 mmol) in DCM (2 mL) at 0 °C for 5 minutes. The resulting mixture was stirred at rt for 12 hours. The solvent was removed under reduced pressure and the crude product was purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield ((1r,4r)-4-(5((1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)carbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)methyl methanesulfonate (100 mg, 57%) as a colorless solid. m / z (ESI+), [M+H]+= 515. Synthesis of intermediate Int XVI: 6-Cyclopropoxy-2-((1r,4r)-4-formylcyclohexyl)-N -(imidazo[1,2-b]pyridazin-3-yl)-2H indazol-5-carboxamide ((1r,4r)-4-(5-Bromo-6-cyclopropoxy-2H-indazol-2-yl)cyclohexyl)methanol
[0221] Tri-n-butylphosphine (9.09 g, 44.94 mmol) was added to TEA (6.26 mL, 44.94 mmol), 5-bromo-4-cyclopropoxy-2-nitrobenzaldehyde (4.50 g, 15.73 mmol) and ((1r,4r)-4-aminocyclohexyl)methanol hydrochloride (2.48 g, 14.98 mmol) in iPrOH (90 mL). The resulting mixture was stirred at 80 °C for 4 h, concentrated, diluted with DCM (500 mL) and washed with water (200 mL χ 3). The organic layer was dried with Na2SO4, filtered, concentrated and purified by silica gel chromatography (eluting with EtOAc at 0 to 100% on PE) to yield a brown oil. The oil was ground with petroleum ether to produce ((1r,4r)-4-(5-bromo-6-cyclopropoxy-2H-indazol-2yl)cyclohexyl)methanol (2.20 g, 40.2%) as a colorless solid. 1H NMR (500 MHz, DMSO-d6) δ 8.30 (1H, d), 7.96 (1H, d), 7.40 (1H, s), 4.50 (1H, br. s), 4.40 (1H, br. t), 3.96 (1H, br. s), 3.29 (2H, d), 2.05 - 2.20 (2H, m), 1.80 - 2.00 (4H, m), 1.40 - 1.55 (1H, m), 1.15 (2H, br. q), 0.85 - 0.95 (2H, m), 0.70 - 0.80 (2H, m). m / z (ESI+), [M+H]+= 365 / 367 (1:1). 6-Cyclopropoxy-2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)2H-indazol-5-carboxamide Petition 870260111673, dated 10 / 29 / 2026, p. 150 / 831 146 / 375
[0222] A mixture of ((1r,4r)-4-(5-bromo-6-cyclopropoxy-2H-indazol-2-yl)cyclohexyl)methanol (1.00 g, 2.74 mmol), imidazo[1,2-b]pyridazin-3-amine (1.10 g, 8.21 mmol), Pd(OAc)2 (123 mg, 0.55 mmol), 1,3-bis(diphenylphosphino)propane (452 mg, 1.10 mmol) and TEA (73.82 mL, 27.38 mmol) in MeCN (15 mL) was stirred under a CO₂ atmosphere at 15 atm and 100 °C for 16 h. The reaction mixture was filtered through celite. The filtrate was concentrated to produce 6-cyclopropoxy-2-((1r,4r)-4(hydroxymethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2H-indazole-5-carboxamide (1.00 mg, 82%), which was used without further purification. m / z (ESI+), [M+H]+= 447. 6-Ciclopropoxi-2-((1 r,4 r)-4-formilciclo-hexil)-N-(imidazo[1,2-b ]piridazin-3-il)-2 Hindazol-5-carboxamida (Int XVI)
[0223] To a solution of 6-cyclopropoxy-2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-2H-indazol-5-carboxamide (2.00 g, 4.48 mmol) in DCM (200 mL) was added Dess-Martin periodinan (2.47 g, 5.82 mmol) in portions. The resulting mixture was stirred at rt for 2 h, then concentrated and purified directly by silica gel chromatography (eluting with 0 to 10% IPA in EtOAc) and additionally by C18 flash chromatography (eluting with 0 to 30% MeCN in water) to yield 6-cyclopropoxy-2-((1r,4r)-4-formylcyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-2H-indazol-5-carboxamide (200 mg, 10.1%) as a yellow solid. 1H NMR (500 MHz, DMSO-dβ) δ 9.71 (1H, s), 8.61 - 8.81 (3H, m), 8.21 (1H, dd), 8.14 (1H, s), 7.61 (1H, s), 7.28 (1H, dd), 4.50-4.64 (1H, m), 4.30 (1H, br. s), 2.45 (1H, td), 2.15 - 2.25 (2H, m), 2.05 - 2.15 (2H, m), 1.95 - 2.05 (2H, m), 1.41 - 1.51 (2H, m), 1.13 - 1.23 (2H, m), 1.03 - 1.13 (2H, m). m / z (ESI+), [M+H]+= 445. Petition 870260111673, dated 10 / 29 / 2026, p. 151 / 831 147 / 375 Synthesis of intermediate Int XVII: 1-(2-Methyl-1-(piperidin-4-yl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione tert-butyl 4-(4-Bromo-2-methyl-1H-indol-1-yl)piperidine-1-carboxylate
[0224] CS2CO3 (12.4 g, 38.08 mmol) was added to a solution of 4-bromo-2-methyl-1H-indol (4.0 g, 19.04 mmol) and tert-butyl 4-(tosyloxy)piperidine-1-carboxylate (20.3 g, 57.12 mmol) in DMF (70 mL) at 25 °C. The resulting solution was stirred at 100 °C for 16 h. The reaction mixture was concentrated, diluted with DCM (250 mL), and washed with water (100 mL x 2). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by C18 flash chromatography (eluting with MeCN at 0-90% in water (FA at 0.05%)) to yield tert-butyl 4-(4-bromo-2-methyl-1-hindol-1-yl)piperidine-1-carboxylate (850 mg, 11%) as a brown solid. 1H NMR (400 MHz, DMSO-d6) δ 7.49 (1H, d), 7.18 (1H, br. s), 6.97 (1H, t), 6.21 (s, 1H), 4.42 - 4.55 (1H, m), 4.02 - 4.20 (2H, m), 2.88 - 3.08 (2H, m), 2.48 (3H, s), 2.15 - 2.30 (2H, m), 1.72 - 1.85 (2H, m), 1.48 (9H, s). m / z (ESI+), [M+H]+= 393 / 395 (1 :1). ter-butyl 4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-2-methyl-1H-indol-1-yl)piperidine-1carboxylate
[0225] EPhos Pd G4 ({dicyclohexyl[3-(1-methylethoxy)-2',4',6'tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate) (374 mg, 0.41 mmol) was added to a mixture of tert-butyl 4-(4-bromo-2-methyl-1H-indol-1yl)piperidine-1-carboxylate (800 mg, 2.03 mmol), dihydropyrimidine2,4(1H,3H)-dione (464 mg, 4.07 mmol) and Cs2CO3 (1325 mg, 4.07 mmol) in 1,4dioxane (10 mL) at 25 °C under nitrogen. The resulting suspension was stirred at 80 °C for 16 h. The reaction mixture was filtered through celite and then concentrated. The Petition 870260111673, dated 10 / 29 / 2026, p. 152 / 831 148 / 375 crude product was purified by C18-flash chromatography (eluting with 0 to 50% MeCN in water (FA at 0.05%)) to yield tert-butyl 4-(4-(2,4-dioxotetrahydropyrimidin1(2H)-yl)-2-methyl-1H-indol-1-yl)piperidine-1-carboxylate (300 mg, 34.6%) as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 10.31 (1H, s), 7.41 (1H, d), 7.04 (1H, br. s), 6.90 (1H, d), 6.18 (s, 1H), 4.45 - 4.55 (1H, m), 4.05 - 4.20 (2H, m), 3.70 - 3.80 (2H, br. s), 2.85 - 3.08 (2H, m), 2.70 - 2.80 (2H, br. s), 2.45 (3H, s), 2.15 - 2.32 (2H, m), 1.78 - 1.85 (2H, m), 1.45 (9H, s). m / z (ESI+), [M+H]+= 427. 1-(2-Methyl-1-(piperidin-4-yl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione (Int XVII)
[0226] 4 M HCl in dioxane (1.5 mL, 6.00 mmol) was added to tert-butyl 4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-2-methyl-1H-indol-1-yl)piperidine-1-carboxylate (300 mg, 0.70 mmol) in DCM (1.5 mL) at 25 °C. The resulting solution was stirred at 25 °C for 1 h. The reaction mixture was adjusted to pH 8 with saturated aqueous NaHCO3 and then concentrated. The crude product was dissolved in DCM (50 mL) and then washed with water (25 mL χ 2). The organic layer was dried with Na2SO4, filtered, and concentrated to yield 1-(2-methyl-1-(piperidin-4-yl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione (160 mg, 70%). 1H NMR (300 MHz, DMSO-d6) δ 10.31 (1H, br. s), 7.59 (1H, d), 7.04 (1H, t), 6.89 (1H, d), 6.15 (s, 1H), 4.20 - 4.40 (1H, m), 3.74 (2H, t), 3.01 - 3.20 (2H, m), 2.75 (2H, t), 2.67 (2H, t), 2.43 (3H, s), 2.20 - 2.40 (2H, m), 1.68 - 1.80 (2H, m). m / z (ESI+), [M+H]+= 327. Synthesis of intermediate Int XVIII: 1-(3-methyl-1-(piperidin-4-yl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione tert-butyl 4-(4-Bromo-3-methyl-1H-indol-1-yl)piperidine-1-carboxylate
[0227] Potassium tert-butoxide (10.58 g, 94.25 mmol) was added to tert-butyl 4-(tosiloxy)piperidine-1-carboxylate (16.75 g, 47.13 mmol) and 4-bromo-3 Petition 870260111673, dated 10 / 29 / 2026, p. 153 / 831 149 / 375 methyl-1H-indol (9.90 g, 47.13 mmol) in DMF (100 mL) under N2. The resulting solution was stirred at 100 °C for 12 h. The reaction mixture was diluted with DCM (500 mL) and washed with saturated NH4Cl (200 mL χ 3). The organic layer was dried with Na2SO4, filtered, and concentrated. The residue was purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield tert-butyl 4-(4-bromo-3-methyl-1H-indol-1yl)piperidine-1-carboxylate (3.20 g, 17.3%) as a brown solid. 1H NMR (400 MHz, DMSO-d6) δ 7.54 (1H, d), 7.40 (1H, d), 7.15-7.19 (1H, m), 6,987.02 (1H, m), 4.54 (1H, br. t), 4.00 - 4.22 (2H, m), 2.80 - 3.03 (2H, m), 2.10 (3H, s), 1.84 - 1.95 (2H, m), 1.70 -1.84 (2H, m), 1.43 (9H, s). m / z (ESI+), [M+H]+= 393 / 395 (1 :1). tert-butyl 4-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-3-methyl-1H-indol-1yl)piperidine-1-carboxylate
[0228] To a suspension of Cul (232 mg, 1.22 mmol), trans-1,2-cyclohexanediamine (139 mg, 1.22 mmol), 3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (1.715 g, 7.32 mmol) and tert-butyl 4-(4-bromo-3-methyl-1H-indol-1yl)piperidine-1-carboxylate (2.40 g, 6.10 mmol) in dioxane (24 mL) under N2, tripotassium phosphate (3.89 g, 18.31 mmol) was added. The resulting suspension was stirred at 100 °C for 12 h. The reaction mixture was diluted with DCM (300 mL) and washed with saturated aqueous NH4Cl (200 mL χ 3). The organic layer was dried with Na2SO4, filtered, and concentrated. The residue was purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield tert-butyl 4-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-3-methyl-1H-indol-1-yl)piperidine-1-carboxylate (1.20 g, 36.0%) as a colorless solid. 1H NMR (400 MHz, DMSO-d6) δ 7.52 (1H, d), 7.24 (2H, d), 7.14 (1H, t), 6.93 (1H, br.d), 6.87 (2H, d), 5.76 (1H, s), 4.87 (1H, d), 4.77 (1H, d), 4.49 - 4.50 (1H, m), 4.03 - 4.21 (2H, m), 3.78 - 3.86 (1H, m), 3.73 (3H, s), 3.60 - 3.68 (1H, m), 2.85 -3.10 (4H, m), 2.05 (3H, s), 1.86 - 1.97 (2H, m), 1.70 - 1.86 (2H, m), 1.44 (9H, s). m / z (ESI+), [M+Na]+= 569. 1-(3-metil-1-(piperidin-4-il)-1H-indol-4-il)di-hydropirimidina-2,4(1H,3H)-diona (XVIII) Petition 870260111673, on 10 / 29 / 2026, page. 154 / 831 150 / 375\N—(NH' NΗΝΎ W
[0229] Triphilic acid (2 mL, 22.52 mmol) was added to 4-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-3-methyl-1H-indol-1-yl)piperidine-1 tert-butyl carboxylate (850 mg, 1.55 mmol) in TFA (4 mL). The resulting mixture was stirred at 60 °C for 3 hours. The mixture was purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield 1-(3-methyl-1-(piperidin-4-yl)1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione (427 mg, 55.9%) as a gray solid. 1H NMR (400 MHz, DMSO-d6) δ 10.39 (1H, s), 7.53 (1H, d), 7.19 (1H, t), 7.18 (1H, s), 6.95 (1H, d), 4.64 - 4.75 (1H, m), 3.84 (1H, dt), 3.61 (1H, dt), 3.42-3.55 (2H, m), 3.08-3.25 (2H, m), 2.77 (2H, t), 2.23 (3H, s), 2.03-2.18 (4H, m). m / z (ESI+), [M+H]+= 327. Synthesis of intermediate Int XIX: 1-(1-([1,4'-Bipiperidin]-4-yl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione tert-butyl 4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-yl)-[1,4'-bipiperidine]-1'carboxylate
[0230] 4-Oxopiperidine-1-carboxylate tert-butyl (287 mg, 1.44 mmol) was added to 1-(1-(piperidin-4-yl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione (synthesis described in document no. WO2022069520) (450 mg, 1.44 mmol) in a mixture of DCE (4 mL) and DMF (4 mL). The resulting mixture was stirred at 70 °C for 16 hours. NaBH3CN (305 mg, 1.44 mmol) was added and the mixture was stirred at 70 °C for 3 hours. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography on silica (eluting with 0 to 100% MeOH in DCM) to yield tert-butyl 4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-yl)-[1,4'-bipiperidine]-1'-carboxylate (600 mg, 84%) as a colorless solid. m / z (ESI+), [M+H]+= 496. -(1 -([1,4'-Bipiperidin]-4-yl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione (Int XIX) Petition 870260111673, dated 10 / 29 / 2026, p. 155 / 831 151 / 375
[0231] (4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-yl)-[1,4'-bipiperidine]-1'-tert-butyl carboxylate (320 mg, 0.65 mmol)) was added to formic acid (4 mL). The resulting mixture was stirred at 40 °C for 2 h. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography. C18 (eluting with 3% ACN to 80% in 10 mM NH4HCO3) to produce 1-(1-([1,4'-bipiperidin]-4-yl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione (350 mg, 63%) as a colorless solid. m / z (ESI+), [M+H]+= 396. Synthesis of intermediate Int XX: N -(Imidazo[1,2-b]pyridazin-3-yl)-2-((1r,4r)-4-(2-iodoethyl)cyclohexyl)-6-methoxy-2 Hindazol-5-carboxamide 2-((1 p,4 p)-4-(5-Bromo-6-methoxy-2 H-indazol-2-yl)cyclo-hexyl)ethan-1-ol
[0232] Tri-n -butylphosphine (21.19 g, 104.73 mmol) was added to TEA (19.46 mL, 139.64 mmol), 5-bromo-4-methoxy-2-nitrobenzaldehyde (9.08 g, 34.91 mmol) and 2-((1r,4r)-4-aminocyclohexyl)ethan-1-ol (5.00 g, 34.91 mmol) in iPrOH (50 mL). The resulting mixture was stirred at 80 °C for 14 h. Two parallel batches of the above reaction were set up. After completion, the two batches were combined, diluted with water (250 mL) and extracted with EtOAc (300 mL χ 3). The organic layer was dried with Na2SO4, filtered, concentrated, and purified by silica gel chromatography (eluting with 3 to 25% EtOAc on PE) to yield 2-((1r,4r)-4-(5-bromo-6-methoxy-2H-indazol-2-yl)cyclohexyl)ethan-1-ol (5.00 g, 50%) as a yellow solid. 1H NMR (500 MHz, DMSO-dβ) δ 8.27 (1H, s), 7.96 (1H, s), 7.11 (1H, s), 4.30 - 4.45 (2H, m), 3.86 (3H, s), 3.48 (2H, q), 2.05 - 2.15 (m, 2H), 1.80 - 1.95 (4H, m), 1.45 1.55 (1H, m), 1.39 (2H, d), 1.10 - 1.20 (2H, m). m / z (ESI+), [M+H]+= 353 / 355 (1:1). 2-((1r,4r)-4-(2-Hydroxyethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2 Hindazol-5-carboxamide Petition 870260111673, dated 10 / 29 / 2026, p. 156 / 831 152 / 375
[0233] A mixture of 2-((1r,4r)-4-(5-bromo-6-methoxy-2H-indazol-2-yl)cyclohexyl)ethan-1-ol (2.00 g, 5.66 mmol), imidazo[1,2-b]pyridazin-3-amine (2.278 g, 16.98 mmol), Pd(OAc)2 (254 mg, 1.13 mmol), 1,3-bis(diphenylphosphine)propane (934 mg, 2.26 mmol) and TEA (7.89 mL, 56.62 mmol) in MeCN (25 mL) was stirred under CO atmosphere at 15 atm and 100 ° C for 14 h. The reaction mixture was filtered and the collected solid was washed with hot MeCN (~80 °C, 250 mL) and concentrated to dryness to yield 2-((1r,4r)-4-(2-hydroxyethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3yl)-6-methoxy-2H-indazol-5-carboxamide (531 mg, 22%). 1H NMR (500 MHz, DMSOd6) δ 11.04 (1H, s), 8.63 (1H, d), 8.58 (1H, s), 8.57 (1H, s), 8.14 (1H, d), 8.05 (1H, s), 7.26 (1H, s), 7.22 (1H, dd), 4.35 - 4.48 (2H, m), 4.11 (3H, s), 3.43 - 5.52 (2H, m), 2.09 - 2.20 (2H, m), 1.81 - 1.98 (4H, m), 1.50 (1H, br. s), 1.35 - 1.44 (2H, m), 1.10 - 1.21 (2H, m). m / z (ESI+), [M+H]+= 435. 2-((1 r,4 r)-4-(5-(imidazo[1,2-b ]pyridazin-3-ylcarbamoyl)-6-methoxy2H-indazol-2-yl)cyclohexyl)ethyl methanesulfonate
[0234] Methanesulfonic chloride (81 μL, 1.04 mmol) was added to a solution of 2-((1r,4r)-4-(2-hydroxyethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide (300 mg, 0.69 mmol) and TEA (289 μL, 2.07 mmol) in DCM (20 mL). The resulting solution was stirred at rt for 3 h. The reaction mixture was diluted with DCM (20 mL) and washed with saturated aqueous NaHCO4 (50 mL χ 3). The organic layer was dried with Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography (eluting with 0 to 4% EtOAc in PE) to yield 2-((1r,4r)-4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)ethyl methanesulfonate (300 mg, 85%) as a colorless solid. m / z (ESI+), [M+H]+= 513. Petition 870260111673, dated 10 / 29 / 2026, page 157 / 831 153 / 375 N-(Imidazo[1,2-b]pyridazin-3-yl)-2-((1r,4r)-4-(2-iodoethyl)cyclohexyl)-6-methoxy-2 Hindazol-5-carboxamide (Int XX)
[0235] Lithium iodide (379 mg, 2.83 mmol) was added in portions to a solution of 2-((1r,4r)-4-(5-(imidazo[1,2-b]pyridazin-3ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)ethyl methanesulfonate (290 mg, 0.57 mmol) in acetonitrile (10 mL) at 10 °C under N2. The resulting mixture was stirred at 70 °C for 10 h. The crude product was purified by C18-flash chromatography (eluting with MeCN at 40 to 60% in water) to yield N-(imidazo[1,2-b]pyridazin-3-yl)-2-((1r,4r)4-(2-iodoethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide (250 mg, 81.2%) as a colorless solid. m / z (ESI+), [M+H]+= 545. Synthesis of intermediate Int XXI: N -(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1r,4r) -4-(2-iodoethyl)cyclohexyl)-6-methoxy-2H-indazole-5-carboxamide N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1r,4r)-4-(2-hydroxyethyl)cyclohexyl)-6methoxy-2H-indazol-5-carboxamide
[0236] Pd(OAc)2 (114 mg, 0.51 mmol), 2-((1r,4r)-4-(5-bromo-6-methoxy-2Hindazol-2-yl)cyclohexyl)ethan-1-ol (synthesis described in Int XX) (900 mg, 2.55 mmol), 3-amino-1-cyclopropylpyridin-2(1H)-one (1148 mg, 7.64 mmol), 1,3bis(diphenylphosphino)propane (420 mg, 1.02 mmol) and TEA (3.55 mL, 25.48 mmol) in MeCN (15 mL) were stirred under a CO₂ atmosphere at 40 atm and 100 °C for 13 h. The reaction mixture was poured into water (200 mL) and extracted with EtOAc (200 mL x 3). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude residue was purified by C18 flash chromatography (eluting with 0 to 50% acetonitrile in water) to yield N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-(2r) ... Petition 870260111673, dated 10 / 29 / 2026, pp. 158 / 831 154 / 375 hidroxietil)ciclo-hexil)-6-metoxi-2H-indazol-5-carboxamida (300 mg, 26%) combined with solid color. RMN de 1H (500 MHz, DMSO-dβ) δ 11.06 (1H, s), 8.57 (2H, d), 8.44 (1H, dd), 7.30 (1H, dd), 7.21 (1H, s), 6.29 (1H, t), 4.42 - 4.48 (1H, m), 4.39 (1H, s), 4.09 (3H, s), 3.42 - 3.52 (3H, m), 2.10 - 2.19 (2H, m), 1.83 - 1.95 (4H, m), 1.45 - 1.56 (1H, m), 1.37 - 1.45 (2H, m), 1.22 - 1.10 (2H, m), 1,00 -1.10 (2H, m), 0.88 - 0.95 (2H, m).m / z (ESI+), [M+H]+= 451. Metanosulfonato de 2-((1 r,4 r)-4-(5-((1-ciclopropil-2-oxo-1,2-di-hydropiridin-3il)carbamoil)-6-metoxi-2H-indazol-2-il)ciclo-hexil)etila
[0237] Methanesulfonic anhydride (433 mg, 2.49 mmol) was added to TEA (520 μL, 3.73 mmol) and N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-(2-hydroxyethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide (280 mg, 0.62 mmol) in DCM (6 mL) at 25 °C. The resulting solution was stirred at 25 °C for 1 h. The reaction mixture was poured into water (150 mL) and extracted with DCM (150 mL χ 3). The organic layer was dried with Na2SO4, filtered, and concentrated to yield 2-((1r,4r)-4-(5-((1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)carbamoyl)-6-methoxy-2-hindazol-2-yl)cyclohexyl)ethyl methanesulfonate as an orange solid, which was used in the next step without further purification. m / z (ESI+), [M+H]+= 529. N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1r,4r)-4-(2-iodoethyl)cyclohexyl)-6methoxy-2H-indazol-5-carboxamide (Int XXI)
[0238] Lithium iodide (192 mg, 1.44 mmol) was added to TEA (200 μL, 1.44 mmol) and 2-((1r,4r)-4-(5-((1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)carbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)ethyl methanesulfonate (380 mg, 0.72 mmol) in THF (8 mL) at 25 °C. The resulting solution was stirred at 60 °C for 1 h. The crude product was purified by C18 flash chromatography (eluting with 0 to 80% acetonitrile in water) to yield N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-(2 Petition 870260111673, dated 10 / 29 / 2026, page 159 / 831 155 / 375 iodoethyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida (250 mg, 62%) as a colorless solid. NMR de1H (500 MHz, DMSO-dβ) δ 11.04 (1H, s), 8.55 (1H, s), 8.42 (1H, br, d), 7.28 (1H, br, d), 7.20 (1H, s), 6.27 (1H, t), 4.38 - 4.49 (1H, m), 4.07 (3H, s), 3.41 - 3.48 (1H, m), 3.30 - 3.40 (2H, m, sobreposto com água), 2.10 - 2.18 (2H, m), 1.83 - 1.94 (4H, m), 1.72 - 1.81 (2H, m), 1.48 (1H, br, s), 1.12 - 1.22 (2H, m), 1.00 - 1.07 (2H, m), 0.87 - 0.93 (2H, m). m / z (ESI+), [M+H]+= 561. Intermediary Summary Int XXII: 1-(1-(2-(Piperazin-1-yl)ethyl)-1 H -indole-4-yl)di-hidropyrimidine-2,4(1 H ,3 H)-diona 4-(3-(4-methoxybenzyl)-2,4-dioxotetra-hidropyrimidin-1(2 H)-yl)-1 H-indol-1 -carboxylate de
[0239] A mixture of 3-(4-methoxybenzyl) dihydropyrimidine-2,4(1 H , 3 H )-dione (9.89 g, 42.21 mmol), tert-butyl 4-bromo-1 H-indole-1-carboxylate (12.50 g, 42.21 mmol), EPhos Pd G4 (methanesulfonate de{dicyclohexyl[3-(1-methylethoxy)-2',4',6'tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine}(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II)) (3.88 g, 4.22 mmol), from EPhos (dicyclohexyl(3-isopropoxy-2',4',6'-tri-isopropyl-[1,1'-biphenyl]-2yl)phosphane) (2.26 g, 4.22 mmol) and Cs2CO3 (27.50 g, 84.41 mmol) in dioxane (13 mL) under N2 was stirred at 100 °C for 12 h. The reaction mixture was diluted with DCM (750 mL) and washed with saturated aqueous NH4Cl (350 mL χ 3). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield tert-butyl 4(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-carboxylate (4.20 g, 22%) as a yellow solid.RMN de1H (400 MHz, DMSO-d6) δ 8.03 (1H, d), 7.70 (1H, d), 7.37 (1H, t), 7.26 (2H, d), 7.20 (1H, d), 6.88 (2H, d), 6.62 (1H, d), 4.84 (2H, s), 3.81 (2H, t), 3.73 (3H, s), 2.98 (2H, t), 1.65 (9H, s). m / z (ESI+), [M+H]+= 450. -(1 H-Indol-4-il)-3-(4-metoxibenzil)di-hydropirimidina-2,4(1 H,3 H)-diona Petition 870260111673, on 10 / 29 / 2026, page. 160 / 831 156 / 375
[0240] A solution of tert-butyl 4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidine-1(2H)-yl)-1H-indol-1-carboxylate (10.00 g, 22.25 mmol) in DCM (60 mL) and TFA (30 mL) was stirred at rt for 2 h. The reaction mixture was concentrated and then purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield 1-(1H-indol-4-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)dione (4.20 g, 54%) as a brown solid. 1H NMR (300 MHz, DMSO-d6) δ 11.27 (1H, s), 7.32-7.40 (2H, m), 7.26 (2H, d), 7.10 (1H, t), 6.93 (1H, d), 6.88 (2H, d), 6.29-6.36 (1H, m), 4.84 (2H, s), 3.80 (2H, t), 3.73 (3H, s), 2.95 (2H, t). m / z (ESI+), [M+H]+= 350. tert-butyl 4-(2-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1yl)ethyl)piperazine-1-carboxylate
[0241] A mixture of tert-butyl 4-(2-chloroethyl)piperazine-1-carboxylate (534 mg, 2.15 mmol), potassium iodide (14 mg, 0.09 mmol), cesium carbonate (839 mg, 2.58 mmol) and 1-(1H-indol-4-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (300 mg, 0.86 mmol) in DMF (16 mL) was stirred at 80 °C under N2 for 8 h. The reaction mixture was diluted with EtOAc (50 mL) and washed with saturated aqueous NH4Cl (50 mL χ 2). The organic layer was dried with Na2SO4, filtered, and concentrated to yield tert-butyl 4-(2-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1-hindol-1-yl)ethyl)piperazine-1-carboxylate (500 mg), which was used directly without further purification. m / z (ESI+), [M+H]+= 562. -(1 -(2-(Piperazin-1 -yl)ethyl)-1H-indol-4-yl)dihydropyrimidine-2,4(1 H ,3 H )-dione (Int XXII) Petition 870260111673, dated 10 / 29 / 2026, pp. 161 / 831 157 / 375
[0242] Triphilic acid (2 mL, 22.52 mmol) was added to tert-butyl 4-(2-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidine-1(2H)-yl)-1H-indol-1-yl)ethyl)piperazine-1-carboxylate (500 mg) in DCM (4 mL). The resulting solution was stirred at 60 °C for 2 h. The reaction mixture was concentrated and then purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield 1-(1-(2-(piperazin-1-yl)ethyl)-1H-indol-4-yl)dihydropyrimidine-2,4(1H,3H)-dione (250 mg, 85%) as a yellow oil. 1H NMR (300 MHz, DMSO-d6) δ 10.34 (1H, s), 7.47 (1H, d), 7.45 (1H, br. s), 7.16 (1H, t), 6.98 (1H, d), 6.40 (1H, d), 4.31 (2H, t), 3.79 (2H, t), 3.06 (4H, br. s), 2.76 (4H, q), 2.65 (4H, br. s). m / z (ESI+), [M+H]+= 562. Intermediate synthesis Int XXIII: 6-Cyclopropoxy- N -(imidazo[1,2- b ]pyridazin-3-yl)-2-(piperidin-4-yl)-2 H -indazol-5carboxamide 6-Cyclopropoxy-5-nitro-2H-indazole
[0243] Hydrazine (288 g, 7194 mmol) was slowly added to 4-cyclopropoxy-2-fluoro-5-nitrobenzaldehyde (324 g, 1439 mmol) in EtOH (3000 mL) at 20 °C under nitrogen. The resulting solution was stirred at 20 °C for 30 minutes and then heated to 80 °C for 2 h before the solvent was removed under reduced pressure. The residue was poured into water (2 L) and extracted with EtOAc (3 x 1 L). The organic layer was dried with Na2SO4 and concentrated. The crude product was purified by flash chromatography on silica (eluting with EA at 0 to 100% on PE) to yield 6-cyclopropoxy-5-nitro-2H-indazole (160 g, 51%) as a red solid. 1H NMR (300 MHz, DMSO-dβ) δ 0.67-0.82 (2H, m), 0.85-0.94 (2H, m), 4.07-4.17 (1H, m), 7.46-7.53 (1H, m), 8.14-8.23 (1H, m), 8.43 (1H, s), 13.36 (1H, br.s). m / z (ESI+), [M+H]+= 220. 6-Cyclopropoxy-2H-indazol-5-amine Petition 870260111673, dated 10 / 29 / 2026, p. 162 / 831 158 / 375
[0244] Palladium hydroxide on carbon (26 g, 182.5 mmol) and 6-cyclopropoxy-5-nitro-2H-indazole (40 g, 182.5 mmol) in MeOH (500 mL) were stirred under a nitrogen atmosphere at 25 °C for 12 hours. Then, the reaction mixture was filtered through silica. The solvent was removed under reduced pressure to yield 6-cyclopropoxy-2H-indazole-5-amine (30 g, 87%) as a yellow solid. The product was used without further purification. m / z (ES+) [M+H]+= 190. 6-Cyclopropoxy-5-iodo-2H-indazole, / 1
[0245] Sodium nitrite solution (24.6 g, 356.7 mmol) in water (10 mL) was added dropwise to 6-cyclopropoxy-2H-indazol-5-amine (45 g, 237.8 mmol) in acetic acid (500 mL) at 0 °C under N2 for 30 minutes. The resulting solution was stirred at 0 °C for 1 h. Then, potassium iodide (79 g, 476 mmol) in water (10 mL) was added dropwise at 0 °C for 30 minutes. The resulting solution was stirred at 60 °C for 12 h. The reaction mixture was poured into water (250 mL) and extracted with EtOAc (1 x 500 mL). The organic layer was dried with Na2SO4 and concentrated. The crude product was purified by flash chromatography on silica (eluting with 0 to 50% EtOAc in PE) to yield 6-cyclopropoxy-5-iodo-2H-indazole (21 g, 29%) as a pale yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 0.69-0.77 (2H, m), 0.81-0.93 (2H, m), 3.99 (1H, tt), 7.30 (1H, d), 7.91 (1H, d), 8.18 (1H, s). m / z (ES+), [M+H]+= 302. tert-butyl 4-(6-Cyclopropoxy-5-iodo-2H-indazol-2-yl)piperidine-1-carboxylate
[0246] A solution of tert-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate (11.2 g, 40.0 mmol), 6-cyclopropoxy-5-iodo-2H-indazole (6.0 g, 20.0 mmol), and potassium hydroxide (2.2 g, 40 mmol) in THF (300 mL) was stirred at 65 °C for 10 hours. The crude reaction mixture was cooled to room temperature, diluted with EtOAc (500 mL), and neutralized by the addition of saturated chloride solution. Petition 870260111673, dated 10 / 29 / 2026, p. 163 / 831 159 / 375 ammonium (120 mL). The product was extracted with ethyl acetate and the organic layer was dried with MgSO4, filtered and evaporated to produce the crude product. The crude product was purified by flash chromatography on silica (eluting with 0 to 30% ethyl acetate in petroleum ether) to produce tert-butyl 4-(6-cyclopropoxy-5-iodo-2H-indazol-2-yl)piperidine-1-carboxylate (7.0 g, 72%) as a yellow residue. 1H NMR (300 MHz, DMSO-d) 3H), 1.44 (s, 9H), 0.88 (m, 3H), 0.72 (d, 2H). m / z (ES-), [M+H]+ = 484. tert-butyl 4-(6-Cyclopropoxy-5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2H-indazol-2-yl)piperidine1-carboxylate
[0247] 4-(6-Cyclopropoxy-5-iodo-2H-indazol-2-yl)piperidine-1-carboxylate tert-butyl (5.0 g, 10.3 mmol), imidazo[1,2-b]pyridazin-3-amine (2.8 g, 20.7 mmol), TEA (4.3 mL, 31.0 mmol), Pd(OAc)2 (0.2 g, 1.0 mmol) and 1,3-bis(diphenylphosphino)propane (0.4 g, 1.0 mmol) in MeCN (100 mL) were stirred under 10 atm carbon monoxide at 90 °C for 10 hours. The solvent was removed under reduced pressure and the crude product was purified directly by silica flash chromatography (eluting with 9-10% MeOH in DCM) followed by C18 flash chromatography (eluting with 0-100% MeCN in water (0.1% formic acid)) to yield tert-butyl 4-(6-cyclopropoxy-5(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2H-indazol-2-yl)piperidine-1-carboxylate (0.9 g, 17%) as a yellow solid. m / z (ES+), [M+H]+= 518. 6-Cyclopropoxy-N-(imidazo[1,2-b]pyridazin-3-yl)-2-(piperidin-4-yl)-2 H-indazol-5carboxamide (Int XXIII) Petition 870260111673, dated 10 / 29 / 2026, p. 164 / 831 160 / 375
[0248] Hydrogen chloride (20 mL, 80.0 mmol) was added to tert-butyl 4-(6-cyclopropoxy-5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-2H-indazol-2-yl)piperidine-1-carboxylate (2.9 g, 5.6 mmol) in DCM (20 mL) at 25 °C. The resulting solution was stirred for 30 minutes before the pH was adjusted to pH 8 with saturated aqueous NaHCO3. The reaction mixture was concentrated, then diluted with chloroform (750 mL) and washed with water. The organic layer was dried with Na2SO4 and concentrated to yield 6-cyclopropoxy-N-(imidazo[1,2-b]pyridazin-3-yl)-2-(piperidin4-yl)-2H-indazol-5-carboxamide (1.6 g, 68%) as a dirty white solid. 1H NMR (400 MHz, DMSO-dβ) δ 0.98-1.05 (2H, m), 1.05-1.19 (2H, m), 1.87-2.02 (2H, m), 2.02-2.1 (2H, m), 2.59-2.7 (2H, m), 3.04-3.12 (2H, m), 4.19-4.28 (1H, m), 4.46-4.59 (1H, m), 7.21 (1H, dd), 7.55 (1H, s), 8.07 (1H, s), 8.15 (1H, dd), 8.59-8.67 (3H, m), 10.93 (1H, s). m / z (ES+), [M+H]+= 418. Synthesis of intermediate Int XXIV: N -(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazin-1-yl)benzamida 4-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)-3-fluorophenyl)piperazine-1 -carboxylate de terbutila
[0249] To a solution of 3-aminopiperidine-2,6-dione (1.22 mmol) in DMF (6 mL) was added 4-(4-(ter-butoxycarbonyl)piperazin-1-yl)-2-fluorobenzoic acid (305 mg, 0.94 mmol), DIPEA (350 mL, 2.01 mmol) and 2-(3H[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium(V) hexafluorophosphate (736 mg, 1.94 mmol) sequentially. The reaction mixture was diluted with DCM (100 mL), washed with water (150 mL χ 5) and concentrated to ~3 mL of product solution in DMF. The product solution was purified by silica gel chromatography (eluting with 0 to 5% methanol in dichloromethane) and additionally by C18 flash chromatography (eluting with 5 to 95% acetonitrile in water (FA 0.1%)) to yield tert-butyl 4-(4-((2,6dioxopiperidin-3-yl)carbamoyl)-3-fluorophenyl)piperazine-1-carboxylate, (291 mg, 71%) as a colorless solid. 1H NMR (500 MHz, CDCh) δ 7.97 (2H, t), 7.96 (1H, s) 7.41 (1H, dd), 6.71 (1H, dd), 6.52 (1H, dd), 4.78 (1H, dtd), 3.58 (4H, br. t), 3.31 Petition 870260111673, dated 10 / 29 / 2026, p. 165 / 831 161 / 375 (4H, br. t), 2.76 - 2.88 (2H, m), 2.68 - 2.76 (1H, m), 1.95 (1H, qd), 1.48 (9H, s). m / z (ESI+), [M+H]+= 435. N-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazin-1-yl)benzamide (Int XXIV)
[0250] One A solution of tert-butyl 4-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)-3-fluorophenyl)piperazine-1-carboxylate (133 mg, 0.31 mmol) in TFA (708 μL, 9.18 mmol) was stirred at rt for 15 minutes. Then, the mixture was concentrated, basified with DIPEA / DCM (1 mL / 5 mL) and concentrated to yield a mixture of N-(2,6-dioxopiperidin-3-yl)-2-fluoro-4-(piperazin-1-yl)benzamide and DIPEATFA salt, which was used in the next step without further purification. m / z (ESI+), [M+H]+= 335. Intermediate synthesis Int XXV: 6-Cyclopropoxy- N -(imidazo[1,2- b ]pyridazin-3-yl)-2-((1 r,4 r) -4-(iodomethyl)cyclohexyl)-2 H -indazol-5-carboxamide
[0251] Methyltriphenoxyphosphonium iodide (6.08 g, 13.4 mmol) was added to 6-cyclopropoxy-2-((1r,4r)-4-(hydroxymethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2-hindazol-5-carboxamide (described in Intermediate XVI) (2.0 g, 4.48 mmol) in pyridine (40 mL). The resulting mixture was stirred at 25 °C for 10 minutes and then concentrated. The crude product was directly purified by C18 flash chromatography (eluting with 0 to 100% MeCN in water (FA at 0.1%)) to yield 6-cyclopropoxyN-(imidazo[1,2-b]pyridazin-3-yl)-2-((1r,4r)-4-(iodomethyl)cyclohexyl)-2H-indazol-5-carboxamide (1.0 g, 40%) as a yellow solid. m / z (ESI+), [M+H]+= 557. Petition 870260111673, dated 10 / 29 / 2026, page 166 / 831 162 / 375 Synthesis of intermediate Int XXVI: 1-(2-Methyl-4-(4-(piperazin-4-ylmethyl)piperidin-1-yl)phenyl)dihydropyrimidine2,4(1H,3H)-dione 3-((4-Bromo-2-methylphenyl)amino)propanoate methyl
[0252] Methyl acrylate (2 mL, 21.5 mmol), 4-bromo-2-methylaniline (2 g, 10.8 mmol) and LiBF4 (100 mg, 1.1 mmol) were stirred at 70 °C for 16 h. The reaction was diluted with MTBE and washed with brine before being concentrated. The crude product was purified by C18 flash chromatography (eluting with 20% to 80% ACN in 0.1% ammonia) to yield methyl 3-((4-bromo-2-methylphenyl)amino)propanoate (1.9 g, 66%) as a yellow oil. m / z (ESI+), [M+H]+= 272. 3-(1-(4-Bromo-2-methylphenyl)ureido)methylpropanoate
[0253] Methyl 3-((4-Bromo-2-methylphenyl)amino)propanoate (1.9 g, 7.06 mmol) in acetic acid (20 mL) and water (5 mL) was treated with potassium cyanate (0.56 mL, 14.11 mmol). The reaction was then stirred at rt for 16 h. The reaction was poured into water and extracted with EtOAc (3 x 50 mL). The organic phase was washed with brine before being concentrated to yield methyl 3-(1-(4-bromo-2-methylphenyl)ureido)propanoate (2.2 g, 99%) as a colorless oil. m / z (ESI+), [M+H]+= 315. -(4-Bromo-2-methylphenyl)dihydropyrimidine-2,4(1H,3H)-dione
[0254] Methyl 3-(1-(4-bromo-2-methylphenyl)ureido)propanoate (2.2 g, 7 mmol) in acetonitrile (13.6 mL) was heated to 60 °C before the addition of N,N,N-trimethyl-1-phenylmethanaminium hydroxide solution (4.76 mL, 10.5 mmol). The reaction was stirred. Petition 870260111673, dated 10 / 29 / 2026, p. 167 / 831 163 / 375 for 20 min before being concentrated. The residue was suspended in saturated aqueous NH4O solution for 30 minutes before the solid was collected and washed with water to yield 1-(4-bromo-2-methylphenyl)dihydropyrimidine-2,4(1H,3H)-dione (1.85 g, 94%) as a colorless solid. m / z (ESI+), [M+H]+= 283. 1-(4-Bromo-2-methylphenyl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione
[0255] 1-(4-Bromo-2-methylphenyl)dihydropyrimidine-2,4(1H,3H)-dione (1.84 g, 6.5 mmol) and potassium carbonate (1.8 g, 13.00 mmol) in DMSO (11 mL) were treated with 1-(chloromethyl)-4-methoxybenzene (1.32 mL, 9.75 mmol). The resulting suspension was stirred for 16 h, then poured into 200 mL of water and extracted with EtOAc (3 x 50 mL). The organic phase was washed with brine before being concentrated to an oil. The crude product was purified by flash chromatography on silica (eluting with MTBE at 20% to 100% on heptane) to yield 1-(4-bromo-2-methylphenyl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (2.6 g, 99%) as a colorless foam. m / z (ESI+), [M+H]+= 403. tert-butyl 4-((1-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-3methylphenyl)piperidin-4-yl)methyl)piperazine-1-carboxylate
[0256] Cesium carbonate (1.2 g, 3.72 mmol), XPhos PdG3 (157 mg, 0.19 mmol), XPhos (59 mg, 0.12 mmol), tert-butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate (703 mg, 2.48 mmol) and 1-(4-bromo-2-methylphenyl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(1H,3H)-dione (500 mg, 1.24 mmol) in 1,4-dioxane (6.2 mL) were heated at 100 °C for 16 h. The reaction was diluted with EtOAc and washed with water and then with brine before being dried and concentrated to form an oil. The crude product was purified by flash chromatography on silica (eluting with EtOAc) Petition 870260111673, dated 10 / 29 / 2026, page 168 / 831 164 / 375% to 100% in heptane) to produce 4-((1-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-3-methylphenyl)piperidin-4-yl)methyl)piperazine-1-carboxylate tert-butyl (560 mg, 75%) as a colorless foam. m / z (ESI+), [M+H]+= 606. -(2-Methyl-4-(4-(piperazin-4-ylmethyl)piperidin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)dione (Int XXVI)
[0257] 4-((1-(4-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-1(2H)-yl)-3methylphenyl)piperidin-4-yl)methyl)piperazine-1-carboxylate tert-butyl (525 mg, 0.87 mmol) in 2,2,2-trifluoroacetic acid (5 mL, 64.81 mmol) was treated with trifluoromethanesulfonic acid (0.5 mL, 5.65 mmol). The reaction was heated to 70 °C for 5 min. The resulting mixture was concentrated before being diluted with DCM (40 mL) and cooled in an ice bath. The reaction was then neutralized by the cautious addition of TEA. The reaction was again concentrated and the crude product was purified by C18 flash chromatography (eluting with 0% to 70% ACN in 0.1% ammonia) to yield 1-(2-methyl-4-(4-(piperazin-4-ylmethyl)piperidin-1-yl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione (330 mg, 99%) as a colorless foam. m / z (ESI+), [M+H]+= 386. Intermediate synthesis Int XXVII: N -(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1r,4r)-4-(iodomethyl)cyclohexyl)-6-methoxy-2H-indazole-5-carboxamide
[0258] Lithium iodide (260 mg, 1.94 mmol) was added to a solution of ((1r,4r)-4-(5-((1-cyclopropyl-2-oxo-1,2-dihydropyridine-3yl)carbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)methyl methanesulfonate (Int XV) (500 mg, 0.97 mmol) in THF (10 mL) under nitrogen. The resulting solution was stirred at 50 °C for 12 h. The reaction mixture was directly purified by C18 flash chromatography (eluting Petition 870260111673, dated 10 / 29 / 2026, p. 169 / 831 165 / 375 com MeCN a 0 a 70 % in água (TFA a 0,5 %)) for produzir N-(1-ciclopropil-2-oxo1,2-di-hydropiridin-3-il)-2-((1 r,4 r)-4-(iodometil)ciclo-hexil)-6-metoxi-2 H-indazol-5carboxamida (495 mg, 93%) combined with solid amarelo. RMN de1H (300 MHz, DMSOd6) δ 11.06 (1H, s), 8.57 (1H, s), 8.56 (1H, s), 8.43 (1H, dd), 7.30 (1H, dd), 7.23 (1H, s), 6.28 (1H, t), 4.38 - 4.52 (m, 1H), 4.08 (3H, s), 3.45 (1H, td), 3.30 (2H, d), 2.16 (2H, br. d), 1.87 - 2.05 (m, 4H), 1.53 (1H, br. s), 1.26 (2H, br. q), 1.00 - 1.11 (m, 4H), 0.87 - 0.95 (m, 2H). m / z (ESI+), [M+H]+= 547. Síntese de intermediário Int XXVIII: 3-(2-metil-4-(piperazin-1-il)fenil)piperidina-2,6-diona 2,6-bis(benziloxi)-3-(4-bromo-2-metilfenil)piridina
[0259] [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (2.5 g, 3.37 mmol) was added to (2,6-bis(benzyloxy)pyridin-3-yl)boronic acid (11.3 g, 33.68 mmol), tribasic potassium phosphate (14.3 g, 67.36 mmol) and 4-bromo-1-iodo-2-methylbenzene (10 g, 33.68 mmol) in water (30 mL) and 1,4-dioxane (120 mL) at 25 °C under nitrogen. The resulting solution was stirred at 90 °C for 2 hours. The reaction mixture was poured into water (350 mL), extracted with EtOAc (3 x 350 mL), the organic layer was dried with Na2SO4 before being filtered and concentrated. The crude product was purified by flash chromatography on silica (eluting with 0% to 2% EtOAc in petroleum ether) to yield 2,6-bis(benzyloxy)-3-(4-bromo-2-methylphenyl)pyridine (12.0 g, 77%) as an orange solid. m / z (ESI+), [M+H]+= 460. tert-butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3-methylphenyl)piperazine-1-carboxylate Petition 870260111673, dated 10 / 29 / 2026, page 170 / 831 166 / 375
[0260] 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl (2.4 g, 5.21 mmol) was added to CS2CO3 (8.5 g, 26.07 mmol), RuPhos PdG2 (4.1 g, 5.21 mmol), 2,6bis(benzyloxy)-3-(4-bromo-2-methylphenyl)pyridine (12 g, 26.07 mmol) and tert-butyl piperazine-1-carboxylate (4.9 g, 26.07 mmol) in 1,4-dioxane (130 mL) at 25 °C under nitrogen. The resulting solution was stirred at 90 °C for 15 h. The reaction mixture was poured into water (350 mL), extracted with EtOAc (3 x 350 mL), the organic layer was dried with Na2SO4 before being filtered and concentrated. The crude product was purified by flash chromatography on silica (eluting with 5% to 10% EtOAc in petroleum ether) to yield tert-butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3-methylphenyl)piperazine-1-carboxylate (10 g, 68%) as an orange solid. m / z (ESI+), [M+H]+= 566. tert-butyl 4-(4-(2,6-dioxopiperidin-3-yl)-3-methylphenyl)piperazine-1-carboxylate _ x oX °AWXX HN^x—7O THE
[0261] Pd / C (1.9 g, 17.68 mmol) and tert-butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3-methylphenyl)piperazine-1-carboxylate (10 g, 17.68 mmol) in EtOH (150 mL) was stirred under a hydrogen atmosphere at 25 °C for 13 h. The reaction mixture was filtered through filter paper and evaporated. The crude product was purified by flash chromatography on silica (eluting with 20% to 25% EtOAc in petroleum ether) to yield tert-butyl 4-(4-(2,6-dioxopiperidin-3-yl)-3-methylphenyl)piperazine-1-carboxylate (2 g, 29%) as a colorless solid. m / z (ESI+), [M+H]+= 388. 3-(2-Methyl-4-(piperazin-1-yl)phenyl)piperidine-2,6-dione (Int XXVIII)0 hhn4 \= / x / o
[0262] 4-Methylbenzenesulfonic acid (444 mg, 2.58 mmol) was added to tert-butyl 4-(4-(2,6-dioxopiperidin-3-yl)-3-methylphenyl)piperazine-1-carboxylate (500 mg, 1.29 mmol) in EtOAc (8 mL) at 25 °C. The resulting solution was stirred at 50 °C for 15 h. The solvent was removed under reduced pressure and the crude product was purified by C18 flash chromatography (eluting with 0% to 25% MeCN in water) to yield Petition 870260111673, dated 10 / 29 / 2026, pp. 171 / 831 167 / 375 the salt 4-methylbenzenesulfonate of 3-(2-methyl-4-(piperazin-1-yl)phenyl)piperidine-2,6dione (300 mg, 52%) as a colorless solid. m / z (ESI+), [M+H]+= 288. Synthesis of intermediate Int XXIX: 3-(3-methyl-4-(piperidin-1-yl)-1H-indazol-1-yl)piperidine-2,6-dione 3-(4-Bromo-3-methyl-1H-indazol-1-yl)piperidine-2,6-dione
[0263] Sodium hydride (6.82 g, 284.28 mmol) was added to 4-bromo-3-methyl-1H-indazole (20 g, 94.76 mmol) in THF (200 mL) and DMSO (100 mL) cooled to 0 °C for 30 min under nitrogen. Potassium iodide (12.58 g, 75.81 mmol) and 3-bromopiperidine-2,6-dione (27.3 g, 142.14 mmol) were added to the above mixture at 0 °C for 10 min under nitrogen. The resulting mixture was stirred at rt for 16 h. The reaction mixture was rapidly cooled with aqueous NH4Cl. (100 mL), extracted with EtOAc (100 mL) and the organic layer was dried with Na2SO4 before being filtered and concentrated to produce 3-(4-bromo-3-methyl-1-hindazol-1-yl)piperidine-2,6-dione (30.0 g, 98%) as a gray solid, which was used without further purification. m / z (ESI+), [M+H]+= 322. terbutyl 4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-1H-indazol-4-yl)piperazine-1-carboxylate
[0264] Pd-PEPPSI IPentCl (652 mg, 0.78 mmol) was added to Cs2CO3 (10.11 g, 31.04 mmol), tert-butyl piperazine-1-carboxylate (4.34 g, 23.28 mmol), and 3-(4-bromo-3-methyl-1H-indazol-1-yl)piperidine-2,6-dione (5 g, 15.52 mmol) in dioxane (50 mL) under nitrogen. The resulting mixture was stirred at 100 °C for 12 hours. The reaction mixture was diluted with EtOAc (350 mL) and washed with water (3 x 250 mL). The organic layer was dried with Na2SO4 before being filtered and concentrated to produce the crude product, which was purified by C18-flash chromatography (eluting Petition 870260111673, dated 10 / 29 / 2026, p. 172 / 831 168 / 375 with MeCN at 0 to 100% in water) to produce tert-butyl 4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-1H-indazol-4-yl)piperazine-1-carboxylate (400 mg, 6%) as a brown solid. m / z (ESI+), [M+H]+= 428. 3-(3-methyl-4-(piperazin-1-yl)-1H-indazol-1-yl)piperidine-2,6-dione (Int XXIX)
[0265] 4-Methylbenzenesulfonic acid (322 mg, 1.87 mmol) was added to tert-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-1H-indazol-4-yl)piperazine-1-carboxylate (400 mg, 0.94 mmol) in EtOAc (8 mL). The resulting mixture was stirred at 50 °C for 12 h. The solvent was removed under reduced pressure and the crude product was purified by C18 flash chromatography (eluting with 0% to 30% MeCN in water) to yield the bis 4-methylbenzenesulfonate salt of 3-(3-methyl-4-(piperazin-1-yl)-1Hindazol-1-yl)piperidine-2,6-dione (240 mg, 38%) as a colorless solid. m / z (ESI+), [M+H]+= 328. General protocol for reductive amination
[0266] The primary amine (or amine salt) (0.08 mmol) in DMSO (1.3 mL) was stirred with triethylamine (0.03 mL, 0.20 mmol) for 3.5 h at rt and then added to N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)-2H-indazol-5-carboxamide (Int I) (27 mg, 0.07 mmol). The resulting mixture was stirred for 2 h at 40 °C before the addition of 2-methylpyridine borane (0.9 mL, 0.13 mmol) in DMSO (0.9 mL) and acetic acid (0.13 mL, 2.33 mmol). Stirring of the mixture was continued for 50 h at 40 °C before being cooled at rt. Next, the reaction was rapidly cooled with i-PrOH (500 μL), followed by concentrating the reaction mixture to a volume of 0.3 mL. Additional DMSO (0.3 mL) was added to obtain a solution of the crude product in DMSO (total volume ca. 0.6 mL) which was purified by HPLC prep. Petition 870260111673, dated 10 / 29 / 2026, p. 173 / 831 169 / 375 Examples Example 1 and Example 2 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H benzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclohexyl)-N -(imidazo[1,2-b]pyridazin3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 1 and Isomer 2 3-(4-(4-Aminobutyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine2,6-dione
[0267] Rh / C (5 wt% Rh) (1.0 g, 0.5 mmol) was added to 3-(4-(4-aminobut-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Int VIII) (600 mg, 1.8 mmol) in MeOH (60 mL). The resulting mixture was stirred at 25 °C for 2 h under hydrogen. The precipitate was collected by filtration, washed with MeOH (50 mL), and dried under vacuum to yield 3-(4-(4-aminobutyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (350 mg, 57%) as a yellow solid, which was used without further purification. m / z (ESI+), [M+H]+= 331. 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 H-benzo[ d ]imidazol-4yl)butyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5carboxamida
[0268] A mixture of Ti(Oi-Pr)4 (602 mg, 2.1 mmol), 3-(4-(4-aminobutyl)-3methyl-2-oxo-2,3-di-hidro-1 H-benzo[d]imidazol-1-yl)piperidine-2,6-diona (350 mg, 1.1 mmol) and N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxi-2-(4-oxociclo-hexil)-2H-indazolPetição 870260111673, de 29 / 10 / 2026, pág. 174 / 831 170 / 375 5-carboxamide (Int I) (428 mg, 1.1 mmol) in DCM (5 mL) and EtOH (5 mL) under N2 was stirred for 2 h before the slow addition of NaBHaCN (100 mg, 1.6 mmol). The resulting mixture was stirred at 25 °C for 1 h. The reaction was rapidly cooled with ice water and the mixture was concentrated under reduced pressure. The crude product was purified by C18-flash chromatography (eluting with MeCN at 25 to 40% in water) to yield 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)butyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (200 mg, 26%) as a yellow solid. m / z (ESI+), [M+H]+= 719. - Isomer 1 (Example 1) and Isomer 2 (Example 2) llSÔMERO 2
[0269] A mixture of NaOAc (103 mg, 1.3 mmol), formaldehyde (37% in water) (0.06 mL, 0.8 mmol) and 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)butyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin3-yl)-6-methoxy-2H-indazol-5-carboxamide) in DCM (10 mL) and MeOH (10 mL) was stirred at 25 °C under N2 for 2 h before the slow addition of NaBH(OAc)3 (265 mg, 1.3 mmol). The resulting mixture was stirred for 15 minutes. The reaction was rapidly cooled with ice water and the mixture was extracted with DCM (3 x 25 mL). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by preparative HPLC (column: XBridge Prep OBD C18, 30*150 mm, 5 μm; mobile phase A: water (NH4HCO3 10 mM + NH4OH at 0.1%), phase Petition 870260111673, dated 10 / 29 / 2026, p. 175 / 831 171 / 375 moves B: ACN; vazão: 60 mL / min; gradient: 35 % of B to 43 % of B at 9 min, starting, 43 % of isocrático B) to produce 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo2,3-di-hydro-1 H-benzo[ d] imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamida - Isomer 1 (56 mg, 17 %) and 2(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 H-benzo[ d] imidazol-4yl)butyl(methyl)amino)ciclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5carboxamida - Isômero 2 (30 mg, 9 %), both as bitter solids.
[0270] Isômero 1: RMN de1H (300 MHz, DMSO-dβ) δ 1,37 - 1,72 (8H, m), 1,80 - 2,06 (6H, m), 2,11 - 2,24 (3H, m), 2,23 - 2,29 (3H, m), 2,80 - 2,99 (4H, m), 3,59 (3H, s), 4,13 (3H, s), 4,39 - 4,53 (1H, m), 5,32 - 5,43 (1H, m), 6,83 - 6,94 (1H, m), 6,94 - 7,02 (2H, m), 7,18 - 7,28 (2H, m), 8,06 (1H, s), 8,10 - 8,18 (1H, m), 8,56 - 8,60 (2H, m), 8,62 - 8,67 (1H, m), 11,05 (1H, s), 11,11 (1H, s). m / z (ESI+), [M+H]+= 733.
[0271] Isômero 2: RMN de1H (300 MHz, DMSO-d6) δ 1,47 - 1,73 (7H, m), 1,73 - 2,11 (7H, m), 2,14 - 2,30 (4H, m), 2,73 - 3,02 (6H, m), 3,57 (3H, s), 4,13 (3H, s), 4,50 - 4,75 (1H, m), 5,26 - 5,50 (1H, m), 6,81 - 7,06 (3H, m), 7,11 - 7,39 (2H, m), 8,03 - 8,09 (1H, m), 8,11 - 8,18 (1H, m), 8,54 - 8,69 (3H, m), 10,98 - 11,18 (2H, m). m / z (ESI+), [M+H]+= 733. Exemplo 3 e Exemplo 4: 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl))-3-methyl-2-oxo-2,3-di-hydro-1 H benzo[ d] imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino byazo)[1,2,he-cycl ]pyridazine-3-yl)-6-methoxy-2 H -indazole-5-carboxamide - Isomer 1 and Isomer 2 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl))-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[ d] imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)amino)zocyclo[1-(hexyl)- b]pyridazine-3-yl)-6-methoxy-2H-indazole-5-carboxamide
[0272] 3-(4-(3-(4-Aminopiperidin-1-yl)prop-1-in-1-yl)-3-methyl-2-oxo-2,3-di-hydro1H-benzo[d]imidazol-1-yl)piperidin-2,6-dione (Int VII) (800 mm Petition 870260111673, dated 10 / 29 / 2026, p. 176 / 831 172 / 375 was added to N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)-2H-indazol-5-carboxamide (Int I) (818 mg, 2.0 mmol) and Ti(Oi-Pr)4 (2.0 mL, 2.0 mmol) in MeOH (7 mL) and DCM (1 mL). The resulting mixture was stirred at 25 °C for 2 h. NaBH3CN (254 mg, 4.1 mmol) was added to the mixture and stirring continued for 10 min. The reaction was rapidly cooled with ice water and the mixture was concentrated under reduced pressure. The crude product was purified by C18-flash chromatography (eluting with MeCN at 0 to 100% in water) to yield 2-(4-((1-(3(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop2-yn-1-yl)piperidin-4-yl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2hindazol-5-carboxamide (240 mg, 15%) as a brown solid. m / z (ESI+), [M+H]+= 784. 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1 (Example 3) and Isomer 2 (Example 4)
[0273] 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)prop-2-yn-1-yl)piperidin-4-yl)amino)cyclohexyl)-N-(imidazo[1,2b ]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (240 mg, 0.3 mmol) was added to NaOAc (75 mg, 0.9 mmol), to formaldehyde (37% in water) (0.02 mL, 0.3 mmol) in DCM (4 mL) and in MeOH (1 mL). The resulting mixture was stirred at 25 °C for 2 h. NaBH3CN (38 mg, 0.6 mmol) was added and the reaction mixture was stirred at 25 °C for 10 min before the reaction was abruptly cooled with ice water. The mixture was extracted with DCM (50 mL), the organic layer dried with Na2SO4, filtered, and concentrated. The crude product was purified by preparative HPLC. Petition 870260111673, dated 10 / 29 / 2026, p. 177 / 831 173 / 375 (column: XSelect CSH Prep C18 OBD, 19 x 250 mm, 5 µm; mobile phase A: water (FA at 0.1 %), mobile phase B: MeOH; vacuum: 25 mL / min; gradient: 32 % of B to 52 % of B in 0.5 min, B isocratic) to produce 2-(4-((1-(3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 H-benzo[ d] imidazole-4-yl)prop-2-in-1-yl) piperidin-4-yl) (methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 Hindazol-5-carboxamide - Isomer 1 (40 mg, 16 %) and 2-(4-((1-(3-(1-(2,6-dioxopiperidin3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 H-benzo[ d] imidazol-4-yl)prop-2-in-1-yl)piperidin-4yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamide - Isomer 2 (34 mg, 14%), both as solids.
[0274] Isômero 1: RMN de1H (400 MHz, DMSO-dβ) δ 1,54 - 1,74 (4H, m), 1,81 - 2,11 (7H, m), 2,16 - 2,34 (4H, m), 2,36 - 2,44 (2H, m), 2,59 - 2,82 (4H, m), 2,83 2,99 (4H, m), 3,60 (2H, s), 3,66 (3H, s), 4,12 (3H, s), 4,41 - 4,56 (1H, m), 5,36 - 5,45 (1H, m), 6,99 - 7,06 (1H, m), 7,09 - 7,19 (2H, m), 7,20 - 7,27 (2H, m), 8,05 (1H, s), 8,14 - 8,15 (1H, m), 8,54 - 8,61 (2H, m), 8,62 - 8,66 (1H, m), 11,04 (1H, s), 11,12 (1H, s). m / z (ESI+), [M+H]+= 798.
[0275] Isômero 2: RMN de1H (400 MHz, DMSO-d6) δ 1,61 - 1,74 (2H, m), 1,76 - 1,92 (6H, m), 1,94 - 2,07 (3H, m), 2,24 - 2,34 (3H, m), 2,36 - 2,44 (3H, m), 2,60 2,79 (3H, m), 2,83 - 3,04 (5H, m), 3,61 (2H, s), 3,66 (3H, s), 4,13 (3H, s), 4,57 - 4,78 (1H, m), 5,30 - 5,47 (1H, m), 6,99 - 7,05 (1H, m), 7,09 - 7,19 (2H, m), 7,20 - 7,25 (1H, m), 7,28 (1H, s), 8,05 (1H, s), 8,15 - 8,18 (1H, m), 8,60 (1H, s), 8,62 - 8,67 (1H, m), 8,69 (1H, s), 11,05 (1H, s), 11,12 (1H, s). m / z (ESI+), [M+H]+= 798. Exemplo 5 e Exemplo 6: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 H benzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N -(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2 H -indazol-5-carboxamida - Isomer 1 and Isomer 2 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 H-benzo[ d ] imidazol-4yl)but-3-in-1-yl)amino)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H- indazol5-carboxamida Petition 870260111673, 29 / 10 / 2026, pág. 178 / 831 174 / 375
[0276] A mixture of Ti(Oi-Pr)4 (540 mg, 1.9 mmol), 3-(4-(4-aminobut-1-yn1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Int VIII) (310 mg, 1.0 mmol) and N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)2 H-indazol-5-carboxamide (Int I) (384 mg, 1.0 mmol) in DCM (10 mL) and in EtOH (10 mL) was stirred under N2 at 25 °C for 2 h before slow addition of NaBH3CN (90 mg, 1.4 mmol). The resulting mixture was stirred for 1 h. The reaction was rapidly cooled with ice water and the mixture was concentrated under reduced pressure. The crude product was purified by C18-flash chromatography (eluting with 25-40% MeCN in water) to yield 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)but-3-yn-1-yl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (200 mg, 30%) as a yellow solid. m / z (ESI+), [M+H]+= 715. 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 H-benzo[d]imidazol-4yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazine-3-yl)-6-methoxy-2 Hindazol-5-carboxamide - Isomer 1 (Example 5) e Petition 870260111673, dated 10 / 29 / 2026, p. 179 / 831 175 / 375
[0277] A mixture of NaOAc (103 mg, 1.3 mmol), formaldehyde (37% in water) (0.06 mL, 0.8 mmol) and 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)but-3-yn-1-yl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (300 mg, 0.4 mmol) in DCM (10 mL) and in MeOH (10 mL) under N2 at 25 °C was stirred for 2 h before the slow addition of NaBH(OAc)3 (267 mg, 1.26 mmol). The resulting mixture was stirred for 15 minutes. The reaction was rapidly cooled with ice water and the mixture was extracted with DCM (3 x 50 mL). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by C18-flash chromatography (eluting with 0 to 50% MeCN in water), followed by preparative HPLC (column: Xselect CSH C18 OBD, 30 x 150 mm, 5 μm; mobile phase A: water (FA at 0.1%), mobile phase B: MeCN; flow rate: 60 mL / min; gradient: 29% B to 42% B over 7 min).Further purification of the first elution isomer by preparative HPLC (column: XBridge Prep OBD C18, 30 x 150 mm, 5 μm; mobile phase A: water (10 mM NH4HCO3 + 0.1% NH4OH), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 38% B to 45% B over 7 min) yielded 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)but-3-yn-1-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 1 (35 mg, 11%). Further purification of the second elution isomer by preparative HPLC (column: Xselect CSH F-Phenyl OBD, 19 x 250 mm, 5 μm; mobile phase A: water (FA at 0.1%), mobile phase B: MeOH; flow rate: 25 mL / min; gradient: 31% B to 45% B over 9 min) yielded 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1-H-Edition 870260111673, 29 / 10 / 2026, p. 180 / 831. 176 / 375 benzo[d]imidazol-4-il)but-3-in-1 -il) (metil)amino)ciclo-hexil)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamida - Isômero 2 (49 mg, 16 %), ambos como solid amarelos.
[0278] Isômero 1: RMN de 1H (400 MHz, DMSO-d6) δ 1.47 - 1.63 (2H, m), 1.87 - 2.10 (5H, m), 2.16 - 2.25 (2H, m), 2.30 (3H, s), 2.57 - 2.80 (7H, m), 2.82 - 2.99 (1H, m), 3.70 (3H, s), 4.13 (3H, s), 4.40 - 4.55 (1H, m), 5.34 - 5.46 (1H, m), 6.97 - 7.03 (1H, m), 7.04 - 7.16 (2H, m), 7.20 - 7,25 (1H, m), 7,27 (1H, s), 8,06 (1H, s), 8,14 8,19 (1H, m), 8,56 - 8,60 (2H, m), 8,62 - 8,68 (1H, m), 11,05 (1H, s), 11,12 (1H, s). m / z (ESI+), [M+H]+= 729.
[0279] Isômero 2: RMN de1H (400 MHz, DMSO-dβ) δ 1.59 - 1.69 (2H, m), 1.91 - 2.00 (5H, m), 2.28 (3H, s), 2.32 - 2.47 (2H, m), 2.55 - 2.96 (8H, m), 3.67 (3H, s), 4.12 (3H, s), 4.51 - 4.62 (1H, m), 5.30 - 5.43 (1H, m), 6.90 - 6-99 (1H, m), 7.01 - 7.15 (2H, m), 7.21 - 7.25 (1H, m), 7.28 (1H, s), 8,06 (1H, s), 8,14 - 8,17 (1H, m), 8,56 (2H, s), 8,64 (1H, d), 11,06 (1H, s), 11,11 (1H, s). m / z (ESI+), [M+H]+= 729. Example 7 and Example 8: 2-(4-((2-(1-((1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hidro-1 Hbenzo[ d ]imidazol-4-il)metil)piperidin-4-il)etil)(metil)amino)ciclo-hexil)-N (imidazo[1,2- b) ]piridazin-3-il)-6-metoxi-2 H -indazol-5-carboxamida - Isômero 1 e Isômero 2 -Metil-7-vinil-1,3-di-hydro-2H-benzo[d]imidazol-2-ona
[0280] Pd(dppf)Cl2 - CH2Cl2 (2.5 g, 3.1 mmol) was added to K2CO3 (8.5 g, 61.7 mmol), 7-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (7.0 g, 30.8 mmol) and 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (4.8 g, 30.8 mmol) in 1,4-dioxane (75 mL) and water (25 mL) at 25 °C under N2. The resulting mixture was stirred at 80 °C for 4 h, cooled to rt and then concentrated under reduced pressure. The crude product was purified by flash chromatography on silica (eluting with EA at 0 to 100% on PE) to yield 1-methyl-7-vinyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (4.1 g, 76%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 3.48 (3H, s), 5.24–5.53 Petition 870260111673, dated 10 / 29 / 2026, pp. 181 / 831 177 / 375 (1H, m), 5.58 - 5.85 (1H, m), 6.88 - 6.95 (1H, m), 6.96 - 7.00 (1H, m), 7.10 - 7.15 (1H, m), 7.32 - 7.44 (1H, m), 10.95 (1H, s). m / z (ESI+), [M+H]+= 175. 3-Methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-carbaldehyde
[0281] Potassium osmate(VI) dihydrate (Os 51 to 52%) (1.7 g, 4.6 mmol) was added to 2,6-dimethylpyridine (4.9 g, 45.9 mmol), sodium metaperiodate (9.8 g, 45.9 mmol), and 1-methyl-7-vinyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (4.0 g, 23.0 mmol) in 1,4-dioxane (60 mL) and water (20 mL) at 25 °C under N2. The resulting mixture was stirred at 25 °C for 2 h. The reaction mixture was diluted in water (100 mL) and extracted with EA (3 χ 100 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica (eluting with EA at 0 to 100% on PE) to yield 3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-carbaldehyde (2.8 g, 69%) as a gray solid. 1H NMR (300 MHz, DMSO-dβ) δ 3.61 (3H, s), 7.22 - 7.25 (1H, m), 7.51 - 7.54 (1H, m), 7.58 - 7.64 (1H, m), 10.30 - 10.49 (2H, m). m / z (ESI+), [M+H]+= 177. 1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4carbaldehyde
[0282] LiHMDS (1 M in THF) (34 mL, 34 mmol) was added to 3-methyl-2-oxo 2,3-dihydro-1H-benzo[d]imidazole-4-carbaldehyde (2.0 g, 11.4 mmol) in THF (30 mL) at 0 °C under N2. The resulting solution was stirred at 0 °C for 1 h, then added to 3-bromopiperidine-2,6-dione (4.4 g, 22.7 mmol) in THF (10 mL). The reaction was stirred at 60 °C for 15 h, then cooled to rt. The reaction was rapidly cooled with saturated NH4Cl (50 mL) and the mixture was extracted with EtOAc (3 x 100 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under reduced pressure to yield 1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H Petition 870260111673, dated 10 / 29 / 2026, pp. 182 / 831 178 / 375 benzo[d]imidazole-4-carbaldehyde (800 mg, 24%) as a gray solid, which was used without further purification. m / z (ESI+), [M+H]+= 288. 4-(2-((4-(5-(Imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2 H-indazol-2-yl)cyclohexyl)amino)ethyl)piperidine-1-carboxylate tert-butyl
[0283] NaBH4 (94.0 mg, 2.5 mmol) was added to N-(imidazo[1,2-b]pyridazin-3yl)-6-methoxy-2-(4-oxocyclohexyl)-2H-indazol-5-carboxamide (Int I) (500 mg, 1.2 mmol), tert-butyl 4-(2-aminoethyl)piperidine-1-carboxylate (565 mg, 2.5 mmol) and NaOAc (304 mg, 3.7 mmol) in MeOH (5 mL) and DCM (5 mL) at 25 °C under N2. The resulting mixture was stirred at 25 °C for 10 h. The reaction was rapidly cooled with saturated aqueous NaHCO3 (20 mL), water, and the mixture was extracted with DCM (2 x 50 mL). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by C18-flash chromatography (eluting with MeCN at 20 to 40% in water) to yield tert-butyl 4-(2-((4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2Hindazol-2-yl)cyclohexyl)amino)ethyl)piperidine-1-carboxylate (500 mg, 65%) as a yellow solid. m / z (ESI+), [M+H]+= 617. Tert-butyl 4-(2-((4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)(methyl)amino)ethyl)piperidine-1-carboxylate
[0284] NaBH4 (49.1 mg, 1.3 mmol) was added to formaldehyde (37% in water) (0.15 mL, 1.9 mmol), to tert-butyl 4-(2-((4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)amino)ethyl)piperidine-1-carboxylate (400 mg, Petition 870260111673, dated 10 / 29 / 2026, pp. 183 / 831 179 / 375 0.7 mmol) and NaOAc (160 mg, 1.9 mmol) in MeOH (8 mL) at 25 °C under N2. The resulting mixture was stirred at 25 °C for 10 h. The reaction was rapidly cooled with ice-cold water and the mixture was extracted with DCM (2 x 50 mL). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by C18-flash chromatography (eluting with MeCN at 20 to 40% in water) to yield tert-butyl 4-(2-((4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)(methyl)amino)ethyl)piperidine-1-carboxylate (300 mg, 73%) as a yellow solid. m / z (ESI+), [M+H]+= 631. N-(Imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-(methyl(2-(piperidin-4-yl)ethyl)amino)cyclohexyl)-2H-indazol-5-carboxamide
[0285] TFA (1 mL, 13.0 mmol) was added to tert-butyl 4-(2-((4-(5-(imidazo[1,2b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl(methyl)amino)ethyl)piperidine-1-carboxylate (300 mg, 0.5 mmol) in DCM (10 mL) at 25 °C under N2. (300 mg 119%), which was used without further purification. 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamide - Isomer 1 (Example 7) and Isomer 2 (Example 8) Petition 870260111673, dated 10 / 29 / 2026, pp. 184 / 831 180 / 375
[0286] NaBH(OAc)3 (240 mg, 1.1 mmol) was added to NaOAc (93 mg, 1.1 mmol), to N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-(methyl(2-(piperidin-4yl)ethyl)amino)cyclohexyl)-2 H-indazol-5-carboxamide (200 mg, 0.4 mmol) and 1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-carbaldehyde (108 mg, 0.4 mmol) in DMF (5 mL) at 25 °C under N2. The resulting mixture was stirred at 25 °C for 10 h. The reaction was rapidly cooled with ice water and the mixture was extracted with EtOAc (2 x 20 mL). The organic layer was dried with Na2SO4, filtered, and concentrated. The crude product was purified by C18 flash chromatography (eluting with MeCN at 0 to 60% in water), followed by SFC preparation.(column: YMC-Actus Triart Diol-HILIC, 3 x 25 cm, 5 μm; mobile phase A: CO2, mobile phase B: MeOH (TEA at 0.1 %); vacuum: 75 mL / min; gradient: 50 % isocratic B) to produce 2-(4-((2-(1((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 H-benzo[ d] imidazol-4yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imida2,2-bzo[ d] ]pyridazin-3-yl)-6methoxy-2 H-indazol-5-carboxamide - Isomer 1 (19 mg, 6 %) and 2-(4-((2-(1-((1-(2,6dioxopiperidin-3-yl))-3-methyl-2-oxo-2,3-di-hydro-benzo-1 H-d imidazol-4yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6methoxy-2 H-indazol-5-carboxamide - Isomer 2 (10 mg, 3 %).
[0287] Isômero 1: RMN de1H (300 MHz, DMSO-dβ) δ 0,90 - 1,09 (2H, m), 1,08 - 1,27 (4H, m), 1,28 - 1,46 (2H, m), 1,45 - 1,61 (2H, m), 1,65 - 1,98 (7H, m), 1,99 2,14 (5H, m), 2,23 - 2,35 (2H, m), 2,45 - 2,87 (5H, m), 3,48 (2H, s), 3,56 (3H, s), 4,00 (3H, s), 4,23 - 4,4 (1H, m), 5,19 - 5,34 (1H, m), 6,70 - 6,79 (1H, m), 6,79 - 6,90 (1H, m), 6,90 - 6,98 (1H, m), 7,05 - 7,17 (2H, m), 7,93 (1H, s), 7,98 - 8,07 (1H, m), 8,41 8,49 (2H, m), 8,49 - 8,57 (1H, m), 10,89 - 11,05 (2H, m). m / z (ESI+), [M+H]+= 802. Petição 870260111673, de 29 / 10 / 2026, pág. 185 / 831 181 / 375
[0288] Isômero 2: RMN de 1H (400 MHz, DMSO-dβ) δ 0.90 - 1.06 (2H, m), 1.08 - 1.27 (3H, m), 1.36 - 1.59 (4H, m), 1.61 - 1.93 (7H, m), 2.01 (3H, s), 2.15 - 2.34 (5H, m), 2.50 - 2.88 (5H, m), 3.47 (2H, s), 3.54 (3H, s), 4.00 (3H, s), 4.38 - 4.52 (1H, m), 5.18 - 5.32 (1H, m), 6.68 - 6.76 (1H, m), 6,78 - 6.86 (1H, m), 6.88 - 6.98 (1H, m), 7.06 - 7.14 (1H, m), 7.16 (1H, s), 7.93 (1H, s), 7.99 - 8.11 (1H, m), 8.44 - 8.57 (3H, m), 10.82 - 11.10 (2H, m). m / z (ESI+), [M+H]+= 802. Example 9 and Example 10: 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hydro-1 H benzo[ d]imidazol-4-il)propil)piperidin-4-il)(metil)amino)ciclo-hexil)-N (imidazo[1,2-b]piridazin-3-il)-6-metoxi-2 H -indazol-5-carboxamida - Isômero 1 e Isômero 2 3-(4-(3-(4-Aminopiperidin-1-il)propil)-3-metil-2-oxo-2,3-di-hydro-1 H-benzo[ d ]imidazol1 -il)piperidina-2,6-diona
[0289] Rh / C (5 wt% Rh) (500 mg, 0.3 mmol) was added to 3-(4-(3(4-aminopiperidin-1-yl)prop-1-yn-1-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Int VII) (900 mg, 2.3 mmol) in MeOH (10 mL) under hydrogen. The resulting mixture was stirred at 25 °C for 5 h, filtered through celite, and concentrated under reduced pressure. The crude product was purified by C18 flash chromatography (eluting with 0 to 30% MeCN in water) to yield 3-(4(3-(4-aminopiperidin-1-yl)propyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (240 mg, 26%). m / z (ESI+), [M+H]+= 400. 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2 H-indazole-5-carboxamide Petition 870260111673, dated 10 / 29 / 2026, p. 186 / 831 182 / 375
[0290] 3-(4-(3-(4-Aminopiperidin-1-yl)propyl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-1-yl)piperidine-2,6-dione (170 mg, 0.4 mmol) was added to N(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)-2 H-indazol-5-carboxamide (Int I) (172 mg, 0.4 mmol) and Ti(Oi-Pr)4 (2.0 mL, 0.4 mmol) in DCM (5 mL) and EtOH (5 mL). The resulting mixture was stirred at 25 °C for 2 h before the addition of NaBH3CN (53 mg, 0.9 mmol) and stirring was continued at 25 °C for 10 min. The reaction was rapidly cooled with ice water and concentrated under reduced pressure. The crude product was purified by C18 flash chromatography (eluting with MeCN at 0 to 100% in water) to yield 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)propyl)piperidin-4-yl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide (114 mg, 34%) as a brown solid. m / z (ESI+), [M+H]+= 788. 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[ d] imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamide - Isomer 1 (Example 9) and Isomer 2 (Example 10)
[0291] 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[ d] imidazol-4-yl)propyl)piperidin-4-yl)amino)cyclo-hexyl)-N-(imidazo[,2b ]pyridazin-3-yl)-6-methoxy-2 H-indazole-5-carboxamide (300 mg, 0.4 mmol) foi Petition 870260111673, of 29 / 10 / 2026, p. 187 / 831 183 / 375 was added to NaOAc (94 mg, 1.1 mmol), formaldehyde (37% in water) (0.03 mL, 0.4 mmol) in DCM (5 mL) and in MeOH (1 mL). The resulting mixture was stirred at 25 °C for 2 h before the addition of NaBH3CN (48 mg, 0.1 mmol) and stirring was continued at 25 °C for 10 min. The reaction was abruptly cooled with ice water, then the mixture was extracted with DCM. The combined organic phases were concentrated under reduced pressure. The crude product was purified by C18-flash chromatography (eluting with MeCN at 0 to 100% in water) followed by SFC preparation.(YMCActus Triart Diol-HILIC, 3 x 25 cm, 5 μm; mobile phase A: CO2, mobile phase B: MeOH (TEA at 0.1 %); vacuum: 75 mL / min; gradient: 50 % of isocratic B for 12 min) to produce 2-(4-(1-(1-(1) -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 Hbenzo[ d] imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazine-3-melthoxy)-2-6 H-indazole-5-carboxamide - Isomer 1 (23 mg, 8 %) and 2-(4((1 -(3-(1 -(2,6-dioxopiperidin-3-yl))-3-methyl-2-oxo-2,3-di-hydro-1 H-benzo[ d] imidazol-4yl)propyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2 H-indazol-5-carboxamide - Isomer 2 (14 mg, 5 %), both yellow as solids.
[0292] Isômero 1: RMN de1H (300 MHz, DMSO-dβ) δ 1,47 - 1,71 (4H, m), 1,72 - 1,85 (4H, m), 1,85 - 2,13 (6H, m), 2,14 - 2,25 (2H, m), 2,29 (3H, s), 2,39 - 2,47 (2H, m), 2,57 - 2,77 (4H, m), 2,81 - 3,08 (6H, m), 3,58 (3H, s), 4,13 (3H, s), 4,43 - 4,5 (1H, m), 5,28 - 5,46 (1H, m), 6,85 - 6,94 (1H, m), 6,94 - 7,05 (2H, m), 7,18 - 7,29 (2H, m), 8,06 (1H, s), 8,11 - 8,18 (1H, m), 8,55 - 8,61 (2H, m), 8,62 - 8,68 (1H, m), 11,05 (1H, s), 11,10 (1H, s). m / z (ESI+), [M+H]+= 802.
[0293] Isômero 2: RMN de1H (400 MHz, DMSO-d6) δ 1,53 - 1,72 (6H, m), 1,73 - 1,96 (7H, m), 1,99 - 2,12 (3H, m), 2,17 (3H, s), 2,3 - 2,41 (2H, m), 2,57 - 2,82 (5H, m), 2,88 - 2,96 (3H, m), 2,97 - 3,06 (2H, m), 3,58 (3H, s), 4,13 (3H, s), 4,59 - 4,63 (1H, m), 5,35 - 5,41 (1H, m), 6,86 - 6,92 (1H, m), 6,94 - 7,01 (2H, m), 7,19 - 7,26 (1H, m), 7,29 (1H, s), 8,06 (1H, s), 8,13 - 8,19 (1H, m), 8,59 (1H, s), 8,62 - 8,68 (2H, m), 10,99 - 11,25 (2H, m). m / z (ESI+), [M+H]+= 802. Exemplo 11 e Exemplo 12: 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1 H benzo[ d] imidazol-5-yl)piperazin-1-yl)piperidin-1-yl)cyclo-hexyl)-N -(imidazo[1,2b ]pyridazin-3-yl)-6-methoxy-2 H -indazol-5-carboxamide - Isomer 1 and Isomer 2 Petition 870260111673, of 29 / 10 / 2026, p. 188 / 831 184 / 375
[0294] N-(Imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)-2H-indazol5-carboxamide (Int I) (38 mg, 0.1 mmol) was added to 3-(3-methyl-2-oxo-5-(4(piperidin-4-yl)piperazin-1-yl)-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (Int XII) (100 mg, 0.2 mmol) in DMSO (2 mL). The resulting mixture was stirred at 30 °C for 1 h before the addition of NaBH3CN (22 mg, 0.4 mmol) and stirring was continued at 50 °C for 14 h before the mixture was cooled to rt.The reaction mixture was purified directly by C18 flash chromatography (eluting with water from 0 to 100% in MeCN) followed by preparative HPLC (XBridge Prep OBD C18 column, 19 x 250 mm, 5 μm; mobile phase A: water (10 mM NH4HCO3 + 0.1% NH4OH), mobile phase B: MeCN; flow rate: 25 mL / min; gradient: 28% B to 38% B in 8 min, followed by 38% isocratic B) to yield 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)piperazin-1-yl)piperidin-1 -yl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 1 (20 mg, 11%) and 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1 Hbenzo[d]imidazol-5-yl)piperazin-1-yl)piperidin-1-yl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 2 (33 mg, 17%), both as yellow solids.
[0295] Isômero 1: RMN de1H (300 MHz, DMSO-dβ) δ 1,32 - 1,65 (4H, m), 1,69 - 2,09 (8H, m), 2,10 - 2,33 (5H, m), 2,57 - 2,78 (6H, m), 2,78 - 3,00 (3H, m), 3,00 3,19 (4H, m), 3,31 (3H, s), 4,13 (3H, s), 4,33 - 4,53 (1H, m), 5,19 - 5,40 (1H, m), 6,55 - 6,68 (1H, m), 6,77 - 6,86 (1H, m), 6,91 - 6,99 (1H, m), 7,17 - 7,30 (2H, m), 8,06 (1H, s), 8,11 - 8,20 (1H, m), 8,50 - 8,61 (2H, m), 8,62 - 8,69 (1H, m), 11,07 (2H, s). m / z (ESI+), [M+H]+= 815.
[0296] Isômero 2: RMN de1H (300 MHz, DMSO-d6) δ 1,33 - 1,56 (2H, m), 1,56 - 1,74 (2H, m), 1,70 - 2,06 (9H, m), 2,11 - 2,45 (4H, m), 2,57 - 2,80 (7H, m), 2,99 Petição 870260111673, de 29 / 10 / 2026, pág. 189 / 831 185 / 375 3,18 (6H, m), 3,31 (3H, s), 4,14 (3H, s), 4,51 - 4,67 (1H, m), 5,22 - 5,38 (1H, m), 6,55 - 6,70 (1H, m), 6,78 - 6,87 (1H, m), 6,89 - 6,99 (1H, m), 7,17 - 7,28 (1H, m), 7,28 7,36 (1H, m), 8,06 (1H, s), 8,12 - 8,21 (1H, m), 8,58 - 8,62 (1H, m), 8,62 - 8,70 (2H, m), 11,06 (2H, s). m / z (ESI+), [M+H]+= 815. Example 13 and Example 14: 2-(4-((1-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[ d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N (imidazo[1,2- b ]pyridazin-3-yl)-6-methoxy-2 H -indazol-5-carboxamida - Isomer 1 and Isomer 2 4-((4-(5-(Imidazo[1,2-b ]pyridazin-3-ylcarbamoyl)-6-methoxy-2 H-indazol-2-yl)cyclohexyl)amino)piperidine-1-carboxylate de tert-butyl
[0297] A mixture of tert-butyl 4-aminopiperidine-1-carboxylate (396 mg, 2.0 mmol), N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-oxocyclohexyl)-2H-indazol-5-carboxamide (Int I) (400 mg, 1.0 mmol) and NaOAc (243 mg, 3.0 mmol) in MeOH (10 mL) and DCM (10 mL) was stirred under N2 at 60 °C for 10 h before the addition of NaBH4 (75 mg, 2.0 mmol). The resulting mixture was stirred at 25 °C for 15 minutes. The reaction was rapidly cooled with ice water and the mixture was extracted with DCM (3 x 50 mL). The organic layer was dried with Na2SO4, filtered and concentrated. The crude product was purified by C18-flash chromatography (eluting with MeCN at 30 to 50% in water) to yield tert-butyl 4-((4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)amino)piperidine-1-carboxylate (400 mg, 68%) as a yellow solid. m / z (ESI+), [M+H]+= 589. tert-butyl 4-((4-(5-(Imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)(methyl)amino)piperidine-1-carboxylate Petition 870260111673, dated 10 / 29 / 2026, pp. 190 / 831 186 / 375
[0298] A mixture of formaldehyde (37% in water) (0.05 mL, 0.7 mmol), 4-((4(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)amino)piperidine-1-carboxylate tert-butyl (400 mg, 0.7 mmol) and NaOAc (167 mg, 2.0 mmol) in MeOH (10 mL) was stirred under N2 at 60 °C for 10 h before the addition of NaBH4 (51 mg, 1.4 mmol). The resulting mixture was stirred at 25 °C for 15 minutes. The reaction was rapidly cooled with ice water and the mixture was extracted with DCM (3 x 50 mL). The organic phase was dried with Na2SO4, filtered and concentrated. The crude product was purified by C18-flash chromatography (eluting with MeCN at 30 to 50% in water) to yield tert-butyl 4-((4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)(methyl)amino)piperidine-1-carboxylate (350 mg, 85%) as a yellow solid. m / z (ESI+), [M+H]+= 603. N-(Imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-(methyl(piperidin-4-yl)amino)cyclohexyl)2 H-indazol-5-carboxamide
[0299] TFA (1 mL, 13.0 mmol) was added to 4-((4-(5-(imidazo[1,2-b]pyridazin-3-ylcarbamoyl)-6-methoxy-2H-indazol-2-yl)cyclohexyl)(methyl)amino)piperidine-1-carboxylate tert-butyl (200 mg, 0.3 mmol) in DCM (3 mL) at 25 °C under N2. The resulting mixture was stirred for 2 h, then concentrated under reduced pressure to yield N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4-(methyl(piperidin-4yl)amino)cyclohexyl)-2H-indazol-5-carboxamide (150 mg, 90%), which was used without further purification. m / z (ESI+), [M+H]+= 503. 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6Petition 870260111673, of 10 / 29 / 2026, p. 191 / 831 187 / 375 methoxy-2H-indazole-5-carboxamide - Isomer 1 (Example 13) and Isomer 2 (Example 14) ISOMER 2
[0300] A mixture of NaOAc (49 mg, 0.6 mmol), N-(imidazo[1,2-b]pyridazin3-yl)-6-methoxy-2-(4-(methyl(piperidin-4-yl)amino)cyclohexyl)-2H-indazole-5-carboxamide (100 mg, 0.2 mmol) and 1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazole-4-carbaldehyde (57 mg, 0.2 mmol) in DMF (5 mL) was stirred at 60 °C under N2 for 10 h before the addition of NaBH(OAc)3 (127 mg, 0.6 mmol). The resulting mixture was stirred at 25 °C for 4 h. The reaction was rapidly cooled with ice water and the mixture was extracted with DCM (3 x 25 mL). The organic layer was dried with Na2SO4, filtered, and concentrated.The crude product was purified by C18-flash chromatography (eluting with 0 to 60% MeCN in water) followed by preparative HPLC (column: Xselect CSH F-Phenyl OBD, 19 x 250 mm, 5 μm; mobile phase A: water (10 mM NH4HCO3 + 0.1% NH4OH), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 34% B to 41% B in 13 min, followed by isocratic 41% B) to yield 2-(4-((1-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d] imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamide - Isomer 1 (19 mg, 11%) and 2-(4-((1-((1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 2 (8 mg, 6%), both as yellow solids.
[0301] Isômero 1: RMN de1H (400 MHz, DMSO-d6) δ 1,40 - 1,77 (4H, m), 1,81 - 2,09 (8H, m), 2,12 - 2,21 (2H, m), 2,25 (3H, s), 2,55 - 2,81 (3H, m), 2,83 - 2,94 (3H, Petição 870260111673, de 29 / 10 / 2026, pág. 192 / 831 188 / 375 m), 3,34 - 3,49 (2H, m), 3,62 (2H, s), 3,69 (3H, s), 4,12 (3H, s), 4,36 - 4,51 (1H, m), 5,34 - 5,45 (1H, m), 6,85 - 6,91 (1H, m), 6,93 - 7,01 (1H, m), 7,03 - 7,11 (1H, m), 7,19 - 7,29 (2H, m), 8,05 (1H, s), 8,12 - 8,17 (1H, m), 8,55 - 8,60 (2H, m), 8,62 - 8,66 (1H, m), 11,05 (1H, s), 11,11 (1H, s). m / z (ESI+), [M+H]+= 774.
[0302] Isômero 2: RMN de1H (400 MHz, DMSO-dβ) δ 1.42 - 1.63 (6H, m), 1.8 2.04 (7H, m), 2.10 (3H, s), 2.25 - 2.41 (3H, m), 2.59 - 2.7 (3H, m), 2.83 - 2.98 (3H, m), 3.62 (2H, s), 3.69 (3H, s), 4.13 (3H, s), 4.52 - 4.63 (1H, m), 5.29 - 5.47 (1H, m), 6.83 - 6.92 (1H, m), 6.93 - 7.02 (1H, m), 7,04 - 7.12 (1H, m), 7.18 - 7.27 (1H, m), 7.30 (1H, s), 8.06 (1H, s), 8.12 - 8.2 (1H, m), 8.59 (1H, s), 8.61 - 8.69 (2H, m), 11.01 - 11.14 (2H, m). m / z (ESI+), [M+H]+= 774. Exemplo 15, Exemplo 16, Exemplo 17 e Exemplo 18: 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-il)-3-metil-2-oxo-2,3-di-hydro-1 H benzo[d]imidazol-4-il)propoxy)propil)(metil)amino)ciclo-hexil)-N-(imidazo[1,2b]piridazin-3-il)-6-metoxi-2 H -indazol-5-carboxamida - Isômero 1, Isômero 2, Isômero 3 e Isômero 4 (3-(Prop-2-in-1-iloxi)propil)carbamate from ter-butila
[0303] NaH (1.0 g, 41.7 mmol) was slowly added to tert-butyl (3-hydroxypropyl)carbamate (4.9 g, 27.8 mmol) and 3-bromoprop-1-yne (6.6 g, 55.6 mmol) in THF (10 mL) at 0 °C under N2. The resulting mixture was stirred at 25 °C for 16 h. The reaction mixture was poured into water (20.0 mL) and extracted with EtOAc (2 x 20 mL). The organic layer was dried with Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica (eluting with 30 to 50% EtOAc in pentane) to yield tert-butyl (3-(prop-2-yn-1-yloxy)propyl)carbamate (800 mg, 14%) as a yellow oil. 1H NMR (300 MHz, MeOD-d4) δ 1.45 (9H, s), 1.71 - 1.80 (2H, m), 2.83 (1H, t), 3.14 (2H, t), 3.57 (2H, t), 4.15 (2H, d). m / z (ESI+), [M+H]+= 214. tert-butyl (3-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4yl)prop-2-yn-1-yl)oxy)propyl)carbamate Petition 870260111673, dated 10 / 29 / 2026, p. 193 / 831 189 / 375
[0304] 4 A molecular sieve (5 mg) was added to dppf Pd G3 (956 mg, 1.0 mmol), dppf (574 mg, 1.0 mmol), CS2CO3 (10.1 g, 31.1 mmol), copper(I) iodide (197 mg, 1.0 mmol), tert-butyl (3-(prop-2-yn-1-yloxy)propyl)carbamate (6.6 g, 31.1 mmol) and 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine2,6-dione (Int VI) (3.5 g, 10.4 mmol) in DMF (3 mL) at 25 °C under N2. The resulting mixture was stirred at 90 °C for 10 h. The reaction mixture was then cooled to rt, filtered, and concentrated. The crude product was purified by C18-flash chromatography (eluting with MeCN at 50-80% in water) to yield tert-butyl (3-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4yl)prop-2-yn-1-yl)oxy)propyl)carbamate) (2.5 g, 51%) as a brown solid. m / z (ESI+), [M+H]+= 471. tert-butyl (3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4yl)propoxy)propyl)carbamate
[0305] Rh / C (5 wt% Rh) (1.0 g, 0.5 mmol) was added to tert-butyl (3-((3-(1(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn1-yl)oxy)propyl)carbamate (2.5 g, 5.3 mmol) in MeOH (50 mL) at 25 °C under H2. The resulting mixture was stirred at 25 °C for 2 h. The precipitate was collected by filtration, washed with MeOH (50 mL) and dried in a vacuum oven to yield tert-butyl (3-(3(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4yl)propoxy)propyl)carbamate (2.0 g, 79%) as a brown solid, which was used without further purification. m / z (ESI+), [M+H]+= 475. Petition 870260111673, dated 10 / 29 / 2026, p. 194 / 831 190 / 375 3-(4-(3-(3-Aminopropoxy)propyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1yl)piperidine-2,6-dione
[0306] TFA (8.0 mL, 103.8 mmol) was slowly added to tert-butyl (3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)propoxy)propyl)carbamate (2.0 g, 4.2 mmol) in DCM (20 mL) at 25 °C under N2. The resulting mixture was stirred at 25 °C for 2 h, then concentrated under reduced pressure. The crude product was purified by C18-flash chromatography (eluting with MeCN at 20 to 40% in water) to yield 3-(4-(3-(3-aminopropoxy)propyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione (1.1 g, 70%) as a yellow solid. m / z (ESI+), [M+H]+= 375. 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)amino)cyclohexyl)-N-(imidazo[1,2-b ]pyridazin-3yl)-6-methoxy-2H-indazol-5-carboxamide
[0307] A mixture of Ti(Oi-Pr)4 (759 mg, 2.7 mmol), 3-(4-(3-(3-aminopropoxy)propyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine2,6-dione (500 mg, 1.3 mmol) and N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-(4oxocyclohexyl)-2H-indazol-5-carboxamide (Int I) (540 mg, 1.3 mmol) in DCM (10 mL) and in EtOH (10 mL) under N2 was stirred at 25 °C for 2 h before the slow addition of NaBH3CN (126 mg, 2.0 mmol) and stirring was continued for 1 h. The reaction was rapidly cooled with ice water and the mixture was concentrated under reduced pressure. The crude product was purified by C18 flash chromatography (eluting). Petition 870260111673, dated 10 / 29 / 2026, pp. 195 / 831 191 / 375 with MeCN at 25 to 40 % in water) to produce 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3yl)-3-methyl-2-oxo-2,3-di-hidro-1 H-benzo[ d] imidazol-4-yl)propoxy)propyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida (400 mg, 39%) as a bitter solid. m / z (ESI+), [M+H]+= 763.
[0308] 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida Isômero 1 (Exemplo 15), Isômero 2 (Exemplo 16), Isômero 3 (Exemplo 17) and Isômero 4 (Exemplo 18) ISOMER 1 TO ISOMER 4
[0309] A mixture of NaOAc (81 mg, 1.0 mmol), formaldehyde (37% in water) (0.05 mL, 0.7 mmol) and 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo2,3-d...
Claims
1. Compound of formula (IA) or pharmaceutically acceptable salt thereof characterized in that: X being: N= / or O ; R1 being -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl or -O-(C1-C6)alkylenyl-O(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 being (C3-C6)cycloalkyl; Q being CH or N; Y being a direct linkage, C(O), CH2, -CH2CH2-, -C(O)CH2-, where CH2 is attached to Q, -CH2C(O)-, where C(O) is attached to Q or -CH2C(O)NMe-, where N is attached to Q; L being -(C1-C6)alkylenyl-NH-*, -(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*; -O-(C1-C6)alkylenyl-NH-*, -O-(C1-C6)alkylenyl-N((C1-C6)alkyl)-*, Petition 870260111673, of 29 / 10 / 2026, page. 381 / 831 2 / 32 - (Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-NH-*, - (Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*,- NH-(Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-O-(Ci-C6)alkylenyl-NH-*, -NH(Ci-C6)alkylenyl-NH-*, - ((Ci-C6)alkyl)-N-(Ci-C6)alkylenyl-N-((Ci-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-*; 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenyl-N-((CiC6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-heterocycloalkylenyl-*, - (Ci-C6)alkylenyl-heterocycloalkylenyl-* of 4 to 6 members, - (Ci-C6)alkylenyl-heterocycloalkylenyl of 4 to 6 members-NH-*, - (Ci-C6)alkylenyl-heterocycloalkylenyl of 4 to 6 members-N-((Ci6)alkyl)-*, -(Ci-C6)alkylenyl-heterocycloalkylenyl of 4 to 6 members 4- to 6-membered alkylenyl-(CiC6)alkylenyl-NH-*, - 4- to 6-membered alkylenyl-(CiC6)alkylenyl-N-((CiC6)alkyl)-*,4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenylheterocycloalkylenyl-*, 4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenylheterocycloalkylenyl-4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkyl-(Ci-C6)alkylenylheterocycloalkylenyl-4- to 6-membered heterocycloalkylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyla)-*, - alkynylenyl-(Ci-C6)alkylenyl-NH-*, - alkynylenyl-(Ci-C6)alkylenyl-N-((Ci-C6)alkyla)-*, Petition 870260111673, of 29 / 10 / 2026, p. 382 / 831 3 / 32 - 4- to 6-membered alkynylenyl-(Ci-C6)alkylenyl-heterocycloalkylenylNH-*, - 4- to 6-membered alkynylenyl-(Ci-C6)alkylenyl-heterocycloalkylenyl-N((Ci-C6)alkyla)-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-*, -(C3-C6)cycloalkylenyl-heterocycloalkylenyl-*, -(C3-C6)cycloalkylenyl-heterocycloalkylenyl-*, -(C1-C6)alkylenyl-C(O)-heterocycloalkylenyl-*,or -heteroaryl-* of 5 to 6 members; because the link marked with an * is attached to Y; Z is Me Petition 870260111673, of 10 / 29 / 2026, p. 383 / 831 4 / 32 or , , and W is N or CH., 2. Pharmaceutically acceptable compound or salt thereof, according to claim 1, characterized in that it is represented by formula (II): (II).
3. Pharmaceutically acceptable compound or salt thereof, according to claim 1, characterized in that it is represented by formula (III): Petition 870260111673, dated 10 / 29 / 2026, p. 384 / 831 5 / 32 (III).
4. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 3, characterized in that X is rN Ah N^ / 5. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 3, characterized in that X is o and R2 is (C3-C6)cycloalkyl.
6. A pharmaceutically acceptable compound or salt thereof, according to claim 5, characterized in that R2 is cyclopropyl.
7. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 or claims 4 to 6, characterized in that Q is CH.
8. A pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 or claims 4 to 6, characterized in that Q is N.
9. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 8, characterized in that R1 is -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkyl-O-(C1-C6)alkyl 10. Pharmaceutically acceptable compound or salt thereof, according to claim 9, characterized in that R1 is -O-(C1-C6)alkyl. Petition 870260111673, dated 29 / 10 / 2026, p. 385 / 831 6 / 32 11. Pharmaceutically acceptable compound or salt thereof, according to claim 10, characterized in that R1 is -OCH3.
12. Pharmaceutically acceptable compound or salt thereof, according to claim 9, characterized in that R1 is -O-cyclopropyl.
13. A pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 12, characterized in that Y is a direct link.
14. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 12, characterized in that Y is CH2.
15. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 12, characterized in that Y is C(O).
16. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 12, characterized in that Y is CH2CH2.
17. A pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 12, characterized in that Y is C(O)CH2 with CH2 attached to Q.
18. A pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 12, characterized in that Y is CH2C(O) with C(O) attached to Q.
19. A pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 12, characterized in that Y is CH2C(O)NMe-, where N is fixed to Q.
20. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 19, characterized in that L is as defined in claim 1, and in that the 4- to 6-membered heterocycloalkylenyl group is piperidine or piperazine, the 4- to 6-membered cycloalkylenyl group is cyclohexyl and the 5- to 6-membered heteroaryl group is pyrazolyl.
21. Compost or pharmaceutically oily salt of the same, in accordance with any of claims 1 to 20, characterized by L being heterocycloalkylenyl-* of 4 to 6 members; Petition 870260111673, dated 10 / 29 / 2026, page. 386 / 831 7 / 32 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-heterocycloalkylenyl-*, - (C1-C6)alkylenyl-heterocycloalkylenyl-* of 4 to 6 members, - (C1-C6)alkylenyl-heterocycloalkylenyl-NH-*, - (C1-C6)alkylenyl-heterocycloalkylenyl-4 to 6 members-N-((C1C6)alkyl)-*, - (C1-C6)alkylenyl-heterocycloalkylenyl of 4 to 6-membered-(C1-C6)alkylenyl-NH-*, - (C1-C6)alkylenyl-heterocycloalkylenyl of 4 to 6 members-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, heterocycloalkylenyl of 4 to 6 members-(C1-C6)alkylheterocycloalkylenyl-* of 4 to 6 members,4- to 6-membered heterocycloalkylenyl-(C1-C6)alkyl, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, - alkynylenyl-(C1-C6)alkylenyl-4- to 6-membered heterocycloalkylenyl-NH-*, - alkynylenyl-(C1-C6)alkylenyl-4- to 6-membered heterocycloalkylenyl-N((C1-C6)alkyl)-*, - alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-* of 4 to 6 members, being that the ligação marked with a * is fixed to Y; e where 4 to 6-membered heterocycloalkylenylates piperidine or piperazine. Petition 870260111673, dated 10 / 29 / 2026, page. 387 / 831 8 / 32, 22. Compost or pharmaceutically oily salt of the same, in accordance with any of claims 1 to 20, characterized by L being heterocycloalkylenyl-* of 4 to 6 members; 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-heterocycloalkylenyl-*, - (C1-C6)alkylenyl-heterocycloalkylenyl-NH-*, - (C1-C6)alkylenyl-heterocycloalkylenyl-N-((C1C6)alkyl)-*, - (C1-C6)alkylenyl-heterocycloalkylenyl-(C1-C6)alkylenyl-NH-*, - (C1-C6)alkylenyl-heterocycloalkylenyl-4 to 6-membered-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylheterocycloalkylenyl-*, 4- to 6-membered heterocycloalkylenyl-(C1-C6)alkylheterocycloalkylenyl-(C1-C6)alkylenyl-NH-*,4- to 6-membered heterocycloalkylenyl-(C1-C6)4- to 6-membered alkylenylheterocycloalkylenyl-(C1-C6)alkylenyl-N-((C1-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenylheterocycloalkylenylNH-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-heterocycloalkylenyl-N((C1-C6)alkyl)-*, - 4- to 6-membered alkynylenyl-(C1-C6)alkylenyl-O-heterocycloalkylenyl-*, and the bond marked with an * is attached to Y; and Petition 870260111673, of 10 / 29 / 2026, p. 388 / 831 9 / 32 where the 4- to 6-membered heterocycloalkylenyl group is piperidine or piperazine.
23. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 20, characterized by L being: Petition 870260111673, dated 10 / 29 / 2026, p. 389 / 831 10 / 32 or Z 24. Pharmaceutically acceptable compound or salt thereof, according to claim 23, characterized in that L is: Petition 870260111673, dated 10 / 29 / 2026, p. 390 / 831 11 / 32 or 25. Pharmaceutically acceptable compound or salt thereof, according to claim 24, characterized in that L is: Petition 870260111673, dated 10 / 29 / 2026, p. 391 / 831 12 / 32, or 26. Pharmaceutically acceptable compound or salt thereof, according to claim 25, characterized in that L is 27. Pharmaceutically acceptable compound or salt thereof, according to claim 26, characterized by L being Petition 870260111673, dated 10 / 29 / 2026, p. 392 / 831 13 / 32 28. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 27, characterized in that Z is 29. Pharmaceutically acceptable compound or salt thereof, according to claim 28, characterized by Z being Petition 870260111673, dated 10 / 29 / 2026, p. 393 / 831 14 / 32 30. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 29, characterized in that W is CH2.
55. Pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 29, characterized in that W is N.
31. Composed, according to indication 1, characterized by: 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)buti l)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)butyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)prop-2-in-1-yl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2;2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(metil)amino)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-metoxi-2H-indazol-5-carboxamida - Isômero 1; Petição 870260111673, de 29 / 10 / 2026, pág. 394 / 831 15 / 32 2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)but-3-in-1-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2-b]piridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomere 2; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((2-(1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)ethyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2;2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-((1-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)propyl)piperidin-4-yl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 1; 2-(4-(4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2;2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 1; 2-(4-((1-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperidin-4-yl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]piridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isômero 1; Petição 870260111673, de 29 / 10 / 2026, pág. 395 / 831 16 / 32 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1Hbenzo[d]imidazol-4-yl)propoxy )propyl)(methyl)amino)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamida - Isomer 2;2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 3; 2-(4-((3-(3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)propoxy)propyl)(methyl)amino)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 4; 2-(4-((2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5carboxamide - Isomer 1; 2-(4-((2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5carboxamide - Isomer 2; 2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1yl)ethyl)amino)ciclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide - Isomer 1;2-(4-((2-(4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide - Isomer 2; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazole-5-carboxamide - Isomer 1; 2-(4-((2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)ethyl)amino)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazole-5-carboxamide - Isomer 2; 2-((1r,4r)-4-((4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro1 H-benzo[d]imidazol-5-yl)piperazin-1 -yl)piperidin-1 -yl)methyl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide;Petition 870260111673, of 29 / 10 / 2026, p. 396 / 831 17 / 32 N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-5-yl)piperazine-1yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methyl-2-toxyl-H-H-incarzone; 2-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((3-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxy)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indacarboxamida; 2-((1r,4r)-4-(4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hydro1 H-benzo[d]imidazol-4-yl)prop-2-in-1 -yl)oxy)piperidine-1-carbonyl)cyclo-hexyl)-N(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide;N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-(4-((3-(1-(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-4-yl)prop-2-in-1yl)oxi)piperidine-1-carbonyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamida; and N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamida; 2-((1 r,4 r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2 H)-yl)-1 H-indol-1 yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; 2-((1 r,4 r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)cyclohexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamida;2-((1 r,4 r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2 H-indazol5-carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 397 / 831 18 / 32 N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6methoxy-2 H-indazol-5-carboxamide; 2-((1 r,4 r)-4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazine-1-carbonyl)cyclo-hexyl)-N-(imidazo[1,2-b ]pyridazin-3-yl)-6-methoxy-2-Hindazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,4dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-6methoxy-2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)-1 H-indol-1 -yl)piperidin-1 yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida;N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,6dioxopiperidin-3-yl)-1 H-indol-1-yl)piperidin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamida; 6-cyclopropoxy-2-((1r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1(2H)-yl)1H-indol-1-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-2-methyl-1 Hindol-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-3-methyl-1 Hindol-1 -yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 -yl)[1,4'-bipiperidin]-1'-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida;2-((1 r,4r)-4-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 -yl)[1,4'-bipiperidina]-1'-carbonyl)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin-3-yl)-6-metoxi-2Hindazol-5-carboxamida; Petição 870260111673, de 29 / 10 / 2026, pág. 398 / 831 19 / 32 2-((1 r,4r)-4-((4-((4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 yl)methyl)pipendin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-(2-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 il)piperidin-1-yl)ethyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-(2-(4-(4-(2,4dioxotetra-hidropyrimidin-1(2H)-yl)-1H-indol-1-yl)piperidin-1-yl)ethyl)cyclo-hexyl)-6-methoxi2H-indazol-5-carboxamida;2-((1r,4r)-4-((4-((4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1 il)piperidin-1-il)metil)piperidin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6metoxi-2H-indazol-5-carboxamida; 2-((1r,4r)-4-(4-((4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1 il)piperidin-1-il)methyl)piperidina-1-carbonil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)6-metoxi-2H-indazol-5-carboxamida; 2-(4-((4-(2-(4-(4-(2,4-dioxotetra-hidropirimidin-1 (2H)-il)-1 H-indol-1il)piperidin-1-il)etil)piperidin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6metoxi-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-(2-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1 H-indol-1 il)etil)piperazin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2Hindazol-5-carboxamida; 6-ciclopropoxy-2-(1 -(2-(4-(4-(2,4-dioxotetra-hydropyrimidin-1 (2H)-il)-1 Hindol-1-il)pipendin-1-il)acetil)pipendin-4-il)-N-(imidazo[1,2-b]pindazin-3-il)-2H-indazol5-carboxamida;6-cyclopropoxy-2-(1 -(2-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 Hindol-1 -yl)piperidin-1 -yl)-2-oxoethyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 6-cyclopropoxy-2-(1 -(2-(4-((4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 Hindol-1-yl)methyl)piperidin-1-yl)acetyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 399 / 831 20 / 32 2-((1 r,4r)-4-((4-(6-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindol-2-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-1 H-indol-4-yl)piperazin1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; 2-((1r,4r)-4-((4-(4-((2,6-dioxopiperidin-3-yl)carbamoyl)-3fluorophenyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida;and N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-((2,6dioxopiperidin-3-yl)carbamoyl)-3-fluorophenyl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy2H-indazol-5-carboxamide; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-5-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(1 -(2,6dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1H-benzo[d]imidazol-5-yl)piperidin-1yl)methyl)cyclo-hexyl)-6-methoxi-2H-indazol-5-carboxamida 6-cyclopropoxy-2-((1r,4r)-4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo2,3-di-hidro-1 H-benzo[d]pyridazin-5-yl)piperidin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazine-3-yl)-2H-indazol-5-carboxamida;2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]pyridazin-4-yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazine-3-yl)6-methoxy-2H-indazol-5-carboxamida; 6-cyclopropoxy-2-((1r,4r)-4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo2,3-di-hidro-1 H-benzo[d]pyridazin-4-yl)piperazin-1 -yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-2H-indazol-5-carboxamide; 2-((1 r,4r)-4-((4-((1 -(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-di-hidro-1 Hbenzo[d]imidazol-4-yl)methyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin3-yl)-6-methoxy-2H-indazol-5-carboxamida; Petition 870260111673, 29 / 10 / 2026, pág. 400 / 831 21 / 32 2-((1 r,4r)-4-((4-((1 -(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-3methylphenyl)pipendin-4-yl)methyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2b]pyridazine-3-yl)-6-methoxy-2H-indazol-5-carboxamida;N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-((1 -(4-(2,4dioxotetra-hydropynmidine-1(2H)-yl)-3-methylphenyl)pipendin-4-yl)methyl)piperazine-1yl)methyl)cyclo-hexyl)-6-methoxy-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(6-(2,4dioxotetra-hydropyrimidin-1(2H)-yl)-1-methyl-1H-indol-2-yl)piperidin-1-yl)methyl)cyclo-hexyl)6-methoxy-2H-indazole-5-carboxamide; 6-cyclopropoxy-2-((1r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2H-indazol-5-carboxamide; N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,6dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2H-carboxylate; 2-((1r,4r)-4-((4-(4-(2,6-dioxopipendin-3-yl)-3-methylphenyl)piperazin-1yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamyl;N-(1 -ciclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(4-(2,6dioxopiperidin-3-yl)-3-metilfenil)piperazin-1-yl)metil)ciclo-hexyl)-6-methoxy-2H-indazol-5-carboxamide; 2-((1r,4r)-4-((4-(4-(4-(2,6-dioxopipendin-3-yl)fenil)piperazin-1-yl)pipendin1-il)metil)ciclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5-carboxamide; 2-((1r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)-3-methoxyphenyl)piperazin-1yl)methyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide; 2-((1r,4r)-4-(2-(4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)ethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazole-5-carboxamide; N-(1 -ciclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-(2-(4-(4-(2,6dioxopiperidin-3-yl)fenil)piperazin-1-yl)ethyl)ciclo-hexyl)-6-methoxy-2H-indazol-5-carboxamide;Petition 870260111673, de 29 / 10 / 2026, pág. 401 / 831 22 / 32 2-((1r,4r)-4-((4-(6-(2,6-dioxopipendin-3-yl)piridin-3-yl)piperazin-1yl)metil)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin-3-yl)-6-metoxi-2H-indazol-5carboxamida; 2-((1r,4r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)piperazin1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol-5carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1r,4r)-4-((4-((1-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5yl)piperidin-4-yl)methyl)pipe razin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-7-methoxy-1-oxoisoindolin-5yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol5-carboxamida;N-(1 -cyclopropyl-2-oxo-1,2-di-hydropyridin-3-yl)-2-((1 r,4r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-7-methoxy-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)cyclo-hexyl)-6methoxy-2H-indazol-5-carboxamide; 2-((1 r,4r)-4-((4-(3-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindazol-7-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(3-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindazol-7-yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida; 2-((1 r,4r)-4-(2-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 il)piperidin-1-yl)-N-methylacetamido)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6methoxy-2H-indazol-5-carboxamida; 2-((1 r,4r)-4-((4-(2-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 yl)acetyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida;Petition 870260111673, 29 / 10 / 2026, pág. 402 / 831 23 / 32 2-((1 r,4r)-4-((4-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 il)cyclo-hexyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pindazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomer 1; 2-((1 r,4r)-4-((4-(4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 H-indol-1 il)cyclo-hexyl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida - Isomere 2; 6-cyclopropoxy-2-(1 -(((1 r,4r)-4-(4-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)1 H-indol-1-yl)cyclo-hexyl)methyl)piperidin-4-yl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-yl)-3-methyl-1 H-indazol-4yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2H-indazol5-carboxamida;6-ciclopropoxy-2-((1r,4r)-4-((4-(1-(2,6-dioxopiperidin-3-il)-3-metil-1) Hindazol-4-il)piperazin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-2H-indazol5-carboxamida; 2-((1 r,4r)-4-((4-(1 -(2,6-dioxopiperidin-3-il)-3-metil-1 H-indazol-5il)piperazin-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol5-carboxamida; 2-((1r,4r)-4-((4-(1-(2,6-dioxopiperidin-3-il)-3-methyl-1 H-indazol-4-il)-1 Hpirazol-1-il)methyl)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol-5-carboxamida; 2-((1r,4r)-4-((4-(4-(2,4-dioxotetra-hidropirimidin-1(2H)-il)isoquinolin-8il)piperazin-1-il)methyl)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2H-indazol5-carboxamida; 2-((1r,4r)-4-((4-(3-(2,6-dioxopiperidin-3-il)-2-oxo-2,3-dihidrobenzo[d]oxazol-7-il)piperazi n-1-il)metil)ciclo-hexil)-N-(imidazo[1,2-b]piridazin-3il)-6-metoxi-2H-indazol-5-carboxamida;2-((1 r,4r)-4-((4-(1 '-(2,6-dioxopiperidin-3-yl)-2'-oxospiro[cyclopropane-1,3'indolin]-5'-yl)piperazin-1-yl)metil)ciclo-hexyl)-N-(imidazo[1,2-b]piridazin-3-yl)-6-metoxi2H-indazol-5-carboxamida; Petição 870260111673, de 29 / 10 / 2026, pág. 403 / 831 24 / 32 2-((1 r,4r)-4-((4-(7-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)-1 -methyl-1 Hindol-3-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2Hindazol-5-carboxamida; 2-((1 r,4r)-4-((4-(3-(2,4-dioxotetra-hidropyrimidin-1 (2H)-yl)imidazo[1,5a]pyridin-8-yl)piperazin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-6-methoxy2H-indazol-5-carboxamida; N-(1 -cyclopropyl-2-oxo-1,2-di-hidropyridin-3-yl)-2-((1 r,4r)-4-((4-(3-(2,4dioxotetra-hidropyrimidin-1(2H)-yl)benzo[d]isoxazol-6-yl)piperazin-1-yl)methyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamida;2-((1 s,4s)-4-((4-(4-(2,4-dioxotetra-hydropyrimidine-1 (2H)-yl)-1 H-indol-1 il)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazine-26H-carboxynda-yl) 2-((1 s,4s)-4-((4-(6-(2,4-dioxotetra-hydropyrimidine-1 (2H)-yl)-1 -methyl-1 Hindol-2-yl)piperidin-1-yl)methyl)cyclo-hexyl)-N-(imidazo[1,2-b]pyridazine-3-yl)-6-methoxy-2Hindazol-5-carboxamide; or you know pharmaceutically accept two same.; 32. Compound of formula (II) or pharmaceutically acceptable salt thereof: characterized by: X being Petition 870260111673, of 10 / 29 / 2026, page 404 / 831 25 / 32 R1 being -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O(C1-C6)alkyl, wherein -O-(C1-C6)alkyl, -O-(C3-C6)cycloalkyl, -O-(C1-C6)alkylenyl-O-(C1-C6)alkyl are optionally substituted by 1 to 3 substituents independently selected from halogen, (C1-C6)alkyl and (C1-C6)alkoxy; R2 being (C3-C6)cycloalkyl; Y being a direct link, C(O), CH2, CH-2CH2 or -CH2C(O)NMe-, where N is attached to the carbon of the ring; L being: Petition 870260111673, of 10 / 29 / 2026, p. 405 / 831 26 / 32 Z being Me Petition 870260111673, of 10 / 29 / 2026, p. 406 / 831 27 / 32 Me or and W being CH or N.
33. Compound characterized by being 2-((1 r,4 r)-4-((4-(2-(2,6dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl) piperazin-1-yl)methyl)cyclohexyl)-N- (imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamide or a pharmaceutically acceptable salt thereof.
34. Compound characterized by being N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5yl)piperazin-1-yl)methyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide Petition 870260111673, of 10 / 29 / 2026, p. 407 / 831 28 / 32 or a pharmaceutically acceptable salt thereof.
35. Compound characterized by being 2-((1 r,4r)-4-((4-(4-(2,4-dioxotetrahydropyrimidin-1 (2 H )-yl)-1 H-indol-1-yl)piperidin-1 -yl) methyl)cyclohexyl)-N-(imidazo[1,2b ]pyridazin-3-yl)-6-methoxy-2 H-indazole-5-carboxamide or pharmaceutically acceptable salt thereof.
36. Compound characterized by being 2-((1r,4r)-4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)methyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3yl)-6-methoxy-2H-indazol-5-carboxamide Petition 870260111673, of 10 / 29 / 2026, p. 408 / 831 29 / 32 or a pharmaceutically acceptable salt thereof.
37. Compound characterized by being 2-((1r,4r)-4-(2-(4-(4-(2,6dioxopiperidin-3-yl)phenyl)piperazin-1-yl)ethyl)cyclohexyl)-N-(imidazo[1,2-b]pyridazin-3-yl)6-methoxy-2H-indazol-5-carboxamide or a pharmaceutically acceptable salt thereof.
38. Compound characterized by being 2-((1 r,4 r)-4-(2-(4-(4-(2,4-dioxotetrahydropyrimidin-1 (2 H )-yl)-1 H-indol-1-yl)piperidin-1 -yl)ethyl)cyclohexyl)-N-(imidazo[1,2b]pyridazin-3-yl)-6-methoxy-2 H-indazol-5-carboxamide or a pharmaceutically acceptable salt thereof.
39. Compound characterized by being N-(1-cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1r,4r)-4-(2-(4-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-1H-indol-1-yl)piperidin-1-yl)ethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide Petition 870260111673, of 10 / 29 / 2026, p. 409 / 831 30 / 32 or a pharmaceutically acceptable salt thereof.
40. Compound characterized by being N-(1-cyclopropyl-2-oxo-1,2-dihydropyridine-3-yl)-2-((1r,4r)-4-(2-(4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-1-yl)ethyl)cyclohexyl)-6-methoxy-2H-indazol-5-carboxamide or a pharmaceutically acceptable salt thereof.
41. Pharmaceutical composition characterized by comprising the pharmaceutically acceptable compound or salt thereof as defined in any one of claims 1 to 40.
42. Pharmaceutical composition, according to claim 41, characterized by further comprising a pharmaceutically acceptable excipient.
43. A method for degrading IRAK4 in a human being, characterized by comprising administering to a human being in need thereof an effective amount of the compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 40 or of the composition as defined in claim 41 or 42.
44. Method for reducing the activity level of IRAK4 in a human being, characterized by comprising the pharmaceutically acceptable compound or salt thereof as defined in any one of claims 1 to 40 or the composition as defined in claim 41 or 42.
45. Method of treating a disease or disorder associated with IRAK4 in a human being, characterized by comprising administering to a human being in need thereof an effective amount of the compound or pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 40 or of the pharmaceutical composition as defined in claim 41 or 42.
46. Method according to claim 45, characterized in that the disease or disorder is a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease or disorder, or a cancer.
47. Method, according to claim 45, characterized in that the disease or disorder is systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, inflammatory bowel disease, atopic dermatitis, hidradenitis suppurativa or psoriasis.
48. A pharmaceutically acceptable compound or salt thereof, according to any one of claims 1 to 40, characterized in that it is intended for use in therapy.
49. Use of the pharmaceutically acceptable compound or salt thereof as defined in any one of claims 1 to 40, characterized in that it is intended for the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease, or cancer.
50. Use of the pharmaceutically acceptable compound or salt thereof as defined in any one of claims 1 to 40, characterized by being intended for the treatment of systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, inflammatory bowel disease, atopic dermatitis, hidradenitis suppurativa or psoriasis.
51. Use of the pharmaceutically acceptable compound or salt as defined in any one of claims 1 to 40, characterized by being employed in the manufacture of a medicament for the treatment of a respiratory disease or disorder, an inflammatory disease or disorder, an autoimmune disease, or cancer.
52. Use of the pharmaceutically acceptable compound or salt as defined in any of claims 1 to 40, characterized by being employed in the manufacture of a medicament for the treatment of systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, Petition 870260111673, dated 10 / 29 / 2026, page 411 / 831 32 / 32 endometriosis, inflammatory bowel disease, atopic dermatitis, hidradenitis suppurativa or psoriasis.
